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Abstract 
 
Radiotherapy involves the treatment of tumours with ionising radiation. Technological 
advances have improved the ability to conform dose distributions to tumours in three 
dimensions (3D) and thereby reduce morbidity. However, sophisticated measurement 
devices are required to verify these complex distributions and ensure their accuracy. 
Radiation-sensitive gels, including polymer and Fricke gels, are a potential solution to 
this 3D dosimetry problem. Scanning these detectors using imaging methods such as 
magnetic resonance imaging (MRI) provides quantifiable images of dose distribution.  
Despite research efforts, 3D gel dosimetry has not yet been implemented as a routine 
dosimetry tool in clinical radiotherapy. This thesis aims to investigate the 
implementation of Fricke gel detectors within a clinical radiotherapy department. The 
existing literature was reviewed to establish what evidence already existed on the 
dosimetric accuracy of Fricke gel detectors. This review highlighted gaps for many 
important dosimetric characteristics and a lack of a systematic approach to the testing of 
these detectors.  
Basic dosimetric characteristics were then investigated using test tube Fricke gel 
samples and an MR spectrometer. These experiments showed an excellent basic 
precision over a dose range of 3 to 20Gy. However, detectors need to be scanned within 
a certain time of irradiation to avoid signal drift. There was no evidence of any 
dependence of response on dose rate, energy or fractionation.  
Larger volume detector samples were analysed using a 3T MRI scanner. Detector 
response was homogeneous and did not vary with volume. Post-irradiation blurring of 
the measured distribution due to ferric ion diffusion was within acceptable limits if 
detectors were scanned within 2 hours following irradiation for typical clinical dose 
gradients.  
Finally, large volume Fricke gel detectors were used to measure complex VMAT 
stereotactic plans, describing the integrated dose distribution with sufficient accuracy 
and demonstrating clear potential to be applied to our clinical practice.   
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Abbreviations 
# fraction of radiotherapy 
1D one dimensional 
2D two dimensional 
3D three dimensional 
3DCRT three dimensional conformal radiotherapy 
BANG bis, acrylamide, nitrogen and gelatine; a type of polymer gel 
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MR magnetic resonance 
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MU monitor unit 
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NHS national health service 
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NPL national physical laboratory 
NSA number of signal averages 
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PRV planning risk volume 
PTV planning target volume 
QA quality assurance 
QC quality control 
R1 spin-lattice (longitudinal) relaxation rate 
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RF radiofrequency 
ROI region of interest 
SABR stereotactic ablative radiotherapy 
SD standard deviation 
SI Système International  
SNR signal to noise ratio 
SRS stereotactic radiosurgery 
SSD source to surface distance 
T Tesla 
T1 spin-lattice (longitudinal) relaxation 
T2 spin-spin (transverse) relaxation 
TCP tumour control probability 
TE echo time 
TI inversion time 
TR repetition time 
TPS treatment planning system 
VMAT volumetric modulated arc radiotherapy 
XO Xylenol orange 
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Chapter 1. Introduction 
1.1 Radiotherapy 
1.1.1 Introduction to Radiotherapy 
Radiotherapy is the treatment of cancer with high energy ionising radiation. The aim is 
to destroy cancer cells while sparing adjacent normal tissue. Photon, electron or heavy 
particle beams may be applied to various clinical situations. This project is concerned 
with the use of megavoltage energy (MV) photons to treat deep seated tumours. 
Radiation dose has the unit of gray (Gy), defined as the amount of energy absorbed per 
kilogram of matter (joules per kilogram). 
The aim of radiotherapy is to eradicate the tumour whilst causing minimal damage to 
surrounding normal tissue, more specifically to achieve a high tumour control 
probability (TCP) with a low normal tissue complication probability (NTCP). The 
therapeutic ratio refers to the ratio between the TCP and NTCP for a given radiation 
dose level.  If the radiation dose is too low, the tumour will not be eradicated, too high 
and unacceptable side effects result.   
One way of improving the therapeutic ratio is to divide radiotherapy treatments into 
small daily fractions (#) delivered over the course of a few weeks. This relies on the 
repair of sub-lethal damage to normal tissue and repopulation of cells, as well as 
increasing tumour damage due to re-oxygenation and redistribution of tumour cells. 
Typical radiotherapy fractionation schedules for conventional radical treatments are 1.5 
to 3Gy per fraction for 15 to 35 daily fractions. Stereotactic radiotherapy involves a 
much higher dose per fraction over fewer fractions, up to 20Gy in a single fraction and 
will be discussed further in section 1.1.6.  
Another way is to improve the conformity of radiation to the tumour target volume, 
reducing the dose received by surrounding organs and consequently allowing dose to 
the tumour to be boosted. Developments in radiotherapy technology over recent years 
have aimed to improve the accuracy and conformity with which radiation doses are 
delivered.  
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1.1.2 Target volumes and organs at risk 
A critical part of the radiotherapy process is the definition of the tumour volume to be 
treated. The International Commission of Radiation Units (ICRU) published several 
reports regarding the definition of tumour volumes and organ at risk [1-3]. The Gross 
Tumour Volume (GTV) is defined as the palpable, visible or demonstrable tumour 
volume. The Clinical Target Volume (CTV) includes the GTV plus a margin for sub-
clinical spread e.g. regional lymph nodes. The CTV must be adequately treated to 
achieve a cure. A third volume, the Planning Target Volume (PTV), is defined which 
includes a margin around the CTV to account for geometric uncertainties in radiation 
dose delivery. These include day to day variations in patient set up and internal organ 
motion.   
Surrounding organs at risk (OARs) are also outlined for example the spinal cord, rectum 
and lungs. These may also have margins added to account for set up uncertainties to 
create Planning Risk Volumes (PRVs).  
In conventional fractionation radiotherapy the aim is to deliver the prescription dose as 
uniformly as possible to the PTV whilst limiting dose to surrounding normal tissue. It is 
recommended that the PTV dose should be within 95 and 107% of the prescription dose 
[1]. Hotspots outside the PTV should be avoided, defined as regions outside PTV 
receiving at least the prescription dose. Doses to OARs should be within defined limits, 
either from published recommendations or data from clinical trials.    
1.1.3 Radiotherapy delivery equipment 
This project is limited to megavoltage photons produced by a Linear Accelerator (linac) 
(Figure 1.1), a brief description of which is given here. All experiments in this project 
were carried out with either a Varian 2100 iX or a Varian Truebeam (Varian Medical 
Systems, Palo Alto, CA) therefore the description here is relevant to these machines.  
To produce a high energy photon beam, an electron beam is accelerated along an 
accelerating waveguide using microwave energy. The electron beam is guided towards 
a tungsten X-ray target using bending magnets. Within the target, the electrons interact 
with atomic orbital electrons and atomic nuclei producing characteristic X-rays and 
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bremsstrahlung photons. The resulting photon beam is peaked in the forward direction, 
therefore a flattening filter is used to create a beam that is flat at depth in tissue.  
An ion chamber within the linac gantry measures the photon fluence passing through 
and checks for beam flatness and symmetry. It also enables calibration of the beam. 
Once a set number of Monitor Units (MU) are reached, the beam is terminated; monitor 
units are related to the fluence measured by the ion chamber. Each linac beam is 
calibrated whereby MU are related to dose to water under defined reference conditions. 
At St. Bartholomew’s Hospital 1cGy = 1 MU at the depth of dose maximum (dmax), 
with a 10x10cm open field and 100cm source to surface distance (SSD). This reference 
dose is measured with a Farmer ionisation chamber with dose calibration traceable to 
the National Physical Laboratory according to the UK photon dosimetry code of 
practice [4].  
The photon beam is then shaped by a series of collimators within the head of the linac 
which will be described in the following sections. The linac gantry rotates around a 
single point in space called the isocentre. The location of the isocentre is displayed 
visually by an optical cross hair projected from the linac head and external laser beams.  
 
Figure 1.1 Varian linac used in this project. 
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The dose distribution is optimised initially by adjusting the number of beams, beam 
direction, relative weighting and radiation energy. Prior to the implementation of 
multileaf collimators (MLCs), beam shaping was limited to rectangular fields up to 
40×40cm
2
 formed by the 2 pairs of tungsten secondary collimator jaws and involved the 
undesired irradiation of normal tissue. 
1.1.4 Conformal radiotherapy 
3D conformal radiotherapy (3DCRT) describes the creation of irregular beam shapes 
(2D) using a multileaf collimator. The multileaf collimator comprises of two banks of 
narrow, high atomic number leaves (usually tungsten) which move independently of 
each other. The Varian linacs used throughout this project have a 120 leaf MLC 
comprising of 2 banks of 60 leaves, the central 20 cm of which are 0.5cm width at the 
isocentre and outer leaves are 1cm leaf width at the isocentre. A “beams eye view” 
projects the MLC position on a simulated radiograph of the patient from the 
radiotherapy beam direction and helps design the MLC shaping to best conform to the 
PTV (Figure 1.2).   
 
Figure 1.2: Beams Eye View showing multileaf collimator shaping around PTV. 
 
However, conformal radiotherapy is limited in its ability to conform dose distributions 
to some irregular tumour volumes, particularly those that are concave in an axial plane 
(Figure 1.3).  
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Figure 1.3: Isodose distribution for a 3DCRT plan treating a head and neck 
tumour with high and low dose PTVs shaded red and orange. There is a large 
region of normal tissue irradiated, including spinal cord. 
 
1.1.5 Modulated radiotherapy 
Modulated radiotherapy techniques such Intensity Modulated Radiotherapy (IMRT) and 
Volumetric Modulated Arc Radiotherapy (VMAT) have been developed to improve the 
conformity of dose distributions to irregularly shaped tumour volumes in 3D. They also 
allow the simultaneous treatment of different PTVs to different doses with a single 
treatment plan for example primary disease and elective lymph nodes. 
IMRT involves multiple intensity-modulated static fields. The dose distribution is 
shaped in three dimensions by altering the intensity or fluence map across each beam 
(Figure 1.4). Delivery of these intensity modulated beams is achieved by the MLC 
leaves moving across the field while the beam is on or by using multiple MLC shapes 
per beam direction. Typically, 5 to 9 beam directions are used. The MLC shields parts 
of the PTV for large amounts of the treatment, therefore total beam-on time is long for 
IMRT (> 5 minutes) and there is an increase in scattered dose to the rest of the patient 
when compared with conformal techniques.  
 
 
 18 
 
 
a 
 
b 
Figure 1.4: Example fluence map for an IMRT field (a) and isodose 
distribution (b) for a head and neck plan. 
 
 
With VMAT, the linac gantry continually rotates around the patient in one or more arcs. 
As the gantry rotates, the MLC leaves move to define different shapes from each 
direction and simultaneously the linac gantry speed and radiation dose rate vary. VMAT 
treatments are much shorter than IMRT. Typically, 1 to 2 arcs are used, with each arc 
taking approximately 1 minute to deliver. As well as improving linac efficiency, shorter 
treatment times reduce the effects of intra-fraction organ motion and potentially allow 
for smaller CTV to PTV margins. RapidArc is the VMAT solution for the Varian linacs 
used throughout this project [5].  
1.1.6 Stereotactic radiotherapy 
Stereotactic radiotherapy is the treatment with high positional accuracy of small, well 
defined tumours. Stereotactic Ablative Body Radiotherapy (SABR) is defined as the 
precise irradiation of an image-defined extracranial lesion with the use of high radiation 
dose in a small number of fractions. Stereotactic Radiosurgery (SRS) delivers high 
doses of radiation precisely to intracranial lesions. Accurate tumour localisation may be 
achieved with immobilisation devices or by imaging during treatment delivery. A 
Cyberknife unit (Accuray Inc., Sunnyvale, CA, USA) is currently in use at our centre 
for the delivery of stereotactic radiotherapy treatments. This is a linac mounted onto a 
robotic arm which allows the delivery of many narrow photon beams from a wide range 
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of directions enabling steep dose fall off away from the tumour.  Stereotactic 
radiotherapy can also be delivered on a conventional linac with appropriate patient 
immobilisation and imaging.  
There has been an increased interest in stereotactic techniques over recent years. NHS 
England have led commissioning programs for SABR for specific treatment sites, and 
awarded contracts aiming to increase the number of patients with brain cancers treated 
with SRS.  
1.1.7 Treatment planning systems 
The treatment planning system (TPS) facilitates many functions in the creation of 
radiotherapy treatment plans, including the importing of CT and other modality images, 
contouring of target volumes and OARs and the calculation and evaluation of dose to 
the patient. CT is the imaging modality of choice, as scanners are widely available, 
geometrically accurate but most importantly can quantify tissue (electron) density 
which is necessary for accurate dose calculation.  
Conformal radiotherapy plans are generally created using forward planning. All beam 
parameters are set by the planner i.e. the number, direction, energy and relative 
weighting of beams as well as field size and MLC shape. The dose distribution is 
calculated, plan evaluated and parameters adjusted iteratively until an acceptable plan is 
achieved.  
For IMRT and VMAT, inverse planning is used. The number of beams, beam direction 
(or arc length) and energy are still commonly set by the planner but an inverse planning 
module determines the MLC positions and other parameters required to fulfil specified 
dose constraints. Within the inverse planning module, dose objectives are applied for 
each target volume and OAR and assigned a relative weighting. For example, PTV dose 
should be within 95% and 107% of the prescription dose. The optimiser determines 
parameters required to best achieve these constraints. For IMRT this is the MLC leaf 
motions for each field and for VMAT it is MLC shape, gantry speed and dose rate at 
each gantry angle.  
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1.2 Radiation dosimetry 
1.2.1 Overview of dosimetry for complex radiotherapy techniques: the challenge 
The verification of the accuracy of dose distributions delivered by modern radiotherapy 
techniques presents a significant challenge. For both IMRT and VMAT, fields are 
composed of many subfields of complex MLC shapes. The accuracy of dose delivery 
depends critically on accuracy of MLC position. For fields with small MLC gaps, sub-
mm errors in MLC cause large dose errors of several percent [6].  A comprehensive 
commissioning programme for modulated radiotherapy techniques was recommended 
following a multi-centre audit of IMRT dosimetry carried out in the United States [7]. 
Dosimetric measurements were carried out in an anthropomorphic phantom and 
demonstrated that approximately one-third of irradiations failed to meet the wide 
criteria that were set of 7% dose agreement and 4mm distance to agreement between 
measurement and stated dose. A lack of a cohesive approach for the quality assessment 
of complex radiotherapy technologies was highlighted [8].  
There are two options for the verification of the dose calculated by the treatment 
planning system; a dosimetric measurement or an independent dose calculation. In 
3DCRT, a second check of the planned dose carried out by hand using basic beam data, 
or using simple spread sheets is reasonably straightforward. For IMRT and VMAT 
there is no simple relationship between the machine settings and dose to a point within 
the field. The dose to a single point cannot easily be calculated by hand from tables of 
basic beam data. In addition, the dose varies in 3D, therefore checking the dose 
accuracy at a single point is no longer adequate. Dose distributions incorporate high 
dose gradients which present additional challenges. More complex secondary dose 
calculation programmes exist, for example based on Monte Carlo calculation methods 
which can carry out a 3D independent dose calculation. However, this only checks part 
of the process, the TPS calculation, whereas the accuracy of dose delivery can depend 
critically on multileaf collimator leaf speed and position. Therefore any QA and 
commissioning programme must also test treatment delivery as well as calculation.  
It was proposed that with the introduction of IMRT there should be a change in the type 
of verification carried out [9]. Rather than separately verifying the correct functioning 
of all the different hardware and software components of IMRT (and now VMAT) 
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delivery, it was recommended to assesses the overall accuracy and reproducibility of 
each IMRT technique. This should be a measurement in a phantom of the dose 
delivered. A radiation detector is positioned within a phantom and used to measure the 
dose delivered by the IMRT or VMAT plan. The dose distribution is also recalculated 
on the phantom within the treatment planning system and measured and calculated 
doses are then compared. A comprehensive QA programme for IMRT should include 
the initial commissioning of any software and delivery equipment, ongoing routine 
quality control and checks on the accuracy of calculation on a per-patient basis [9, 10].  
A range of radiation detectors has been used for VMAT and IMRT dosimetry within 
clinical radiotherapy departments, the most common of which are described in the next 
sections. 
1.2.2 A note regarding absolute and relative dosimetry 
Reference is made in radiotherapy to relative and absolute dose measurements. Relative 
dose measurements are measurements which are normalised in some way. This might 
be at a point in the distribution or 1D scan, an example being normalising a depth dose 
curve to the point of dose maximum to give a percentage depth dose curve. With regard 
to the comparison of two dose distributions, this would be called a relative dose 
comparison if both distributions were normalised to the same point and distributions 
then presented as percentage values. This has commonly been carried out for IMRT and 
VMAT 2D dosimetry, for example with radiographic film in a US dose audit [7]. 
According to Low et al [10], “Absolute dosimeters are defined … as those whose 
results, for absorbed dose to water, require no adjustment or renormalization other than 
those done in accordance with the established dosimetry protocols”. The example given 
is of a small volume ionisation chamber being cross-calibrated against an ionisation 
chamber which has a calibration traceable to a national standards laboratory.  
For IMRT and VMAT dosimetry where the aim is to verify the accuracy of the dose 
predicted by the treatment planning system, it is standard practice to exclude any 
variation in linac output (calibration dose) which might vary by up to ± 2%. This is 
accomplished by performing a calibration reading in an open field (e.g. 1010cm2) and 
correcting for detector response according to the expected dose rather than the actual 
dose (e.g. as measured by a Farmer ionisation chamber). Results are still presented as 
 22 
absolute dose (i.e. in Gy). Commercial software tools for dose distribution analysis, 
such as OmniPro I’mRT used in this project, describe absolute dose in this way. Unless 
stated, this is the definition of absolute dosimetry used in this dissertation.   
1.2.3 Point detectors 
Cylindrical ionisation chambers are the gold standard detector used in clinical 
radiotherapy. Their dose response is traceable to national primary standard detectors at 
the National Physical Laboratory according to UK dosimetry codes of practice [4].  
Cylindrical ionisation chambers are used to calibrate the output of linacs and carry out 
many quality control tests. Their use is limited for IMRT techniques as they measure 
dose at a single point and are in general too large for measurement in particularly high 
dose gradients. However, small volume PinPoint ion chambers are often used in 
conjunction with film measurements whereby the ion chamber measures absolute dose 
at a point and the film gives spatial dose information in 2D.   
1.2.4 Radiochromic film 
Radiochromic film consists of a layer of radiation-sensitive dye on a thin polyester base. 
When irradiated, a colour change is induced and the optical density is related to the 
radiation dose. The film may be readout using a flatbed scanner; it is self-developing i.e. 
no processing is required unlike previously used radiographic film. The most commonly 
used types are GafChromic
TM
 EBT2 and EBT3 (Ashland, Bridgewater, NJ, USA).  The 
optical density-dose response must be characterised by irradiating areas to known doses 
and plotting the calibration curve. Film dosimetry has the advantage of providing a sub-
mm resolution dose information across a 2D plane.  
1.2.5 Electronic portal imaging device 
The electronic portal imaging device (EPID) is mounted on an arm attached the linac 
gantry and allows an amorphous silicon panel to be positioned behind the patient in line 
with the radiation beam. EPIDs were originally designed to acquire MV photon images 
of the beam portal just prior to or during radiotherapy treatment to verify patient 
position. EPID detectors consist of a thin copper layer and a scintillator to create 
photons which are detected by photodiode and electronics.  
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EPIDs may also be used for radiation dosimetry. Used in integrating mode, they can 
capture the whole dose information for a dynamic radiation field. They have been used 
for various applications including routine linac QC, pre-treatment verification of 
modulated radiotherapy plans and as an in-vivo dosimeter by making measurement 
during treatment i.e. with patient in situ (known as transit dosimetry). In terms of 
dosimetric tool for pre-treatment QC, the dose measured at the panel can be compared 
with a prediction of dose to this plane, or the EPID measurement can be used to infer 
the dose within the patient. The latter method results in a 3D distribution, however, 
software reconstruction is required are required to predict the dose within the patient or 
phantom. 
1.2.6 2D and pseudo-3D detector arrays 
There exists a range of 2D and quasi-3D electronic detector arrays. These were 
introduced to streamline routine linac IMRT and VMAT QC and pre-treatment patient 
specific verification. 2D devices consist of a 2D array of ion chambers or diodes 
arranged within a flat panel that can be placed on the couch, held in a mount attached to 
the linac gantry or positioned within a phantom. Examples include the I’mRT MatriXX 
(IBA Dosimetry, Bartlett, TN, USA), an array of 1020 ion chambers with 8mm spacing 
and the MapCheck (Sun Nuclear Corporation, Melbourne, FL), an array of 1527 
semiconductor diode detectors with 7mm spacing. They are best suited to the 
measurement of individual IMRT fields with the device perpendicular to the beam; a 
large angular dependence makes the measurement of VMAT plans difficult with 
corrections required for non-perpendicular beam angles. 
For VMAT, measurement of whole plan is more appropriate therefore different types of 
pseudo-3D arrays have been developed. These include the ArcCheck (Sun Nuclear 
Corporation, Melbourne, FL), where 1386 diode detectors with 1cm spacing are 
arranged in an arc geometry and the Delta4 (Scandidos, Uppsala, Sweden) where 1069 
diode detectors with minimum 5mm spacing are arranged in a cross.   
A selection of the devices currently used for radiation dosimetry at St. Bartholomew’s 
Hospital is shown in Figure 1.5. 
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Figure 1.5: Dosimetric devices currently used at St. Bartholomew’s Hospital for 
IMRT, VMAT and stereotactic dose measurements: (a) PinPoint chamber, (b) 
Radiochromic film, (c) EPID, (d) MatriXX 2D array, (e) MapCheck 2D array, (f) 
ArcCheck 3D array. 
 
1.2.7 Gamma analysis 
Gamma evaluation is very widely used in radiotherapy and allows the comparison of 
measured and calculated IMRT and VMAT dose distributions in terms of both dose 
difference and distance to agreement. Measured distribution may be via EPID, 2D or 3D 
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detector array or radiochromic film and is compared with the dose calculated by the 
treatment planning system. Dose difference is suitable in a low dose gradient region, but 
inadequate in high dose gradients where small spatial shifts result in large dose 
differences. In steep dose gradients, the distance to agreement (DTA) is more 
appropriate. Therefore, the gamma method was introduced to combine both [11, 12]. 
For each pixel or measurement point, the calculated gamma value gives a measure of 
disagreement which may be plotted on a 2D map.  
For a point lying on the reference distribution, usually the measured dose plane, the 
compared distribution needs to contain at least one point for which the gamma value is 
less than 1 i.e. 
       
Equation 1.1 
 
where is a set tolerance for DTA and is a set tolerance for dose difference, ∆𝑟 
is the distance between the reference and compared point and ∆𝐷 is the difference in 
dose. The gamma value is calculated for each point in the reference distribution and the 
presented gamma for that point is the minimum value. The ∆𝑑𝑀 and ∆𝐷𝑀 criteria form 
an acceptance ellipsoid around the reference point. If an evaluated point it located 
within this surface then the reference point will pass as the gamma value is less than 1. 
Tolerances are set for combinations of dose difference and distance to agreement and 
results are commonly presented as the percentage of measured points which pass the 
gamma test .  
1.2.8 Limitations of current systems.  
As discussed in section 1.2.1, a comprehensive programme of QA measurements is 
required for the accurate delivery and verification of IMRT and VMAT radiotherapy, 
including:  
 Definitive dose calibration of a linear accelerator 
 Collection of beam data for input into the treatment planning system, in 
order to optimise the beam model e.g. depth dose curves, beam profiles and 
field size factors 
 Verification of the accuracy of the treatment planning software 

dM
2

DM
2
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 Routine QA measurements of delivery equipment 
 Patient specific quality control measurements whereby the TPS calculated 
dose is verified on a per-patient basis 
 In-vivo dosimetry whereby dose measurements are carried out during 
treatment  
 Full 3D verification of the entire planning and delivery chain 
 Dosimetric audits in an anthropomorphic phantom 
 4D measurements for respiratory motion.  
These different measurements have different detector requirements and therefore each 
radiotherapy department has a range of detectors available. This was presented as 
different levels of dosimetry from Level 1 involving high accuracy ionisation chamber 
measurements for the definitive calibration of radiotherapy beams, to Level 4 the full 
3D dosimetric verification of the entire planning and delivery chain for which a 
multidimensional measurement is required (at least 2D) [9, 13].  
Many of the measurements listed above can be adequately carried out with the detectors 
already in use in radiotherapy and described in the sections 1.2.3 to 1.2.6. For example, 
the collection of beam data for input into the TPS involves scanning in 1D, for which 
small volume ion chambers and diodes are suitable. Patient specific QC is carried out as 
a check of accuracy for every patient plan prior to the start of treatment. Fast, 
streamlined measurements with immediately available results are prioritised at the 
expense of detector resolution and this is reasonable as it is a check of an already 
commissioned technique. Therefore, the pseudo 3D electronic arrays or EPID based 
methods are suitable. A currently active area of research is investigating the use of the 
EPID to make dose measurements during treatment for in-vivo dosimetry (known as 
transit dosimetry).  
However, for the commissioning of new IMRT and VMAT delivery technology, 
treatment planning software and new classes of treatment, a high resolution 3D 
measurement in a phantom is recommended in published guidance [9, 10]. A high 
resolution measurement is particularly important at the commissioning stage to identify 
any issues, for example with the beam model or MLC leaf model in the treatment 
planning system, with the 3D dose calculation algorithms or with the MLC calibration 
and performance of the MLC and other components of the treatment machine. A 
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measurement of the full 3D distribution would increase the confidence in the accuracy 
of radiation dose delivery, and potentially allow treatment margins to be reduced or 
doses to be escalated. The ability to position a 3D detector within geometric and patient 
representative phantoms would provide the ability to carry out an end-to-end test of the 
entire planning and delivery chain.  Despite their individual benefits, for all the 
detectors in current use, none offer the true 3D dose measurement required for 
technique commissioning. In all cases the 3D dose distribution is only sampled at 
discrete points or across 2D planes. This prompted a search for a high resolution 3D 
detector.  
1.3 3D chemical dosimetry 
In principle, this 3D measurement can be carried out using chemical dosimetry which is 
based on the quantification of the extent of a chemical reaction induced by ionising 
radiation. For 3D measurements, chemicals are embedded within a solid structure such 
as a gelatine matrix. Various 3D chemical detectors have been developed including 
Fricke gels, polymer gels and PRESAGE
TM
. Once irradiated, the detector is read out 
with a 3D imaging tool to enable quantification of the 3D dose distribution. This has 
most commonly been accomplished using magnetic resonance imaging or optical-CT 
imaging.  
1.3.1 Types of 3D chemical detector 
Fricke gel dosimetry was proposed in 1984 [14] and is based on the radiation-induced 
oxidation of ferrous ions (Fe
2+
) to ferric ions (Fe
3+
). Ferrous ions are present in the form 
of ferrous ammonium sulphate which in solution form has been used as a radiation 
detector for many decades [15]. When mixed with gelatine or agarose, the spatial dose 
information is preserved. The change in the relative concentration of ferrous and ferric 
ions was shown to alter the T1 and T2 relaxation times enabling 3D quantification of the 
measured dose distribution using magnetic resonance imaging (MRI) [16-20]. The 
radiation also induces a change in optical density, therefore others have investigated the 
use of optical-CT scanners to readout irradiated detectors [21-28]. The benefits of 
Fricke gel dosimetry are that it is based on a well-established dosimetry technique, low 
toxicity chemicals are used and the manufacture process is straightforward requiring 
only simple laboratory facilities. However, a post-irradiation diffusion of ferric ions has 
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been reported [17, 22, 25, 29-33] which causes a blurring of the measured dose 
distribution over time.  
Focus then moved onto polymer gel dosimetry which is based on the radiation-induced 
polymerisation of monomers [34, 35]. The amount of polymerisation, related to the 
radiation dose, is quantified using MRI [35] or optical-CT [36]. Polyacrylamide gels or 
“PAGs” use acrylamide as the monomer [34, 35] but must be manufactured under a 
nitrogen atmosphere in order to eliminate oxygen which otherwise inhibits 
polymerisation. Oxygen must be bubbled through the mixture for several hours during 
manufacture. Other monomers have been evaluated [37]. Normoxic gels overcome this 
limitation by employing antioxidants to scavenge the oxygen allowing gel manufacture 
under normal atmospheric conditions [38]. The use of toxic chemicals, requiring more 
sophisticated lab facilities, is a disadvantage of polymer gel detectors versus Fricke 
gels. In addition, it has been shown that some polymer gel compositions suffer from 
poor inter-sample variation [39], volume dependence [40], and variation in response due 
to integration of radiation dose [41]. Despite much research effort over many years, it 
was recently acknowledged that polymer gel dosimetry is still largely restricted to 
research departments [42].  
Radiochromic dosimeters which attenuate light by absorption have also been proposed. 
PRESAGE
TM
 is a solid polyurethane based plastic material doped with a radiochromic 
leuco dye [43-46]. Ionising radiation causes a colour and therefore optical density 
change which is quantified using optical-CT. It has been reported that this detector 
offers low diffusion post-irradiation compared with gel based compositions [43]. Initial 
studies aimed to characterise some of the dosimetric properties of this detector [44-46]. 
Feasibility studies investigated the use of PRESAGE
TM
 and optical-CT for the 
measurement of small field commissioning data [47] and to measure clinical dose 
distributions within a thorax phantom [48]. However, at the outset of our project, it was 
not readily commercially available nor is it straightforward to manufacture. In addition, 
this detector may only be analysed using an optical-CT scanner, which must also be 
purchased specifically. 
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1.3.2 Imaging systems used for 3D dosimetry read out 
Various methods of 3D imaging have been proposed to quantify in 3D the measured 
dose distribution including MRI [16, 35], optical-CT [23, 36], X-ray CT [49, 50] and 
ultrasound [51]. Of these, the best results have been obtained with MRI and Optical-CT. 
MRI has been used to quantify the delivered dose distribution for both Fricke gel 
dosimetry [14, 16, 18, 52] and polymer gel dosimetry [35, 53, 54]. The analysis method 
is based on a radiation-induced change in the T1 or T2 relaxation times, which will be 
described further in chapter 3. For Fricke gel dosimetry, this change is due to the 
different concentrations of ferrous and ferric ions which are paramagnetic. For polymer 
gel dosimetry, the change is due to the effect of polymerisation on the relaxation time, 
most commonly the T2. The advantage of MRI is that it is a well-established clinical 
imaging modality, with scanners already located within hospitals. However, access to 
them for research purposes can be limited as they carry a heavy clinical workload.  
Optical-CT scanners have been developed for the analysis of 3D chemical detectors [21, 
22, 36, 55, 56]. This is similar in concept to conventional X-ray CT, although visible 
light rather than X-ray radiation is transmitted through the material and detected. Image 
contrast is formed due to light absorption by Fricke detectors, and light scattering by 
polymer gel detectors. The detector, for example a charge coupled device CCD camera, 
rotates to allow the acquisition of a series of image projections at different angles which 
are reconstructed to form the 3D image [55, 56]. Most recent scanners use either a 
parallel beam [56] or cone beam configuration [55, 57]. It is claimed that although cone 
beam systems are less expensive they suffer issues due to stray light artefacts [58], 
whereas parallel beam systems are more costly. 
Optical-CT scanners must be purchased or designed specifically for gel applications. An 
optical-CT scanner would represent an additional investment for a clinical radiotherapy 
department for use specifically for 3D dosimetry, therefore this technology has thus far 
been limited to select research groups [59]. In any case, there are few scanners 
commercially available. 
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1.3.3 Current status 
A large amount of research over many years has focused on chemical composition, gel 
manufacture and imaging analysis however 3D chemical dosimetry has yet to be 
implemented as a routine dosimetric tool in clinical radiotherapy. This was the case at 
the start of this project and is still true now. A recently published text book focuses on 
3D dosimetry, highlighting the importance still placed on finding a suitable system for 
modern dosimetry [58]. Two chapters are dedicated to 3D chemical dosimetry; 
however, it was acknowledged that chemical dosimetry is still largely limited to 
academic centres. This has been attributed to factors including the need for toxic 
chemicals, sophisticated laboratory facilities and access to expensive or bespoke 
scanners [42]. In addition, it was suggested that a factor for the slow uptake of chemical 
dosimetry within clinical radiotherapy departments is due to a lack of confidence in the 
reliability of these detectors.  
The accuracy of measurement of any radiation detector must first be established before 
it is used to measure unknown radiation distributions. Without a quantified 
measurement uncertainty, the level to which the detector can be trusted for 
measurements in complex dose distributions is not known and it is impossible to 
identify the cause of any discrepancies between the measured and planned dose 
distributions.  
There is a variation in the methods and criteria previously used in the literature to 
evaluate 3D chemical dosimeters and compare different chemical compositions. Many 
authors have made comparisons of the detector sensitivity via the dose-response curve 
[25-27, 38, 60]. Publications describing dosimetric characteristics of 3D detectors have 
used a variety of factors such as variation in response with energy [61], dose rate [62] 
and error due to the calibration methodology [63, 64]. These individual factors are all 
relevant, but do not fully predict the overall performance of the detector-imaging 
system. A systematic method for testing new 3D chemical detectors is required for the 
widespread implementation of 3D chemical dosimetry in clinical radiotherapy.  
1.4 Project aims 
The aim of this project is to address these issues and develop a 3D gel detector that is 
simple to manufacture and use in a clinical radiotherapy department, that operates over 
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a clinically relevant dose range and has a proven dosimetric performance with 
quantified measurement uncertainties.  
The dosimetric characteristics of the selected detector will be systematically evaluated 
over two dose ranges of clinical relevance: 0 to 3Gy relevant to conventional 
fractionation schemes and 5 to 20Gy for high dose per fraction stereotactic techniques.  
An emphasis will be placed on the evaluation of the basic dosimetric performance and 
quantification of measurement uncertainties. A logical and practical method for the 
testing of new 3D chemical detectors will be developed.  
1.5 Thesis scope 
This thesis is written by a radiotherapy physicist and prompted by difficulties 
encountered in verifying the accuracy of complex radiation distributions in clinical 
practice. It follows on from previous work by this research group, investigating a 
commercially available polymer gel detector which highlighted substantial uncertainties 
in the accurate measurement of radiation doses even in simple radiation fields [39, 40].   
It was therefore decided to investigate a detector that could be manufactured in-house 
within a clinical radiotherapy department. We set requirements that the detector should 
be simple to manufacture with only basic laboratory facilities and that the irradiated 
detector should be readout using existing imaging equipment available within our 
hospital.  Of the available detector types and readout methods, Fricke gels and MRI best 
fulfil these requirements and were therefore selected for this work. Fricke gel detectors 
involve only low toxicity chemicals and require very basic laboratory facilities, 
therefore could be manufactured in a simple lab within the radiotherapy physics 
department at St. Bartholomew’s Hospital. Clinical MRI scanners are located in the 
same building.  
Once manufacture and readout methods were established, our Fricke-MR system was 
fully commissioned as if it was a commercial product and we were the end user before 
application to complex VMAT distributions. 
1.6 Thesis structure 
This thesis is organised into 7 chapters. Chapter 2 contains a more detailed overview of 
Fricke gel detectors including a structured literature review of previous work carried out 
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on the dosimetric characterisation of Fricke gel detectors. This review highlighted areas 
with little evidence, and a lack of systematic approach to testing 3D chemical detectors, 
particularly under clinically relevant irradiation conditions.  
Within chapter 3, methods for the manufacture of a Fricke gel detector are described. A 
literature review was carried out to identify a starting point for the detector composition 
used in this project. An overview of the MR theory relevant to the readout of Fricke gel 
detectors is presented. MR scan and measurement protocols were developed for an 
NMR spectrometer and a whole-body MRI scanner.   
The experimental work is described in the following chapters. Detector characteristics 
were systematically investigated with increasingly complex dose distributions. Chapter 
4 describes measurements in simple radiation fields, where small volume detectors were 
irradiated to known doses to establish basic detector characteristics of inter-sample 
variation, chemical stability, dose rate and energy dependence. Test tube samples were 
irradiated and read out with a bench-top NMR scanner. Experiments on large detector 
volumes were then carried out, analysed with the MRI scanner, and are the subject of 
chapter 5. The homogeneity of response and variation with detector volume were 
investigated as well as the post-irradiation diffusion of ferric ions.  
Calibration methods were then established. The optimised detector-imaging system was 
then finally used to measure the delivered dose for simple and complex VMAT 
treatment plans, described in chapter 6. The project is summed up, including 
recommendations for future work, in chapter 7.  
1.7 Statement of originality 
A large body of work already exists on the subject of 3D chemical dosimetry and it is 
reviewed in chapter 2. However, the work previously carried out has largely been 
concentrated in research laboratories and much of it has focused on the customisation of 
the chemistry of the detectors, detector manufacture and imaging protocols. There has 
been a lack of structured approach to the testing of the final customised detector and 
imaging system, as would be normally carried out for any other radiation detector. This 
was recently acknowledged by key researchers in the field of 3D chemical dosimetry. In 
a recently published textbook on 3D dosimetry, it was commented in regards to polymer 
gel dosimetry that “A major obstacle that has hindered the wider dissemination of 
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polymer gel dosimetry in radiotherapy centers is a lack of confidence in the reliability 
of the measured dose distribution” [42]. A further analysis of the reasons behind the 
slow uptake of this dosimetry technique by clinical radiotherapy departments was 
presented [65]. Here it was stated that “Despite significant progress in the capability of 
multi-dimensional dosimetry systems, it is striking that true 3D dosimetry systems are 
today largely found in academic institutions or specialist clinics” and “the goal of 
widespread clinical implementation remains elusive”. In terms of proposed reasons, the 
authors highlighted issues including the requirement for substantial expertise for 
particular detector systems, that some systems exhibit dosimetric issues including with 
sensitivity and stability and that there are issues with the economics and practicality of 
techniques in non-research settings.  
The work presented within this thesis aims to address these concerns by (1) the 
selection and customisation of a detector-imaging system with focus on implementation 
within a clinical radiotherapy department and (2) a full and structured quantitative 
dosimetric characterisation of the detector before applying the detector to complex 
clinical techniques. In contrast to the previous approaches, the detector system was fully 
commissioned using the same approach that would be applied to a commercial detector 
system. 
Regarding the expertise necessary to implement 3D chemical dosimetry within a 
clinical radiotherapy department, in this project primary considerations when selecting a 
detector and imaging method were the ease of detector manufacture, toxicity of 
chemicals, cost and the local availability of scanners. This is discussed in chapter 3 
which describes the development of imaging processes and detector manufacture with a 
very strong focus on applicability and use within a clinical radiotherapy department.  
The main area of novelty was the definition at the outset of quantified dosimetric 
requirements of a 3D detector and the development of a structured plan to evaluate the 
dosimetric uncertainty of the detector. For other detector types, such as radiochromic 
film, there exists published guidance for their implementation and commissioning [66]. 
There is currently not a similar guide for 3D chemical dosimetry. To address this an 
analysis of the entire detector-imaging process was first carried out in order to identify 
the factors which should be investigated to quantify the uncertainty for 3D chemical 
dosimetry (chapter 2).  
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A review of the existing literature on Fricke gel dosimetry was then carried out which 
highlighted major areas with lack of evidence and an unstructured approach to detector 
characterisation. Therefore, the aim of the first sets of experiments of this project was to 
fill in these gaps in evidence by undertaking measurements to quantify dosimetric 
uncertainties for this detector. This systematic characterisation for one particular 
detector and imaging combination has not been presented previously in the literature. 
As outlined in section 1.2.8, the intended application of 3D dosimetry not currently 
fulfilled by existing dosimetric devices is a high resolution measurement of 3D dose 
distributions delivered by modulated radiotherapy techniques to a water equivalent, or 
patient mimicking, phantom during the commissioning stage of new technology, 
software or for classes of treatment. The final experimental chapter described the use of 
Fricke gel detectors to measure high dose per fraction VMAT plans and quantitatively 
compared results versus the treatment planning system. Again, because of the 
previously documented large range of chemical formulations proposed for chemical 
dosimetry, there is sparse evidence in the literature for Fricke gel measurements of 
VMAT plans. The measurement of complex VMAT plans with a fully commissioned 
Fricke gel-MR system has not been previously reported.  
Results from this project have been presented at the UK Biennial Radiotherapy Meeting 
of the Institute of Physics and Engineering in Medicine (IPEM):  
2010: The dosimetric characterisation of 3D chemical detectors (a literature review) 
2018: The dosimetric characterisation of an in-house method for Fricke gel dosimetry 
applied to the verification of stereotactic VMAT plans 
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Chapter 2. The dosimetric characterisation of Fricke 
gel detectors: a review of the literature 
2.1 Introduction 
2.1.1 Aims of this chapter 
An important part of the commissioning process for any radiation detector is an 
investigation into each of the factors which might affect its measurement uncertainty. 
According to the National Institute of Standards and Technology (NIST): “a 
measurement is only complete when it is accompanied by a quantitative statement of its 
uncertainty” [67]. There are many potential sources of uncertainty for radiation 
detectors used in radiotherapy dosimetry, such as dependence of response on radiation 
energy, dose rate, temporal and spatial instability and angular dependence [68, 69]. 
These factors are specific to each detector type and depend on the construction, 
geometry and operation of the detector. As highlighted in chapter 1, and previously 
discussed in the literature, an important reason for the slow uptake of 3D chemical 
dosimetry by clinical radiotherapy departments is a lack of confidence with their 
dosimetric performance. The aim of this chapter is to outline the potential sources of 
uncertainty for Fricke gel dosimetry, review the literature in terms of existing evidence 
and identify gaps. From this, a plan will be developed to quantify the dosimetric 
characteristics of a Fricke gel detector.  
Before this can be carried out, the general requirements of a detector for the 3D 
measurement of complex radiotherapy distributions should be defined. As discussed in 
chapter 1, detector requirements depend on the intended application of the detector. The 
aim of this project is to implement a method for high resolution dosimetry as part of the 
pre-clinical commissioning of VMAT radiotherapy, for which it is recommended that a 
high resolution 3D dose measurement is carried out [9]. This should be a direct 
measurement of dose in a phantom, not requiring software back projection methods to 
predict dose to the phantom. The first basic requirements are therefore a 3D 
measurement and that this should be a direct dose measurement in a phantom.  
The dosimetric and geometric uncertainty need to be adequate for the intended 
measurement and this needs to be quantified. When comparing measured to calculated 
dose distributions, any deviation between the two distributions has several potential 
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causes; uncertainty with the delivery of radiation, uncertainty with the dose calculation, 
or uncertainty connected to the measurement device itself. International guidance 
documents were reviewed with the aim of setting a tolerance for dosimetric uncertainty 
of a 3D measurement detector [9, 58, 70, 71]. These reports discuss the subject of 
uncertainty in radiotherapy in depth but, even in the more recent documents, a clear 
statement of uncertainty required of a 3D dosimeter is lacking. This is partly due to 
there being different dosimetric requirements for different types of radiotherapy 
treatment for example high dose per fraction stereotactic techniques versus conventional 
fractionations or palliative radiotherapy. There are also different requirements for 
different regions within one dose distribution; high dose, high dose gradient and low 
dose regions which will be discussed more fully subsequently [9, 70].  
A comprehensive report was recently published by the International Atomic Energy 
Agency (IAEA) regarding uncertainty in radiotherapy [70]. The impact of dose 
uncertainties with radiotherapy delivery on radiobiological outcomes (NTCP and TCP) 
were considered. Based on this analysis, it was recommended to aim for systematic 
uncertainties in radiotherapy delivery within 1-2% and random uncertainties within 3-
5%. The main focus of the remainder of this report was on what level of accuracy is 
currently achievable in clinical practice. The many various sources of uncertainty in the 
calculation and delivery of radiotherapy were considered for example (but not limited 
to) processes for dose calibration, QC, imaging and outlining of the target volumes and 
critical structures. Of relevance to this project, the uncertainty associated with treatment 
planning systems was split into different regions of the dose distribution;  high dose, 
low gradient (2%),  high dose gradient (2 to 4mm) and low dose, low gradient (3 to 
5%). For the end to end measurement of dose verification in a phantom, incorporating 
errors in calculation and delivery, the suggested tolerance was 3 to 10% or 2mm.  
According to Ahmed et al [72], there is a dilemma regarding IMRT dosimetry in that 
the uncertainty of the detectors used to perform dosimetric measurements is of the same 
order of magnitude as the desired uncertainty in the delivered dose, rather than an order 
of magnitude smaller as usually required for metrology. An ideal detector would have a 
dosimetric uncertainty of much less than 1%, and it will be seen in the next paragraphs 
that this is not achieved by any detector offering spatial information of dose 
distributions. It was presented in another way, that one of the factors limiting overall 
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accuracy in radiotherapy is the limit to the measurement accuracy practically achievable 
using today’s instrumentation [58]. 
Requirements for the geometric uncertainty again depend on the specific technique. At 
St. Bartholomew’s Hospital, the distance to agreement criteria when comparing 
measured to calculated distributions is set at 1mm for stereotactic radiotherapy and 2-3 
mm for standard dose per fraction VMAT in agreement with other published dose audits 
[73-75]. Therefore, it might be desirable to set a sub-mm limit for the geometric 
uncertainty for the detector and scanner combination. For 3D chemical dosimetry, it is 
the scanner resolution that determines the geometric uncertainty. However, there is an 
inherent compromise between dosimetric uncertainty and scan resolution, as highlighted 
previously specifically for 3D chemical dosimetry [76]. These authors proposed a 
tolerance of 1mm for the spatial resolution of this dosimetry system.  
An ideal detector might have a tolerance of < 1% for dosimetric uncertainty depending 
on the treatment technique under investigation, however it will be seen that this is not 
achieved by the detectors currently used for 2D or pseudo-3D dosimetry. It would 
therefore be reasonable to set aims for 3D dosimetry based on an assessment of 
dosimetric and geometric uncertainty achieved for 2D detectors currently used for 
IMRT and VMAT dosimetry. The performance of typical detectors currently used for 
IMRT, VMAT and stereotactic dosimetry were therefore reviewed and this is presented 
in table 2.1. There is a wide range of detectors used within radiotherapy for IMRT 
dosimetry and for each type of detector a variety of different models, geometry 
construction and measurement methodology. Presented are the detectors currently in use 
at St. Bartholomew’s Hospital for VMAT and stereotactic radiotherapy dosimetry 
which are representative of the detectors used by a typical clinical radiotherapy 
department. Many sources of uncertainty potentially contribute to the overall detector 
uncertainty. These are specific to each different detector; significant effects are 
summarised in table 2.1. The overall dosimetric performance figures in this table were 
extracted from a reference text book [58] and key publications; for the PinPoint 
chamber [77, 78], radiochromic film [79-81], Varian EPID [82, 83].  
It can be clearly seen that none of the detectors in current use comply with the basic 
requirement of a true 3D dose measurement. Ionisation chambers are considered the 
“gold standard” detector in radiotherapy in terms of accuracy and precision. However, 
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they only measure at a single point and are too large, even the small volume PinPoint 
detector presented here. The EPID does not offer a direct measurement of dose, 
requiring software to reconstruct the dose back onto a phantom or the patient. The 
measurement resolution of the ArcCheck does not fulfill requirements, with the detector 
spacing greater than 0.5cm. 2D radiochromic film is commonly used for the verification 
of dose distributions for VMAT and IMRT. Although only 2D, it is high resolution and 
potentially could be used to evaluate multiple planes. However, each film measurement 
requires a repeated plan irradiation and phantoms can normally only accommodate the 
film in a particular orientation. There is a practical limit therefore to the number of dose 
planes assessed. In terms of the dosimetric accuracy, the 2D detectors presented in table 
2.1 have a typical range of up to 3%. It is therefore common to combine measurements 
that offer spatial dose information, for example radiographic and radiochromic film 
with a point dose measurement, for example with an ionisation chamber [7, 74, 84].  
3D chemical dosimetry complies with the requirement to directly measure a 3D dose 
distribution in a range of phantoms and has the potential to offer a high resolution 
measurement. Considering all the factors outlined in this section regarding ideal and 
realistic dosimetric uncertainty, in this project it will be attempted to maintain 
dosimetric uncertainty for the detector measurement within 3%, for an in-plane 
uncertainty of 1mm. If necessary, combining a 3D gel measurement with a more precise 
but single point dose measurement with an ionisation chamber would be a reasonable 
option similar to a common approach used for 2D dosimetry.  
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Table 2.1 Summary of characteristics for detectors currently used for VMAT dosimetry 
Characteristic  
PinPoint ion chamber 
(0.015cc) 
EBT3 GafChromic film 
(Radiochromic film)  
Varian EPID 
ArcCheck detector 
array 
3D measurement  No No No No 
Direct dose 
measurement 
 Yes Yes No 
Yes (not in high dose 
region. Entrance / 
exit dose measured) 
Absolute (Gy not %)  Yes 
Yes (only with strict 
irradiation and scanning 
protocols) 
Yes Yes 
Water/tissue equivalent  No Yes No No 
Geometric uncertainty  
Point dose 2mm 
diameter, 5mm length 
Depends on scanner 
resolution, typically 
~0.4× 0.4mm 
0.4×0.4mm, but 
mechanical sag 
1mm 
1cm detector spacing 
Dosimetric uncertainty 
Overall 
<1% repeatability but 
energy dependence 
(effect depends on 
field size) 
2-3% 1.5-3% 2-3% 
Notable 
sources of 
uncertainty 
Stem effects, energy 
dependence 
Film orientation & 
position, non-
uniformity, chemical 
instability 
Missing signal, 
back scatter, image 
ghosting, pixel-to-
pixel variation, 
energy dependence 
Energy dependence, 
angular dependence 
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2.1.2 Chapter overview 
The remainder of the chapter focuses on the dosimetric performance for a Fricke-MR 
detector system. A more detailed description of the Fricke gel detector is provided in 
section 2.2. The factors potentially affecting the measurement uncertainty for Fricke gel 
dosimetry were then identified. The whole Fricke gel process, from manufacture and 
irradiation to scanning and analysis, was considered to identify all sources of 
measurement uncertainty specifically for this measurement system. This is presented in 
section 2.3. The Fricke gel literature was then reviewed to identify publications which 
investigated each of these factors, for example variation in dose response with detector 
volume, radiation energy or chemical stability (section 2.4). Finally, the results of this 
structured review were used to develop an experimental plan for this project.  
2.2 Background into Fricke gel detectors 
Fricke gel dosimetry was introduced in chapter 1 and previous research has 
demonstrated sufficient promise with benefits such as simple manufacture to be selected 
for further investigation in this project. There follows a more detailed description of 
Fricke gel dosimetry.  
Fricke gel detectors are a type of chemical detector based on ferrous ammonium 
sulphate. Chemical detectors require a reaction to occur which causes a measurable 
change, for example colour or temperature. When water is irradiated, a series of 
reactions occur resulting in the production of free radicals. These free radicals react 
with the ferrous ions to produce ferric ions. There are a series of reactions, but 
simplified reactions for the three main reaction channels are given below.  
H2O
Ionising Radiation
→               eaq
− , HO•, H•, HO2
• , H3O
+, OH−, H2O2, H2 
The hydroxyl HO
•
 reacts with a ferrous ion to produce a ferric ion: 
Fe2+ + HO•  →  Fe3+  + HO− 
The hydrogen peroxide produces two ferric ions per molecule: 
Fe2+ + H2O2  →  Fe
3+ + HO• + HO− 
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and, Fe2+ +  HO• →  Fe3+ + HO−  
or in simplified form: 
2 Fe2+ + H2O2 →  2 Fe
3+ + 2 HO− 
Finally, the hydroperoxyl radical can react to create three ferric ions. This reaction 
channel can be simplified to: 
HO2
• +H+ + 3 Fe2+ → 3Fe3+ + 2HO− 
Both ferrous and ferric ions are paramagnetic species but with different relaxivities. 
Relaxivity is the degree to which the species enhances the MR longitudinal and 
transverse relaxation rates (R1 or R2). R1 and R2 are related to the concentration of 
ferrous and ferric ions and therefore, to the delivered radiation dose. The different 
concentrations of ferrous and ferric ions also affect the optical density of the sample, 
therefore delivered radiation dose may also be determined by quantifying the OD using 
optical methods. This was first made use of in Fricke solution dosimetry [15], a well-
established dosimetry technique, using spectrophotometer readout.  
The analysis of Fricke detectors using MRI was proposed by Gore et al [14]. The 
change in the relative concentration of ferrous and ferric ions was shown to alter the T1 
and T2 relaxation times. Fricke solution samples were irradiated and a linear 
relationship between R1 and radiation dose was demonstrated. It was then proposed that 
mixing the Fricke solution with a gelling agent such as gelatine or agarose would 
produce a solid 3D detector where radiation dose would be preserved in 3D. This was 
accomplished in the late 1980s [16, 85] and followed by many studies reporting the use 
of Fricke gel detectors with MRI for 3D radiotherapy dosimetry [17-20, 26, 29, 31, 86-
88]. Optical methods have also been used to read out irradiated Fricke gels [21-28].  
Many publications reported the investigation of different chemical compositions, such 
as varying concentrations of ferrous ammonium sulphate and sulphuric acid [28, 56, 89, 
90], gelling agents [17, 19, 23, 25, 91, 92] and the use of other components such as 
xylenol orange [22, 28, 31] and saccharides [27]. These will be reviewed in more detail 
in chapter 3 in order to identify an evidence based starting point for the detector 
composition used in this project. Many of these focussed on optimising the dose 
response (i.e. detector sensitivity) when comparing the different chemical compositions.  
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Researchers have applied Fricke gel detectors to a variety of clinical applications for 
example proton beams [93], neutron beams [94] and high dose rate brachytherapy [88, 
95]. In terms of external photon beams, Fricke gel detectors have been used to measure 
small radiation fields [96], MLC properties [97] and distributions delivered using 
stereotactic radiotherapy techniques e.g. Gamma Knife [98-100].  
Despite promising results, Fricke gel dosimetry is still not widely used in clinical 
radiotherapy departments. Prior to use as a dosimetry tool for the verification of these 
complex distributions, a systematic analysis of dose uncertainty is required. A summary 
of the literature on the dosimetric testing for Fricke gel detectors is the subject of the 
next section.  
2.3 A critical analysis of the Fricke gel measurement process. 
2.3.1 Overview 
It is necessary to commission any detector used for radiation dosimetry to establish its 
limitations in the measurement of radiation dose and determine the overall measurement 
uncertainty [68, 101]. Properties which dosimetrically characterise a general radiation 
dosimeter are described in these reference texts including precision, accuracy, energy 
dependence, dose rate dependence and chemical effects. These provide a starting point 
for the testing of 3D chemical detectors. However, sources of uncertainty are specific to 
each different type of detector and need to be identified for 3D chemical detectors. An 
AAPM report into the characterisation of radiochromic film, usefully lays out the 
different detector characteristics which should be considered for this 2D chemical 
detector [66]; no similar reference exists for 3D chemical dosimetry, however, concepts 
are similar therefore can be extended to 3D chemical detectors. Characteristics have 
been proposed for 3D polymer gel dosimetry [42] but key factors are absent for 
example detector homogeneity. 
To identify the factors which potentially affect the measurement accuracy specifically 
for 3D chemical detectors, dosimetric characteristics outlined in the text books and 
guidance documents referenced above were considered, along with an analysis of the  
entire measurement process as follows. 3D chemical detectors are manufactured in 
batches, either in-house or as commercial products. They are then stored prior to being 
irradiated with the proposed radiotherapy treatment plan. Additional calibration samples 
 43 
are irradiated with known radiation doses. The irradiated detector and calibration 
samples are then scanned with the optimised 3D imaging protocol. The dose response 
relationship is characterised by plotting signal versus dose for the calibration samples. 
This is used to convert image signal to measured dose distribution which may then be 
compared against the dose predicted by the treatment planning system using analysis 
software.  
Chemical detectors may be affected by the ambient conditions during storage and 
therefore the time between manufacture, irradiation and scanning; there may be spatial 
and dosimetric instability over time. The radiation dose rate and energy delivered at the 
detector may vary. The homogeneity of response across large volume 3D detectors also 
needs to be considered. As integrating detectors, another consideration is how they 
integrate the dose from multiple beams compared with an identical dose delivered in a 
single shot. These chemical detectors must be calibrated to convert imaging signal to 
dose. This is accomplished by irradiating additional samples to known doses and 
plotting their characteristic dose-response curve. The calibration process itself may 
introduce measurement uncertainties depending on the number and volume of samples 
used and curve fitting of the dose response relationship.    
A summary of these potential sources of measurement error for 3D chemical detectors 
is presented in Figure 2.1. A brief description of each is provided in the following 
section. Then the Fricke literature was then reviewed to identify publications addressing 
each of the factors in turn, described in section 2.4.   
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2.3.2 Scanner properties 
Variation in the imaging response across the scan volume arises from the random 
fluctuations in image intensity (image noise) and unwanted signals in the image (image 
artefacts). There is an inherent compromise between SNR, imaging time and resolution. 
A variation in response of repeated scans would contribute to the overall measurement 
uncertainty if calibration and experimental samples are scanned sequentially. 
2.3.3 Detector properties 
Inter-sample variation 
To characterise the dose response of chemical detectors, additional detector samples are 
typically irradiated to known radiation doses. It is common practice for experimental 
and calibration samples for a particular experiment to originate from the same batch. As 
such, the inter-sample variation is an important factor that should be evaluated. When 
evaluating the inter-sample variation, it is necessary to control all other potential 
contributions to measurement uncertainty. This is accomplished by irradiating samples 
 
Figure 2.1:  Summary of potential sources of error for 3D chemical detectors.  
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from the same batch at the same time, with identical radiation conditions and scanning 
all samples at the same time.  
Dose response 
The dose response i.e. the signal versus delivered dose has been commonly used to 
evaluate different 3D chemical detectors and to compare different chemical 
compositions. A steeper response allows greater differentiation between doses; 
uncertainties for example due to inter-sample variation will be magnified for detectors 
with a lower dose response. The shape of the dose response curve is also of interest. A 
linear response is not essential, but simplifies the calibration process requiring fewer 
dose points and therefore calibration samples to characterise the dose response.  
Chemical effects: dosimetric stability 
Chemical reactions may occur due to external factors other than irradiation, for example 
heat and light during storage. In addition, following irradiation chemical reactions may 
take some time to complete. The result of these effects is that the detector signal may 
vary depending on the length of time between manufacture and irradiation, and also the 
time between irradiation and scanning.  
Short term signal instability can introduce additional measurement uncertainties for 
long scanning or analysis sessions. It is important to quantify and minimise 
uncertainties by selecting an appropriate time within which to analyse irradiated 
detectors. Long term signal drift, or variation in response, might limit the shelf life of 
these detectors i.e. the time within which a detector should be used after manufacture.  
Spatial stability (post-irradiation diffusion) 
Any diffusion of ions throughout the gel matrix following irradiation would cause a 
blurring of the dose distribution increasing with time between irradiation and readout. If 
significant this would require the detector to be scanned within a set time of irradiation. 
It would be useful to define the time within which a detector should be scanned to fulfil 
pre-set tolerances on spatial accuracy.   
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Temperature during irradiation and scanning 
The temperature during irradiation can affect the response of detectors, so is a 
characteristic to be considered. However, if experimental and calibration samples are 
irradiated and scanned at the same time, any effect of irradiation or scanning 
temperature on measurement uncertainty should be minimal. In addition, altering the 
temperature of the detector during irradiation is a difficult task. This will not be 
considered further in this project, instead efforts made to control the room temperature 
during irradiation.   
Radiation energy 
A detector may over- or under-respond to different radiation energies if it lacks tissue 
equivalence i.e. if its effective atomic number is quite different to tissue (or water). 
Calibration samples are typically irradiated using a beam of the same radiation quality 
as the experimental sample. However, the radiation energy at the detector depends on 
both the energy set at the treatment machine and the local energy spectrum which is 
influenced by field size and beam modifiers. Energy dependence should be investigated 
over a sufficiently wide energy range for the intended clinical application.  
Dose rate 
Once again, where possible calibration and experimental samples are irradiated using 
the same dose rate set on the treatment machine. However, the set dose rate can vary 
considerably for some techniques such as VMAT and the dose rate deposited at the 
detector also depends on factors such as the distance from the source and beam 
modifying devices. Therefore, the dose rate dependence of 3D chemical detectors 
should also be considered.  
Dose fractionation 
The delivery of most radiotherapy techniques is via multiple treatment fields, rather 
than delivery the dose in a single shot. How a detector integrates the doses delivered in 
multiple sequential beams compared with a single shot is also a characteristic that 
should be investigated.  
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Homogeneity 
Ideally, a 3D detector should display a uniform response across its volume when 
irradiated to a uniform radiation dose. In practice, there may be variations in signal 
across chemical detectors due to detector manufacture and cooling processes. It might 
be possible to correct for any non-uniformity with a pre-irradiation background scan, 
although this adds an additional step in the overall measurement process.  
Volume 
A difference in thermal history and therefore dose response might also occur for 
chemical detectors of different volume and shape. This is particularly important if small 
volume samples are used to calibrate large volume experimental phantoms.  
Detector calibration 
Finally, the calibration process potentially introduces errors. The number of samples, 
number of dose points and volume of samples may affect the uncertainty of the 
measurement as well as the methods used to model the dose response curve. If 
calibration of the detector is carried out using additional samples irradiated to known 
doses, it is imperative to assess the inter sample variation in response. In addition, if 
these samples are of a different volume to the experimental sample, the volume 
dependence must be investigated. How the characteristic dose response curve is 
modelled also affects the dosimetric accuracy.  
2.4 Review of the literature on the dosimetric characteristics of 
Fricke gel detectors 
2.4.1 Introduction 
The Fricke gel literature was then reviewed against each of the detector characteristics 
outlined in the previous section. In this chapter, the focus was only on detector 
performance, as the scanner (MRI) performance is covered specifically in chapter 3.  
Any paper describing Fricke gel detectors was initially considered. Any detector 
composition was included that included at least ferrous ammonium sulphate in a gelling 
material. Papers were included which used both optical and MRI based methods. The 
body of Fricke gel literature was then searched to find evidence for investigation of 
 48 
each dosimetric characteristic in turn. Search tools including Medline and Google 
scholar were used and extensive cross checking of references was carried out, including 
use of Web of Knowledge.  
2.4.2 Literature analysis of detector characteristics 
2.4.2.1 Inter-sample variation 
A systematic review previously demonstrated a lack of evidence for the basic precision 
of 3D gel based detectors [102]. This was found to be the case again in this review. 
Only one paper was found which described the inter sample variation for Fricke gel 
detectors [103]. The standard deviation of the optical density of 10 samples was 
calculated for Fricke gel detectors both pre-irradiation, and following irradiation to 
10Gy using a Co
60
 source. The coefficient of variation was 3% for both unirradiated and 
irradiated gels.  
2.4.2.2 Dose response 
In contrast, many Fricke gel publications have presented the dose response for Fricke 
gel detectors [16, 23, 25, 28, 98]. Many studies have shown a linear dose response for 
doses greater than 20Gy [16, 18, 23, 25, 28, 98] which would cover the clinical range 
required for most radiotherapy techniques. However, others have shown a deviation 
from linear response beyond approximately 10-12Gy [91, 100, 104]. 
The dose sensitivity has been shown to vary depending on the chemical composition, 
for example ferrous ammonium sulphate concentration [24, 89, 90, 105], sulphuric acid 
concentration [18, 24, 28, 89, 90], gelling materials [16] and the addition of chelators 
such as xylenol orange [26, 27, 31, 32]. The impact of chemical composition on dose 
response will be discussed in greater detail in section 3.2.  
It also varies from batch to batch [92] and with storage time and ambient conditions, as 
will be described in the next section. It is therefore necessary to establish the dose 
response for each type of Fricke gel detector and also for each batch of detectors 
manufactured as part of the calibration process which will be described in further detail 
subsequently.  
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2.4.2.3 Chemical stability  
It has been reported in various publications that the optical density (OD) of unirradiated 
and irradiated Fricke gel detectors varies over time for detectors analysed using optical 
methods [22, 23, 25, 27, 28, 91, 92, 106]. This may be quantified by repeating 
measurements of unirradiated or irradiated Fricke gel detectors.   
An initial rapid increase following irradiation due to reaction completion [23, 28, 91, 
92] is followed by a slower increase in signal caused by reactions induced by factors 
other than radiation [22, 27, 28, 86, 92, 106]. A range of reaction completion times of 
10 -15 minutes [23, 91], up to 90 minutes [92] and 2 hours [28] have been reported. 
Waiting 1.5 to 2 hours to carry out the imaging of a detector might not be practical, 
particularly if there is a post-irradiation diffusion of ions that would require detectors to 
be scanned within a short time of irradiation.  
The longer term drift has been quantified and was shown to be approximately 1 to 2% 
per hour; for a ferrous benzoic acid XO gelatine gel (unirradiated and irradiated to 8Gy) 
[22] and for a ferrous xylenol orange gelatine (FXG) detector irradiated to 6Gy analysed 
with optical methods [23]. It has been shown to vary with chemical composition [27, 
28]. Storing detectors at lower temperatures (5 to 10
o
C) reduced the longer term drift in 
signal either pre- or post-irradiation [25, 92, 106], but it was not clear whether these 
samples were also in the dark when in the fridge. Effect of visible light has not been 
specifically investigated however studies where detectors were stored in the dark 
showed low drift of signal versus time [28, 107]. 
In summary, a range of reaction completion times has been previously shown up to 2 
hours and this should therefore be confirmed for the detector in our study. A longer 
term slow drift in signal of approximately 1-2% per hour has been shown to be reduced 
by storage in a refrigerator, however an investigation into the effect of ambient light 
would be a useful study.   
2.4.2.4 Spatial stability (diffusion of ferric ions) 
The post-irradiation diffusion of ferric ions has been widely reported [19, 22, 25, 29-33, 
87, 90, 108-110] which causes a blurring of the measured dose distribution over time. 
Much of the literature has concentrated on the determination of the diffusion coefficient 
for ferrous ions [29-32, 87, 90, 108-110]. Despite a variety of experimental methods 
employed, there is a reasonable agreement between the published diffusion coefficients. 
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The diffusion coefficient was between 1.0 and 1.9 mm
2 
h
-1
 for agarose based detectors 
(1 to 1.5% by weight, bw) [29, 30, 32, 90, 108] and 0.7 and 1.5 mm
2 
h
-1
 for gelatine 
based detectors (4 to 5% bw) [31, 32, 108]. It was shown that this diffusion coefficient 
may be reduced with the addition of xylenol orange [31, 32, 108, 110] or with an 
increase in gelatine concentration [31], however both these steps also cause a reduction 
in the MR dose response. One study showed relatively low diffusion coefficients for 
gelatine based detectors which had been stored at a temperature of 10
o
C [31].  
According to Tseng 2002 (and is logical) “despite good agreement in the measured 
ferric ion diffusion coefficients, it remains unclear in what time scale the degradation of 
initial dose profile becomes apparent” [33]. The degree of blurring over time will be 
dependent on the initial dose gradient [33, 86] therefore any effect might be less 
pronounced for a conventional dose fraction, than for a stereotactic radiotherapy 
delivery.  
The impact of the ferric ion diffusion on a measured dose gradient has been modelled 
[29, 30, 90] and investigated experimentally [19, 22, 32, 33, 87], mostly in terms of a 
visual inspection of dose profiles instead of any quantitative analysis. The modelling 
studies predicted a noticeable loss of edge sharpness for a theoretical step function even 
within 30 minutes to 1 hour of irradiation [30, 90] however this is not particularly 
clinically relevant. The effect on a more realistic radiation penumbra was much less 
pronounced at 1 hour [30] and it was also reported that a 14MeV electron beam could 
be scanned up to 2 hours post-irradiation with little loss of edge information [29]. 
Optical density profiles were measured across a Fricke-agarose detector irradiated with 
a narrow 70kV x-ray beam (2Gy) at 40 minutes and 2 hours post-irradiation and showed 
a visible blurring in the profile over this time frame [22]. These authors suggest 
scanning “within an hour or so”.   
There were few papers which attempted to quantify the degree of spatial uncertainty 
versus dose gradient and time. One study attempted to quantify the degree of blurring of 
the measured distribution for different delivered dose gradients of up to 0 to 40Gy and 
different times post-irradiation [87]. Scans up to 3 hours post irradiation were compared 
with a reference scan in terms of gamma analysis. Gamma failures (3% 2mm) were seen 
only at 3 hours for the steepest dose gradient of 0 to 40Gy. However, the reference 
profile used for comparison was, by the authors’ admission, measured with a detector 
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that was too large, resulting in a less sharp reference profile for comparison. In addition, 
the distance tolerance was 2mm which is potentially too large for precise applications 
such as stereotactic radiotherapy. Tseng et al quoted different scan time limits for 
different dose gradients (0.5h for 4Gy mm
-1
 and 2 hours or more for 2Gy mm
-1
) [33], 
however analysis was based on a single Fricke gel detector irradiated with a steep 
stereotactic plan (40Gy in the centre); they looked at blurring in different dose gradient 
regions of the one distribution.  
In summary, there has been a great deal of work carried out investigating the post-
irradiation diffusion of ferric ions, which has been reported as a factor limiting the use 
of these detectors. However, varying conclusions have been reached in the literature, 
from scanning within 0.5 hours [33, 90], 1 hour [22], 2 hours [29], greater than 3 hours 
[87] or even that the ferric ion diffusion makes the use of Fricke detectors impractical 
altogether [110]. Having to scan within half an hour would limit the practicality of this 
dosimetry technique.  
To conclude, it appears that it is not necessary to repeat experiments establishing 
diffusion coefficient as there is much evidence and good agreement in the literature. A 
useful study to add to the existing body of evidence would be to quantify spatial error 
versus time by comparing measured and known dose profiles versus time post 
irradiation. Two papers have attempted to answer this question, but there were 
experimental weaknesses with both. This should be carried out for a range of clinically 
relevant dose gradients. Results can be used to decide on the time within which 
detectors should be scanned to maintain a defined spatial accuracy. 
2.4.2.5 Energy 
It has been suggested that Fricke gel detectors are reasonably water equivalent [111, 
112], based on analysis of their effective atomic number [111] and theoretical, Monte 
Carlo based, analysis of their radiological properties [112]. This would suggest an 
energy dependence of dose response is unlikely. No energy dependence was seen for a 
Fricke detector irradiated with a range of different quality kV X-ray beams [111]. 
Energy dependence was also investigated for a FBX with polyvinyl alcohol (PVA) 
dosimeter for a range of MV energies (6-15MV) [104] and no effect was seen.  
Whilst no energy dependence has been demonstrated in the literature, only one paper 
has described the experimental investigation of energy dependence for MV photon 
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energies relevant to our study and for only one detector composition. It is recommended 
this is confirmed for our detector and megavoltage energies.  
2.4.2.6 Dose rate dependence  
Dose rate dependence has been previously investigated by several authors [16, 90, 91, 
93, 104]. This has been carried out by changing the dose per pulse [16, 104] and also 
the distance between the source and the detector [16, 90]. This has been studied for 
detectors based on gelatine [16], agarose [90, 91] and PVA [104]. There was no 
evidence of a dose rate dependence of Fricke gel dose response in any of these studies.  
2.4.2.7 Dose fractionation  
There were no papers found which described the dose integration for Fricke gel 
detectors. Although the lack of dose rate effect demonstrated in the previous section 
might suggest that there would also be no effect of dose fractionation, this should still 
be investigated.  
2.4.2.8 Homogeneity and cooling effects 
It was suggested that for certain agarose based Fricke detectors there exists a dose 
variation across large volumes due to the difference in cooling rate at the edge of the 
phantom compared with the centre [89]. This was attributed to the breakdown of the 
agarose chain structure by sulphuric acid which is dependent on temperature. Different 
types of agarose with lower melting points were then investigated. To evaluate 
homogeneity, the dose sensitivity was compared for small vials cooled in the air 
(representing rapid cooling) to those cooled in the centre of a liquid (representing slow 
cooling rate). This was shown to be greater than 5% for most combinations of agarose, 
but reduced for a particular composition. In a further study, it was shown that adding 
certain saccharide additives reduced the non-uniformity, again with similar analysis 
comparing the dose sensitivity of test tube samples [27]. Agarose has a high melting 
point when compared with gelatine. Therefore, non-uniformity might be less of an issue 
for gelatine based detectors which require heating to much lower temperatures. 
Homogeneity should in fact ideally be evaluated by scanning large volume detector 
samples, with a similar geometry to the phantoms to be used for clinical experiments. 
This should be carried out for both unirradiated gels and also gels irradiated with as 
uniform a dose distribution as possible. One paper was found which analysed the 
uniformity of unirradiated ferrous gelatine samples [20]. Uniformity was quantified by 
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calculating the standard uncertainty of the signal in several ROIs positioned across an 
MR scan of the unirradiated detector and was within 1.5%.  
Few studies were found which investigated the homogeneity of response of uniformly 
irradiated detectors. In one, a ferrous sulphate agarose gel was irradiated with a 3 field 
plan (1 anterior plus 2 lateral beams) which was designed to produce a uniform 
distribution over a dummy PTV region [113]. However, the measured distribution was 
compared with the TPS in terms of the isodose distribution instead of via any 
quantitative measure of uniformity. Elsewhere, the uniformity of response was 
investigated for a ferrous gelatine detector analysed optically both unirradiated and 
irradiated with a parallel opposed beam arrangement [92]. Standard deviation in signal 
in a large region of interest was within 1.5%; the uniformity of dose distribution 
delivered to the detector was not described for context.  
In summary, surprisingly few publications were found which investigated the 
uniformity of response of large volume detectors irradiated with uniform dose 
distributions. It has been suggested that uniformity might depend on the cooling method 
[89], but possibly more significant for agarose detectors. Results from two studies using 
gelatine based detectors suggest that the detector uniformity is adequate for these 
detectors [92, 114], but in one only was the detector actually irradiated with a uniform 
dose distribution [92]. Therefore, this would benefit further investigation.  
2.4.2.9 Volume dependence 
No studies were found which investigated volume dependence of Fricke gel dose 
response. This is despite the fact that results would influence whether small volume 
samples can be used to calibrate large experimental samples. 
2.4.3 Summary 
The characteristics of Fricke gels were outlined which might affect their dosimetric 
performance and therefore which should be investigated. These were identified from a 
critical analysis of the whole Fricke gel process, basic text books and published 
guidelines and similar analysis for other 2D and 3D chemical detectors. The aim then 
was to review the Fricke gel literature to identify any publication which describes the 
investigation of any of these characteristics. Detectors were considered as long as they 
incorporated at least ferrous ammonium sulphate and a gelling agent. It was hoped to 
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build up a picture of evidence for dosimetric performance versus detector composition. 
Although there has been a great deal of effort in evaluating Fricke gel detectors, this 
proved a difficult task for the following reasons.  
Firstly, there exist many different chemical compositions. Previous publications have 
not tended to systematically investigate many characteristics for a particular recipe. It is 
clear that many characteristics do depend on detector composition, for example the 
gelling agent has been shown to affect the dose response, diffusion and homogeneity. 
Many additives have also been used in different recipes for example, saccharides and 
benzoic acid. Different manufacture methods have been used including cooling methods 
and storage conditions.  
In particular, significant gaps have been highlighted in this review, which is 
summarised as follows. The dose response has been widely investigated, and has been 
shown to be linear over the clinically relevant dose range, to vary from batch-to-batch 
and with time post manufacture, therefore calibration is required for each measurement 
session. It has been shown to depend on chemical composition, therefore needs to be 
characterised for each different composition. The chemical stability has also been the 
subject of several publications which show evidence for a change in the detector 
response over time. It was shown that storing detectors in the fridge reduces the ongoing 
signal drift, however whether ambient light conditions affect the response has not been 
fully explored. A range of reaction completion times has been previously presented, 
which might depend on whether XO is incorporated, this should be investigated for our 
detector to provide clarification.  
The detector response with dose rate has been investigated; with no effect seen. 
However, the detector response versus radiation energy, fractionation and detector 
volume has not been widely studied, nor has inter-sample variation. The homogeneity 
has been considered, with non-uniformity suggested for agarose based detectors, 
however this has often been investigated using test tube samples with different cooling 
methods rather than actually irradiating a large volume detector with a homogeneous 
dose distribution. This would also benefit from additional investigation. Finally, ferric 
ion diffusion has been investigated in many publications, but further work is required 
elucidate the impact of this on the post irradiation blurring of measured dose 
distributions.   
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2.5 Development of an experimental plan 
From this review, an experimental plan was developed as follows. Firstly, a detector 
composition will be selected based on practical considerations and evidence for 
dosimetric performance that does exist; this will be described in chapter 3. A systematic 
characterisation of all detector properties will be carried out according to the plan laid 
out in Figure 2.2.  
In chapter 3, the scanner performance will be established and the detector manufacture 
will be streamlined. Experiments into the basic characteristics will then be carried out 
using test tube samples analysed with an MR spectrometer, including inter sample 
 
Figure 2.2:  Experimental plan for the dosimetric characterisation of Fricke gel 
detectors in this project.  
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variation, dose rate response, fractionation, energy dependence and chemical stability. 
These are the subject of chapter 4. The work will then be extended to larger volume 
samples analysed in a whole-body MR scanner, including volume dependence, inter 
sample variation of larger samples, homogeneity of response to uniform radiation 
distributions and the impact of ferric ion diffusion on clinically relevant dose 
distributions. These are the subject of chapter 5. If the detector performance is adequate, 
the detector will then be applied to increasingly complex radiation scenarios and 
compared against existing detector measurements and is the subject of chapter 6.  
2.6 Conclusion 
In this chapter, a broader overview of the Fricke gel literature was followed by a 
structured literature review of detector characteristics. The absence of a systematic 
approach was demonstrated along with a lack of evidence for many factors. An 
experimental plan was then developed aiming to address this lack of evidence for a 
Fricke gel detector in this thesis.  
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Chapter 3. Development of experimental methodology: 
Fricke gel manufacture and MR analysis methods 
3.1 Introduction 
3.1.1 Aims of this chapter 
The aim of this chapter was to set up the practical methodology related to the 
manufacture and readout of the Fricke gel detectors before moving onto systematic 
testing of an optimised system.  
Firstly, the exact composition of the Fricke gel detector needed to be decided. In order 
to do this, a literature review was carried out to identify publications which analyse the 
different chemical constituents in terms of dosimetric properties, for example detector 
sensitivity. The focus was on simplicity and obtaining a composition with few, low-
toxicity, constituents and a simple manufacture processes in order to be accessible to 
radiotherapy departments with no or limited access to a chemistry laboratory. The aim 
was to provide an evidence based starting point for the detector composition. With the 
detector composition established, the manufacture process was then optimised and 
streamlined again with simplicity and time as a focus.   
The second part of this chapter concentrates on the readout and analysis methods. In this 
project, test tube Fricke gel samples were analysed using a bench top NMR 
spectrometer and larger volume samples analysed using a whole-body MRI scanner. As 
described in chapter 2, the readout of the irradiated detector has the potential to 
introduce measurement errors and uncertainty due to non-uniformity in response across 
a scanner, noise and lack of reproducibility in repeated measurements. There is a trade-
off between signal to noise ratio (SNR), measurement time and spatial resolution with 
any imaging system [76]. An important step in setting up the Fricke gel process was to 
design and optimise spectrometer and scan protocols and to evaluate residual 
measurement uncertainties. 
Inversion recovery and CPMG pulse sequences were used for the T1 and T2 
quantification of test tube Fricke gel samples using the NMR spectrometer. Sequences 
were compared and optimised using copper sulphate quality control samples. Methods 
were then developed for the MR scanning and analysis of irradiated Fricke gel 
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detectors. Pulse sequences were customised for the T1 and T2 quantification of larger 
Fricke gel samples. Image analysis software was developed by modifying plugins 
within OsiriX, an open source image analysis platform [115]. Larger volume copper 
sulphate samples were prepared for the evaluation of scan protocols via well-established 
measures of signal to noise ratio, image homogeneity and repeatability.  
3.1.2 Chapter overview 
Firstly, a structured review of the literature was carried out to identify an evidence 
based starting point for the composition of the Fricke gel detector; this is described in 
section 3.2. The manufacture process is described in section 3.3; this was streamlined to 
fulfil our aim of creating a quick and simple method for Fricke gel manufacture.  
The remainder of the chapter focuses on NMR/MRI methods. A very brief overview of 
the MR theory relevant to this thesis is summarised in section 3.4. Work to commission 
an NMR spectrometer for the analysis of test tube Fricke gel samples is described in 
section 3.5. The optimisation of pulse sequences on the whole-body MR scanner and 
the development of image analysis software is described in section 3.6.  
3.2 Fricke gel composition 
3.2.1 Overview of Fricke gel composition 
The basic components of a 3D Fricke gel dosimeter are ferrous ammonium sulphate, 
sulphuric acid, water and a gelling agent. Ferrous ammonium sulphate provides the 
ferrous ions which are oxidised by the free radicals produced when water is irradiated. 
Ferrous ions are not soluble in neutral solutions [89] therefore, an acidic medium is 
required usually in the form of sulphuric acid. Finally, a gelling agent is necessary to 
spatially fix the ferrous and ferric ions to produce a 3D representation of the irradiated 
dose.  
Benzoic acid and sodium chloride were components of Fricke solution dosimeters and 
consequently have been incorporated in some gel based recipes. Other chemicals have 
been investigated for example xylenol orange (XO) to allow optical analysis and 
decrease ion diffusion and saccharide additives to increase the sensitivity.  
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The literature was reviewed to select a starting composition for the Fricke gel detector. 
In the following sections, each chemical constituent is briefly reviewed in terms of 
published information on dosimetric performance and ease of manufacture.  
3.2.2 Analysis of Fricke gel components 
3.2.2.1 Ferrous ammonium sulphate 
Previous investigations compared the detector sensitivity for different concentrations of 
ferrous ammonium sulphate [24, 89, 90, 105]. It was demonstrated that optimum 
concentrations in terms of detector sensitivity were in the range 0.5 to 2mM with two 
studies agreeing that 0.5mM gave the greatest dose response [24, 89]. A concentration 
of 0.5mM was therefore selected for this project. 
3.2.2.2 Sulphuric acid 
There was slightly conflicting evidence in the literature on the variation in detector 
sensitivity with sulphuric acid concentration with some showing peak sensitivity at 
concentrations of 25mM to 50mM [24, 28, 90] where others demonstrated 
improvements using concentrations of greater than 100mM [18, 89]. However, any 
improvements in sensitivity at these high concentrations were slight and also reported to 
be accompanied by a greater effect of cooling rate on detector homogeneity [89]. From 
a practical perspective, a lower concentration would be desirable to reduce the detector 
toxicity. As there appears to only be small improvements, if any, in the dose response 
for sulphuric acid concentrations greater than 25mM, this concentration was selected.   
3.2.2.3 Gelling agent  
Different gelling materials have been used, most commonly agarose [17, 19, 85, 90, 
114] and gelatine [23, 28, 92, 105] but also alternatives such as polyvinyl-alcohol 
(PVA) [25]. Agarose has been shown to improve the dose response compared with 
gelatine [16] but at the expense of a more significant ferric ion diffusion [32]. In 
addition, the manufacture process for standard agarose types requires heating the gel 
mixture to 95
o
C compared with 45
o
C for gelatine. Oxygen must then be bubbled 
through the solution for at least 5 minutes to replace that lost during heating. Also, a 
non-uniform sensitivity over large detector volumes has been attributed to the variation 
in cooling rate at the centre and edge of the detector [89]. To overcome this, detectors 
using agarose with a lower melting point alongside other additives were proposed [89].  
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Gelatine was selected for our detector due to its ease of manufacture and its reported 
lower post irradiation diffusion. A gelatine concentration of 3-5% by weight (bw) has 
been shown to be optimal in terms of detector strength and dose sensitivity by several 
studies [16, 18, 28, 31]. 5% was selected for this work.  
3.2.2.4 Sodium chloride 
Sodium chloride was often used in Fricke solution dosimeters to counteract the effects 
of organic impurities which is important for absolute dosimetry. Although early studies 
on Fricke gels did include sodium chloride [16, 17, 105, 114], it was soon suggested 
that this is not effective for gel based dosimeters due to the intentional presence of an 
organic gelling material anyway. Fricke gel detectors are not intended as absolute 
dosimeters. In fact a decrease in sensitivity was demonstrated when sodium chloride 
was added [19]. Consequently, this was not added to the detector recipe.  
3.2.2.5 Benzoic acid 
Similarly, benzoic acid was added to Fricke solution detectors to increase the chemical 
yield in a controlled way. Several studies have demonstrated little or no improvement in 
the dose response for Fricke gelatine detectors [18, 32, 52] and again this was not 
included.  
3.2.2.6 Chelating agent 
Xylenol orange and other chelating agents have been investigated to attempt to increase 
the optical-CT dose response and reduce the post irradiation diffusion [31, 32]. A 
reduction in diffusion was normally accompanied by a reduction in the detector 
sensitivity, with the best compromise achieved with xylenol orange. This is now 
commonly added to detectors analysed using optical CT [24]. However, a reduction in 
the MR response has been demonstrated [26, 27, 31, 32]. Xylenol orange was 
investigated in an initial experiment, described in section 4.2.3, but not used thereafter.  
3.2.2.7 Saccharide additives 
Olsson et al demonstrated a variation in sensitivity with cooling rate for agarose based 
Fricke gels causing an inhomogeneous response across large volume detectors [89]. 
This is particularly seen with agarose due to the high temperatures used during 
manufacture. By adding a non-gelling polysaccharide purified from locust bean gum 
(SeaGel) the dependence of sensitivity on cooling rate was reduced for two types of 
agarose. Saccharide additives were also incorporated into a Fricke-agarose-xylenol 
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orange (FAX) detector [27]. Various additives were investigated and all increased the 
optical density-dose sensitivity although the effect on R1-dose sensitivity was moderate 
[26]. This was therefore not included to simplify the manufacture process.  
3.2.3 Summary 
The chemical composition used throughout this work was selected based on the results 
of this review. The basic components of this detector are ferrous ammonium sulphate, 
sulphuric acid, gelatine and distilled water. Concentrations were selected from the 
literature review based on optimised dose response. Although it is recognised that these 
may not combine linearly, in the literature the impact of different chemical components 
on dose response has been investigated independently of each other. This summary is 
based on the best evidence available. Gelatine was selected as the gelling agent for ease 
of manufacture, lower diffusion and fewer anticipated issues due to cooling. Other 
additives were not incorporated due to a lack of evidence for any benefit.  
The final composition of the Fricke gel dosimeters used throughout this thesis was 
0.5mM ferrous ammonium sulphate, 25mM sulphuric acid and 5% gelatine (bw). 
0.1mM xylenol orange was added in an initial experiment, described in chapter 4, to 
establish the effect on dose response, but not used thereafter.  
3.3 Fricke gel manufacture 
3.3.1 Introduction 
The next step was to define the process for the manufacture of Fricke gel detectors. For 
the first few batches of Fricke gel a collaboration with the radiation physics group at the 
National Physical Laboratory (NPL) was set up. Their group had previous experience 
with Fricke gel dosimetry as they had been investigating a similar detector with optical-
CT analysis methods. For these batches, the manufactured gel had to be transferred by 
public transport from the NPL across London to St Bartholomew’s Hospital. It was felt 
that this added an extra potential uncertainty with regards to consistency of storage and 
temperature history which was not necessary in the first instance. Should this project be 
successful, it would be a useful future study to see if the detectors could be transferred 
to other radiotherapy departments for irradiation. However, for the remainder of this 
project,  detector manufacture was carried out within a simple laboratory within the 
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radiotherapy department at St Bartholomew’s Hospital, thus keeping manufacture, 
storage, irradiation and imaging within the same location. Following manufacture, the 
detectors could be immediately placed in the most appropriate storage environment, in 
the dark, or refrigerated.  
3.3.2 Manufacture process 
The final manufacture process for Fricke gels manufactured in the radiotherapy 
department is detailed in the following section, with illustrations in Figure 3.1 and a 
work instruction in Figure 3.2. Batches of Fricke gels were manufactured, producing 
1.05l per session.  
Firstly, two 1000ml volumes of 25mM sulphuric acid were prepared. For each, 50ml of 
0.5M stock solution of sulphuric acid (Fisher Scientific, Loughborough, UK, CAS No. 
7664-93-9) was added to a 1000ml volumetric flask and made up to 1000ml with 
distilled water obtained from a still at St Bartholomew’s Hospital (Autostill 4000X, 
Jencons Scientific Ltd, UK). 4.1g of ferrous ammonium sulphate (Fisher Scientific, 
Loughborough, UK, CAS No.  7783-85-9) was weighed and dissolved in one of the 
sulphuric acid volumes. The other sulphuric acid sample was poured into a 2000ml 
beaker. 52.5g gelatine powder (gelatine from porcine skin, gel strength 300, Sigma 
Aldrich CAS No. 9000-70-8) was added and allowed to dissolve for 15 minutes. This 
mixture was heated to 45
o
C whilst being constantly stirred using a magnetic stirrer after 
which the gelatine had completely melted. The mixture was then removed from the heat 
and allowed to cool to 32
o
C whilst continuing to stir. Finally, 50ml of ferrous 
ammonium sulphate solution was added and the mixture thoroughly stirred.  
The Fricke gel was poured into the desired containers, either bottles or test tubes, details 
of which are given in subsequent chapters. Different storage conditions were 
investigated in chapter 4 and chapter 5, in particular the impact of ambient light and 
cooling methods on the dosimetric properties of the Fricke gel.  
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Figure 3.1: Steps in the manufacture of Fricke gel detectors (a) preparation of 
ferrous ammonium sulphate solution (b) weighing the gelatine powder (c) the 
gelatine is dissolved in sulphuric acid (d) the mixture is stirred and heated to 
45
o
C (e) the gelatine is removed from the heat and allowed to cool to 32
o
C whilst 
continuing to stir. (f) ferrous ammonium solution added and mixture poured into 
the required containers. 
 
3.3.3 Summary 
The Fricke gel composition has been selected and the manufacture process designed. 
The Fricke gel is manufactured from readily available, cheap chemicals with low 
toxicity. The manufacture can be carried out in a laboratory within a clinical 
radiotherapy department and requires only basic equipment. The entire process takes 2 
hours plus cooling time. This is a notable benefit over other chemical detectors which 
involve more toxic chemicals e.g. acrylamide of Polymer gels, which require a fume 
hood, require heating to higher temperatures such as Fricke-agarose or require bubbling 
through with oxygen following manufacture (Fricke agarose and BANG gels.  
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Figure 3.2: Process for the manufacture of Fricke gel detectors.  
 65 
3.4 Brief NMR theory relevant to this thesis 
3.4.1 Introduction 
The next step was to develop methods to read out the irradiated detectors using an NMR 
spectrometer and whole-body MR scanner. The MR analysis of Fricke gel detectors is 
based on T1 or T2 quantification. This dissertation is intended primarily for radiotherapy 
physicists and in this section, a basic theory of relaxation and quantification techniques 
relevant to Fricke gel analysis are discussed. For a more detailed description of the 
principles behind MRI, the reader is directed towards standard text books [116, 117]  
3.4.2 Introduction to relaxation 
A hydrogen nucleus consists of a single proton and is of interest in MRI due to its 
abundance in water and human tissue. The proton can be thought of as spinning on its 
own axis. As protons are positively charged, this results in a magnetic dipole moment; 
the proton acts like a tiny magnet. When a static magnetic field is applied (Bo) the 
proton dipoles align at 54.7
o
 to the field in a parallel or anti-parallel direction (Figure 
3.3), also referred to as “spin up” or “spin down”. Therefore it experiences a torque 
which causes it to precess around the axis of the magnetic field. The frequency of 
precession is called the Larmor frequency. 
There is a slight excess of spins in the spin-up state resulting in a small net 
magnetisation (M0) in the direction of the magnetic field, depicted along the z-axis. The 
protons precess out of phase with each other which means there is no net magnetisation 
in the transverse (xy) plane (Figure 3.4). To obtain a measurable signal, the net 
magnetisation is tipped away from the longitudinal axis by applying a radiofrequency 
(RF) pulse perpendicular to B0 and oscillating at a frequency equal to the resonance 
Larmor frequency. The flip angle is the angle through which the net magnetisation is 
tipped.  
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Figure 3.3: Parallel and anti-parallel spin states of hydrogen nucleus. 
 
 
Figure 3.4: Net magnetisation in the longitudinal (z) direction. 
 
For example, a 90
o
 RF pulse tips the net magnetisation vector into the transverse plane 
where it precesses around the axis of the static field and induces a signal in a receiver 
coil. Following the pulse, the transverse magnetisation (Mxy) and therefore signal 
amplitude rapidly decreases to zero as the protons dephase, this is known as the “Free 
Induction Decay” (Figure 3.5). The process by which the transverse magnetisation 
returns to zero, is known as spin-spin or transverse relaxation and is associated with the 
time constant T2. 
The longitudinal component of the net magnetisation (Mz) increases exponentially back 
to its equilibrium value. This process is known as spin-lattice or longitudinal relaxation 
and is associated with time constant T1. T1 and T2 relaxation times are inherent 
properties of the measured sample (e.g. different tissues in the body will have different 
 B0 
M0 
B0 
y 
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T1 and T2 values). MRI involves the development of RF pulse sequences to enhance the 
difference in T1 and T2 between different tissues hence, creating tissue contrast. This 
project is concerned with the T1 and T2 quantification of irradiated detectors and this is 
described in the next sections.  
 
 
Figure 3.5: Decay of signal and transverse magnetisation following RF pulse. 
 
3.4.3 T1 relaxation 
Immediately after the initial RF pulse, the longitudinal component of net magnetisation 
is altered from its equilibrium value (+Mo). The exponential recovery of Mz following 
an RF pulse is described by the time constant T1 known as the spin-lattice relaxation 
time (Figure 3.6) with T1 being the time required for the longitudinal magnetisation to 
reach (1- 
1
e
) or about 63% of its maximum value (Mo). T1 relaxation is due to the loss of 
energy back to the surrounding environment or “lattice”. The T1 relaxation time is 
dependent on the molecular environment surrounding the proton spins, therefore T1 
depends on the tissue or material type.  
Signal 
Time 
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(a) 
 
(b) 
Figure 3.6: Exponential longitudinal saturation recovery (a) and inversion 
recovery (b) following 90
o
 and 180
o
 RF pulses. 
 
For a 90
o
 saturation pulse, the longitudinal magnetisation is zero immediately following 
the pulse, then recovers according to the equation:  
  
For a 180
o
 inversion pulse, the longitudinal magnetisation is –Mo immediately 
following the pulse, then recovers according to the equation:  
  
The spin-lattice relaxation rate is defined as R1 =
1
T1
. 
3.4.4 T2 relaxation 
The exponential decay of the transverse magnetisation is due to the interaction of 
neighbouring proton spins. It is described by the time constant T2 and is known as spin-
spin or transverse relaxation. T2 is the time required for the transverse magnetization to 
fall to approximately 37% (1/e) of its initial value. 
Following an initial 90
o
 RF pulse, proton spins experience slightly different local 
magnetic fields which causes them to precess around the axis of the static magnetic 
field at slightly different frequencies. The spins become increasingly out of phase and 
the net transverse magnetisation decreases. The local magnetic field experienced by 
Equation 3.1 
 
Equation 3.2 
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each proton varies due to both inhomogeneities in the static field and the magnetic 
moment of neighbouring protons.  (“T2 star”) describes the loss of phase coherence 
due to both of these effects. The T2 relaxation time describes the loss of coherence due 
to spin-spin interactions only and is of interest as this depends on the molecular 
environment surrounding the proton.  
To separate T2 from , signal echoes are created (Figure 3.7 and Figure 3.8). Some 
time after the initial 90
o
 pulse, a further 180
o
 RF pulse is applied. This has the effect of 
reversing the phase of the spins so that faster spins that had a positive phase now have a 
negative phase and vice versa. The spins eventually refocus resulting in a signal echo at 
time known as the echo time (TE).  
This spin echo sequence compensates for the loss in phase coherence due to the 
inhomogeneities in the static field by reversing the phase with the 180
o
 pulse but not for 
the time-varying effects of spin-spin interactions.  
The equation for transverse magnetisation decay following an initial 90
o
 pulse is: 
 
The spin-spin relaxation rate is defined as R2 =
1
T2
.  
 
  

T2
*
  

T2
*
Equation 3.3 
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(a) 
 
(b) 
 
(c) 
 
(d) 
Figure 3.7: Spin echo formation: (a) after 90
o
 RF pulse, (b) after TE/2, loss of 
phase coherence, (c) immediately after 180
o
 pulse and (d) after TE, a signal echo 
forms. 
 
 
Figure 3.8 Transverse decay due to T2* and T2 following a 90
o 
RF pulse. 
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3.4.5 Overview of pulse sequences used for T1 and T2 quantification 
If one makes abstraction of spatial localisation, pulse sequences to quantify T1 and T2 
are essentially the same on a spectrometer and on an imager. However, for the latter, a 
series of images are acquired and the T1 or T2 values are determined on a pixel by pixel 
basis to create a synthetic image known as a T1 or T2 map. Pulse sequences are designed 
to alter the net magnetisation from the equilibrium situation, then measure the 
magnetisation to allow T1 and T2 relaxation curves to be plotted from which T1 and T2 
are quantified.  
For T1 quantification, an initial inversion or saturation pulse is applied, tipping the 
longitudinal net magnetisation through 90
o
 or 180
o
. The benefit of inversion pulse is a 
doubling of the dynamic range. Following the initial inversion pulse, a further 90
o
 pulse 
is applied after an inversion time (TI) to allow the residual magnetisation to be 
measured. This sequence was used for the T1 quantification of test tube samples by the 
spectrometer, and is described in more detail in section 3.5.4. 
The inversion recovery sequence is slow as there is only one measurement made after 
each inversion pulse. After the measurement, it is necessary to wait for the longitudinal 
magnetisation to fully recover before applying the next inversion pulse. The 
measurement times for single measurements with the spectrometer are manageable (a 
few minutes), however, inversion recovery sequences for MR scanning are prohibitively 
long. According to an example presented by Crawley et al, an inversion recovery 
sequence with 10 points, TR of 2.5s and matrix of 256×128 would take 53 minutes 
[118]. Therefore alternative sequences have been developed. In this project, a modified 
Look Locker sequence was used for the T1 quantification of larger Fricke gel samples as 
it was available on the scanner [117, 119-121]. This sequence is usually used in cardiac 
imaging to determine appropriate inversion times for myocardium nulling in perfusion 
imaging. However, it can be easily modified to obtain a series of images that can be 
used for off-line T1-mapping. This is described in more detail in section 3.6.5  
For T2 quantification an initial 90
o
 pulse tips the net magnetisation into the transverse 
plane. This is followed by a series of 180
o
 pulses forming a series of spin echoes 
according to Figure 3.7. The signal amplitude of each echo is plotted versus echo time 
(TE) giving the T2 relaxation curve from which the T2 may be determined according to 
Equation 3.3. The Carr Purcell Meiboom Gill (CPMG) sequence applies a modification 
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to compensate for imperfections in the 180
o
 refocusing pulses [122, 123]. If the initial 
90
o
 degree pulse is applied on the x’ axis, the train of 180o pulses is applied on the y’ 
axis. Due to the imperfections in the 180
o
 pulse, every odd numbered pulse will be too 
small, but even pulses are correct. Therefore, only even numbered pulses are sampled. 
In this project, the CPMG sequence was used for both T2 quantification of test tube 
Fricke gel samples with the spectrometer and large samples using the MR scanner 
(sections 3.5.5 and 3.6.6).  
3.5 Commissioning an NMR spectrometer for the analysis of test 
tube Fricke gel samples 
3.5.1 Overview 
A low field 40MHz (~ 1T) minispec mq-40 MR spectrometer (Bruker, Karlsruhe, 
Germany) was used for the analysis of small test tube samples of Fricke gel. The 
measurement probe assembly has a circulating water supply which allows the 
temperature in the sample probe to be varied. This was controlled by a Julabo F25 
refrigerated-heating circulator (Julabo GmBH, Seelback, Germany). Dedicated software 
includes a range of pre-programmed pulse sequences for T1 and T2 quantification which 
may be customised for specific applications.  
In the first instance, pulse sequences were selected based on those that were already pre-
programmed in the spectrometer software for T1 and T2 quantification. It should be 
noted that absolute T1 and T2 values are not required in this project, merely that the 
values are repeatable and reproducible and that the R1 or R2 (or any other MR signal 
parameter) is linearly related to dose for the Fricke gel detector. Pulse sequences for T1 
and T2 quantification were customised and evaluated in terms of measurement 
precision, linearity and measurement time using copper sulphate quality control 
samples, as described in the following sections.   
3.5.2 Preparation of copper sulphate QC samples 
Copper sulphate solution samples are often used as MR test objects due to the linear 
relationship between Cu
2+
 concentration and relaxation rate [117]. Initial test 
experiments showed expected T1 range of Fricke gels (irradiated over a range of 0 to 
20Gy) to be approximately 900 to 1700ms and the T2 range approximately 600 to 
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1250ms. Copper sulphate samples were prepared with a range of concentrations from 
0.8mM to 10mM selected to cover the range of relaxation rate expected for Fricke gels. 
A 0.1M stock solution of CuSO4 was first prepared by weighing 25g of CuSO4∙5H20 
(Sigma Aldrich, CAS No. 7758-99-8) and making up to 1000ml with ultrapure water 
(deionised, distilled, Fisher Scientific, UK). A series of dilutions were then carried out 
to reach the required concentrations. They were poured into 6mm inner diameter MR 
test tubes (borosilicate glass) (Bruker UK Ltd, UK).  
3.5.3 Measures of pulse sequence performance 
The linearity between relaxation rate and concentration was checked by plotting R1 and 
R2 versus copper sulphate concentration over the range 0.8mM to 10mM. Measurement 
precision (repeatability) was quantified by making 10 repeated measurements of copper 
sulphate samples with concentrations of 0.8mM (approx. T1 1700ms, T2 1500ms) and 
4mM (approx. T1 300ms, T2 250ms) and calculating the coefficient of variation (CV).  
3.5.4 Inversion recovery sequence for T1 quantification 
An inversion recovery pulse sequence was used for T1 quantification with the 
spectrometer. In this sequence, an initial 180
o
 inversion rf pulse is first applied and the 
longitudinal magnetisation is let to recover during an inversion time (TI) which varies. 
A 90
o
 rf pulse is then applied to tip the residual longitudinal magnetisation into the 
transverse plane where it can be detected (signal detection, SD). This is repeated with 
different TIs, resulting in a series of data points of Mz versus TI which allow the T1 
relaxation curve to be plotted as in figure 4.5(b). The NSA is the number of signal 
averages i.e. how many times the sequence is repeated per TI. N is the number of 
different TI values sampled. The sequence can therefore be summarised as: 
[[180
o
 – TI – 90o - SD]NSA]N 
T1 was calculated from the exponential signal recovery curve (Equation 3.2). 
Pulse sequence parameters were set as follows. The TI range was set to adequately 
sample the T1 recovery curve. The initial and final TI are set by the user, and the 
software automatically calculates TI intervals which vary to ensure there are more data 
points at short TIs where the slope of the recovery curve is steep. TR was set to be 
approximately 5 × T1 to ensure full longitudinal recovery between excitations, the NSA 
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was set to 4 and N was set to 10. Sequences were evaluated in terms of measurement 
precision (repeatability) and measurement time. Final settings for the parameters of the 
inversion recovery sequence for T1 quantification are summarised in Table 3.1.  
 
Table 3.1 Inversion recovery protocol for T1 quantification 
Parameter Value 
NSA 4 
N 10 
TI (ms) 50-100 to 2000-5000* 
TR (ms) 3000-7000* 
*dependent on the approximate T1 of the sample 
The coefficient of variation (CV=standard deviation / mean × 100%) for 10 repeated T1 
measurements was <0.2% across the T1 range evaluated. T1 versus copper sulphate 
concentration was linear as shown in Figure 3.9 (R
2
>0.999). As mentioned, the 
inversion recovery sequence is long; for the longest T1 values expected in this project, 
the approximate measurement time was 5 minutes. 
3.5.5 CPMG sequence for T2 quantification 
In a CPMG sequence, an initial 90
o
 pulse tips the net magnetisation into the transverse 
plane. This is followed by a train of N × 180
o
 pulses forming a series of spin echoes 
separated by a time tau (τ). The amplitude of each echo is measured (SD, signal 
detection) and used to determine the T2 according to Equation 3.3. A number of dummy 
echoes (DE) are not sampled before each measured echo. This whole sequence is 
repeated a number of times (NSA) and the signal averaged:  
[90
o
 – 𝜏 – [(180o – 𝜏 - )DE (180
o
 – 𝜏 - )SD – 𝜏 -]N]NSA 
Pulse sequence parameters were set and evaluated using the copper sulphate QC 
samples. The TR was set to be greater than 5xT1 to ensure full longitudinal 
magnetisation recovery between each excitation and the NSA was 4. This gave adequate 
precision with sufficiently short measurement times. DE, τ and N were varied to 
optimise measurement precision and ensure adequate sampling of the T2 relaxation 
curve within the constraints that τ is recommended to be <1ms and N is limited to a 
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maximum of 250 within the Minispec software. The final settings are presented in Table 
3.2. 
Table 3.2 CPMG protocol for T2 quantification 
Parameter Value 
NSA 4 
N 250 
τ (ms) 1.0 
Dummy echoes 5-13*  
TR (ms) 7000 
*depending on approx. T2 
The CV for 10 repeated T2 measurements was < 0.1% over a T2 range of 115ms to 
1300ms. The relationship between relaxation rate and CuSO4 concentration was again 
linear for R2 as seen in Figure 3.9 (R
2
 >0.999).  
 
Figure 3.9: Relaxation rate versus CuSO4 concentration for R1 and R2. 
 
3.5.6 Summary 
Pulse sequences have been designed for the T1 and T2 quantification of test tube Fricke 
gel detectors using an NMR spectrometer and evaluated using copper sulphate QC 
samples resulting in a precision (CV <0.2%) and linearity (R
2
 > 0.999) adequate for the 
determination of R1 and R2 in this project when considered with regard to the 3% aim 
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for overall uncertainty. This was evaluated over the R1 and R2 ranges anticipated for 
Fricke gel dosimetry. 
3.6 Commissioning an MRI scanner for analysis of large volume 
Fricke gel samples 
3.6.1 Overview 
A Philips Achieva 3T Tx MRI scanner in conjunction with an 8-element head coil 
(Philips Medical System, Best, The Netherlands) was used to image larger volume 
Fricke gel samples for investigations into the homogeneity of Fricke gel detectors and 
the diffusion of ferric ions.  
The aim of this section was to develop methods for the mapping of larger volume Fricke 
gel samples. For now, this was limited to 2D dose maps, sufficient for the basic 
characterisation work in this project with the aim to extend it to 3D in the future.  
Pulse sequences were optimised to carry out 2D T1 and T2 quantification in acceptable 
times. Software was required for the analysis of the acquired image set, converting 
images to T1 maps then dose maps. The development of bespoke analysis software was 
carried out within OsiriX image analysis platform. Pulse sequences were evaluated 
using copper sulphate QC samples.  
3.6.2 Preparation of copper sulphate QC samples 
Copper sulphate QC samples were again used for the comparison and optimisation of T1 
and T2 quantification scan sequences. In addition to the test tube samples described in 
section 3.5.2, larger QC samples were prepared. 1l samples of CuSO4 were created with 
approximate concentrations of 0.5mM, 1.5mM, 4mM and 7mM. 
3.6.3 Parameters for evaluation of pulse sequences  
Parameters used to evaluate different pulse sequences were the scan repeatability, 
linearity, image uniformity, scan time and a measure of the  signal to noise ratio (SNR) 
according to international guidance [124]. The test tube copper sulphate samples were 
used to assess the linearity of R1 and R2 versus copper sulphate concentration. It is 
known that R1 and R2 should be linear versus CuSO4 concentration therefore, this was 
evaluated as a test of pulse sequence performance. Three larger volume CuSO4 samples 
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(concentrations 1.5mM, 4mM and 7mM) were used to evaluate the image uniformity, 
image noise and SNR, see Figure 3.10.  
 
Figure 3.10: Scan of 1l volume copper sulphate samples used for pulse sequence 
evaluation. 
 
The scan uniformity was determined by positioning a 1cm
2
 ROI in the areas of 
minimum signal intensity and maximum signal intensity and calculating the percentage 
image uniformity (PIU) [124]: 
 
Equation 3.4 
 
The repeatability is the coefficient of variation of the mean signal within a ROI of 10 
scans. The image noise, and therefore SNR, would usually be assessed using regions of 
interest (ROI) in the background region of the image, outside of the samples. T1 and T2 
maps are synthetic rather than an acquired image, where the signal outside of the copper 
sulphate or Fricke gel samples was set to zero to limit computation. It is therefore not 
possible to carry a standard SNR measurement against the background. Instead, the 
ratio of the mean signal to the standard deviation within a 45cm
2
 ROI positioned in the 
phantom was used as an indication of the SNR. It is recognised that this include effects 
due to the T2 fit, image artefacts and inhomogeneity in the sample itself. In the final 
assessment of the optimised T1 and T2 scan protocols, the inverse was used to provide 
an indication of scan uncertainty i.e. the s.d./mean expressed as a percentage. These will 
be referred to as SNR and scan uncertainty (%).  
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3.6.4 Development of image analysis software for T1 and T2 quantification 
Image processing software was required to convert acquired MR images into T1 or T2 
maps. The scans acquired are a series of images at different inversion times for T1 
quantification and different echo times for T2 quantification where the pixel values 
represent the residual magnetisation at that time.  
This software was required to carry out the following functions: 
 Import the MR image series in DICOM (digital imaging and communications in 
medicine) format.  
 For every pixel in each acquired image, extract the magnetisation signal creating 
a series of data points of signal versus time.  
 From this data, calculate the T1 or T2 for each pixel. This step will be described 
in further detail under the sections on T1 and T2 quantification.  
 Display the T1 or T2 map and allow this to be saved, analysed and exported.  
 Optionally convert to R1, R2 map or a dose map, depending on the test. 
OsiriX is a multi-modality, open source imaging platform based on the objective-C 
programming language [115]. The basic software enables standard image processing 
functions such as importing and exporting images, plotting profiles or performing 
analysis using regions of interest. Additional software plugins are available to carry out 
more specialised functions and the user can also develop their own plugins to fit 
specific requirements.   
There already existed plugins for T1 and T2 quantification which had some basic 
functionality but required modifications for our pulse sequences and applications. Two 
plugins were developed to carry out T1 and T2 quantification of irradiated Fricke gel 
detectors. This is described in further detail in Appendix A, and specifics of T1 and T2 
sequences are described in the next sections.   
3.6.5 Look Locker pulse sequence for T1 quantification 
The Look Locker sequence was developed to carry out fast T1 quantification and is 
usually used in cardiac imaging to determine appropriate TI for myocardial signal 
suppression [119, 120, 125]. In the Look Locker sequence, each initial inversion pulse 
is followed by a series of pulses with a small flip angle (e.g. 10
o
). The residual net 
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magnetisation is tipped by this small angle away from the z-axis resulting in a small 
component in the transverse plane which may be measured. This component and the 
transverse signal depend on the TI (time between inversion pulse and the small flip 
angle pulse).  
In contrast to the inversion recovery sequence, many points on the inversion recovery 
curve are sampled following each inversion pulse, greatly reducing scan times. 
However, the application of small flip angle pulses perturbs the recovery of the 
longitudinal magnetisation and results in a different signal recovery curve. The time 
constant characterising the recovery is no longer T1, but instead is termed T1 effective 
(T1eff) [117]. 
For this work, it is sufficient to know that the signal equation is of the form: 
Mz = A – B exp (-TI / T1eff)  
where A and B are unknown parameters. This is less straightforward to program when 
compared with an exponential curve. From the data series (TI, Mz), a non-linear least 
squares fitting routine is used to find the three unknown parameters A, B and T1eff. The 
T1 plugin in OsiriX was modified to incorporate a Levenberg-Marquardt non-linear 
least squares routine to determine T1eff. T1 can be calculated from the T1eff, TI, and 
knowledge of the flip angle but this is not necessary for our work. An accurate 
determination of the T1 value is not required. T1eff will suffice as it is related to dose in a 
similar, linear way, which is confirmed in a subsequent experiment.  
Look Locker pulse sequence parameters to be set were: flip angle, number of data 
points/phases (N), number of signal averages (NSA), slice thickness, pixel size, TI 
interval and TR. A clinical cardiac pulse sequence was used with a simulated heart 
trace. The R-R interval determined the TR which was 2s. The slice thickness was set to 
5mm throughout. The impact of other sequence parameters on the signal to noise ratio 
was investigated in a series of investigations using the copper sulphate QC samples as 
follows. Default parameters were: flip angle 7
o
, N = 25, NSA = 3 and pixel size 1.4mm 
then each parameter was varied in turn. The flip angle was varied between 3
o
 and 15
o
, N 
was varied: 15, 25, 51 and different combinations of pixel size and NSA were 
investigated. Results are shown in Table 3.3 to Table 3.5. 
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Table 3.3 SNR versus flip angle 
Flip angle (
o
) 
SNR 
Sample A 
T1 ≈ 800ms 
Sample B 
T1 ≈ 420ms 
Sample C 
T1 ≈ 230ms 
3 222 168 129 
5 347 234 194 
7 361 248 234 
10 315 300 334 
15 259 261 332 
30 86 122 N/A artefacts 
 
Table 3.4 SNR versus N 
N 
SNR 
Sample A 
T1 ≈ 800ms 
Sample B 
T1 ≈ 420ms 
Sample C 
T1 ≈ 230ms 
15 334 219 145 
25 139 190 109 
51 148 219 115 
 
Table 3.5 SNR versus pixel size and NSA for sample B (T1 ≈ 420ms) 
Pixel size (mm) NSA SNR 
1.4 × 1.4 3 219 
1.4 × 1.4 1 120 
1.0 × 1.0 5 30 
1.0 × 1.0 3 16 
 
These investigations demonstrated an improved SNR with flip angle of 7
o
 to 10
o
, 
therefore 7 was used thereafter. SNR versus N was optimal for N = 15. In terms of the 
flip angle dependence, a larger flip angle transfers more signal into the transverse plane. 
For a long enough TR, it will directly increase the SNR and reduce the uncertainty on 
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the fit. For shorter, T1 full relaxation might not occur between excitation and this will 
affect the calculated T1 values. Similarly, in terms of T1 dependence on N, increasing N 
should improve the fit of the T1 curve and reduce the standard deviation, however, it 
also compromises the SNR of the acquired images which in turn influences the quality 
of the map. Experiments in this project involved steep gradients across the image plane, 
therefore a high in-plane resolution (small pixel size) was required, ideally 1mm or less. 
However, smaller pixel sizes results in lower SNR as demonstrated here. SNR may be 
increased by increasing the NSA, but at a cost of increased scan time. These results 
show that for the Look Locker sequence, it was difficult to maintain adequate SNR for 
the sub-mm pixel size required in this project. 
3.6.6 CPMG pulse sequence for T2 quantification 
A CPMG sequence was used for T2 quantification of large volume samples using the 
scanner. A 90
o
 pulse is followed by a series of 180
o
 pulses at regular intervals (echo 
times TE) to create spin echoes. The resulting image set is a series of 2D images at 
varying TE. The OsiriX plugin plots the magnetisation signal in each pixel versus time 
and uses the signal decay curve (equation 3.3) to quantify T2. From this, a T2 map was 
calculated which may be converted to a dose map if the relationship between T2 and 
dose is known. A copper sulphate sample of 0.5mM concentration was used for this 
experiment. 
Parameters to be set for this sequence were: number of data points (N), number of 
signal averages (NSA), slice thickness, pixel size, TE, TR and refocusing angle. 
Throughout, the TR was set to 2s, echo train length was 32, NSA was 1 and the slice 
thickness was 5mm. The impact of refocusing angle, TE interval and pixel size on SNR 
was investigated. Default parameters were refocusing angle 170
o
 and TE interval 40ms. 
The refocusing angle was varied between 160
o
 to 180
o
, a TE of 30 vs. 40ms was 
compared and the pixel size was varied. Results are shown in Table 3.6 to Table 3.8.  
Table 3.6 Effect of TE on SNR in sample with T2 ≈ 1350ms (pixel size = 0.4mm) 
TE (ms) SNR 
30 124 
40 152 
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Table 3.7 Effect of refocusing angle on SNR in sample with T2 ≈ 1350ms (pixel size 
= 0.9mm) 
Refocusing angle SNR 
160
o 
210 
170
o 
250 
180
o 
210 
 
Table 3.8 Effect of pixel size on SNR (sample T2 ≈ 1350ms) 
Pixel size (mm) SNR 
0.35 × 0.35 150 
0.94 × 0.94 250 
1.0 × 1.0 280 
 
The results demonstrate that SNR is increased for a TE of 40ms compared with 30ms. 
There was little difference in SNR for different refocusing angles; 170
o
 was used 
thereafter. In contrast with T1 quantification using the Look Locker sequence, it is 
possible to acquire T2 maps with much greater SNR, even with pixel sizes of less than 
1mm
2
 and NSA of 1.  
The final sequence for T2 quantification used a refocusing angle of 170
o
, slice thickness 
of 5mm, 32 measured echoes, NSA of 1, TE of 40ms and TR of 2000ms.  
3.6.7 Comparison between T1 and T2 
A direct comparison between T1 and T2 scan results was carried out. Pixel size and slice 
thickness were set to be the same for both scan types (1.01.0mm2 and 5mm). 
Otherwise optimized parameters were set, as described in the previous sections.  One 
large 0.5mM copper sulphate solution sample was surrounded by test tube sample of 
varying T1 and T2. Scans were repeated 10 times. Results were compared in terms of 
SNR, image uniformity, repeatability and linearity.  
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Example T1 and T2 maps of the CuSO4 solution samples are shown in Figure 3.11. The 
results of the scan uncertainty, homogeneity and repeatability for the optimised scan 
sequences are shown in Table 3.9.  
 
(a) 
 
(b) 
Figure 3.11: Example T1 (a) and T2 (b) maps of CuSO4 test samples. 
 
Table 3.9  Scan performance for T1 and T2 quantification sequences 
Parameter T1 sequence T2 sequence 
Scan uncertainty (%) 6.0 0.5 
Image uniformity (%) 96.8 99.8 
Repeatability CV (%) 1.5 0.5 
 
The relationship between relaxation rate and CuSO4 concentration was linear (R
2
 
>0.999) for both R1 and R2 (Figure 3.12 and Figure 3.13). 
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Figure 3.12: Relaxation rate versus CuSO4 concentration for R1. 
 
Figure 3.13: Relaxation rate versus CuSO4 concentration for R2. 
 
The T2 quantification method produced images with much superior signal to noise 
compared with the Look Locker sequence for the same spatial resolution and improved 
image uniformity. The slope of the relaxation rate versus CuSO4 concentration was 
similar for both T1 and T2 quantification methods. T1 versus T2 quantification for Fricke 
gel dosimetry will be investigated further in chapter 4.  
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3.7 Summary of chapter 
In this chapter, the methodology was developed for the manufacture of the Fricke gel 
detectors and the MR processes for the analysis of irradiated detectors. In order to 
decide on a detector composition, the literature was reviewed to find evidence regarding 
the dosimetric performance of different composition Fricke gel detectors. In the absence 
of a systematic evaluation of any one composition, as highlighted in chapter 2, focus 
was mostly on the dose response. Previous investigations tended to compare detector 
compositions in terms of their sensitivity i.e. slope of the dose response curve. An 
optimum composition was selected: 0.5mM ferrous ammonium sulphate, 25mM 
sulphuric acid, 5% gelatine and distilled water.  
A manufacture method was then streamlined within a basic laboratory in a clinical 
radiotherapy department making approximately 1l batches of Fricke gel each session 
which could be poured into test tubes or larger volume containers. The whole process 
takes 2 hours plus cooling time, which will be the subject of further investigation in 
chapter 5.  
Focus then turned to the MR analysis methods. An NMR spectrometer and whole-body 
MRI scanner were commissioned for the T1 and T2 quantification of test tube and larger 
volume Fricke gel samples. For the NMR spectrometer, an inversion recovery sequence 
was selected for T1 quantification and pulse sequence parameters were set to measure T1 
with adequate measurement precision within a practical measurement time of less than 
10 minutes per sample. A CPMG sequence was then used for T2 quantification and 
appropriate pulse sequence parameters were set. Sequences were evaluated using copper 
sulphate QC samples with T1 and T2 covering the range expected for unirradiated and 
irradiated Fricke gels. Both resulted in a  measurement precision of repeated 
measurements of <0.2%. 
Pulse sequences were then customised for a Philips Achieva 3T MRI scanner. Analysis 
software was written within OsiriX, an open source image analysis platform, for the 
creation of T1 and T2 maps and dose maps. A Look Locker sequence was used for T1 
quantification and pulse sequence parameters were set to optimise the sequence in terms 
of SNR. A CPMG sequence was used for T2 quantification, and again, settings selected 
to maximise SNR. Once again, copper sulphate samples were prepared for the 
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evaluation of sequences. The optimised sequences were more fully evaluated in terms of 
scan uncertainty, homogeneity and repeatability. Overall, scan uncertainty was lower 
for optimised protocol for T2 quantification when compared with the optimised (and 
available) T1 protocol for scan times of similar duration. The image uniformity was also 
improved for the T2 CPMG sequence. There has been disagreement in the literature 
over the use of T2 quantification for the analysis of Fricke gel detectors with many 
authors recommending T1 despite issues with adequate SNR for small pixel sizes for 
available scan sequences. Therefore a direct comparison between T1 and T2 
quantification results for small volume Fricke gel detectors should be carried out and 
will be described in chapter 4.  
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Chapter 4. Evaluation of the dosimetric performance 
of small volume Fricke gel detectors 
4.1 Introduction 
4.1.1 Aim of this chapter 
Having established processes for the manufacture of Fricke gel detectors, and MR 
analysis of irradiated detectors in chapter 3, the optimised system could now be 
commissioned. This involves investigating all potential sources of measurement 
uncertainty. The literature review described in chapter 2 highlighted a lack of systematic 
approach to the dosimetric characterisation of 3D chemical detectors and a lack of 
evidence for many factors including inter-sample variation, volume dependence and 
integration. This was used to create an experimental plan for the full dosimetric 
characterisation of the Fricke gel-MR system used in this project (Figure 2.2) following 
a similar approach to that which would be taken if a commercial radiation detector was 
being commissioned for use within the department. According to this plan, basic 
characteristics of inter-sample variation, chemical stability, dose rate dependence, dose 
integration and energy dependence should be quantified first before moving onto 
uncertainties related to larger detector volumes such as homogeneity of response. These 
are the subject of this chapter.  
Many previous investigations into Fricke gel detectors have involved large radiation 
doses and in particular there is very little published information over the 0 to 3Gy range, 
as summarised in chapter 2. The aim of this experimental chapter was to therefore to 
investigate basic dosimetric characteristics of the Fricke gel detector focusing on two 
clinically relevant dose ranges: 0 to 3Gy to cover conventional fractionation schedules 
and 5 to 20Gy to cover stereotactic techniques. All experiments in this chapter were 
carried out using small volume (test tube) detector samples readout using the MR 
spectrometer. T1 and T2 relaxation times were quantified using optimised protocols 
developed in chapter 3. This avoids introducing any uncertainties caused by performing 
relaxometry of larger samples on a whole-body scanner, for example artefacts and non-
uniformity of scanner response and inhomogeneity of the detector response itself.  
Before characterisation measurements were commenced, an initial experiment was 
carried out to examine the impact of adding xylenol orange on the detector response. 
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This has been previously shown to reduce the effect of ferric ion diffusion, but at the 
expense of a much decreased MR response (R1 or R2 versus dose). Dose response 
curves for detectors with and without xylenol orange were compared.  
The first characterisation experiment was the pre- and post-irradiation chemical stability 
of the Fricke gel detector. As described in the literature review of chapter 2, the 
chemical stability has been previously quantified for detectors readout with optical 
methods and has demonstrated a short term increase in signal due to reaction 
completion [23, 28, 91, 92] followed by a longer term signal drift [22, 27, 28, 92, 106]. 
There was some variation in the reaction completion times quoted in the literature of 
between 10 minutes to 2 hours, which would have an impact on the time following 
irradiation that a detector should be scanned. A long reaction completion time might 
conflict with any requirement to scan detectors quickly to avoid blurring due to ferric 
ion diffusion. It was also not clear from the literature whether longer term signal drift 
could be reduced by storing the detectors in the dark. Chemical stability was 
investigated in terms of R1 or R2 versus time.  
The literature review highlighted a lack of evidence of the inter-sample variation of 
Fricke gel detectors (section 2.4). This is an important factor as 3D chemical detectors 
are usually calibrated whereby the dose response is characterised by irradiating 
additional samples with known radiation doses. Establishing that different samples from 
the same detector batch respond similarly is therefore a crucial step. Therefore, the next 
investigations quantified inter-sample variation for this Fricke gel detector by 
irradiating multiple detector samples to the same radiation doses, for a range of doses 
between 0 and 20Gy.  
Results from the inter-sample variation experiment were also used to plot dose response 
in terms of relaxation rate versus dose. Whilst a linear dose response is not absolutely 
necessary, it simplifies calibration as a simple linear regression can be used. A linear 
response has previously been demonstrated for Fricke gels in some studies [16, 23, 25, 
28, 98] whereas others have shown a deviation from linearity [91, 100, 104]. Dose 
response was analysed for this detector in terms of its linearity. In addition, dose 
response was compared for several different batches of detector in order to perform a 
gross check on the consistency of the manufacture process. It is fully expected for 
chemical detectors to perform a calibration for each batch and measurement session. 
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This experiment was repeated with different times between detector manufacture and 
irradiation to investigate the shelf life of a Fricke gel detector.  
A further aim was to compare T1 and T2 quantification methods in terms of their dose 
response and measurement precision. The acquisition of 2D or 3D T1 maps with an 
adequate signal-to-noise ratio (SNR) and high measurement accuracy within a 
reasonable scan time presents a challenge, as was highlighted in chapter 3. Fast T1 
quantification methods, such as the Look-Locker sequence inherently suffer from a 
lower signal-to-noise ratio (SNR) when compared with inversion recovery techniques 
[117]. T2 quantification is more straightforward and was shown in the previous chapter 
to more easily produce T2 maps with higher SNR, lower noise and improved uniformity 
when compared with the optimized Look Locker sequence. However, early studies on 
Fricke gel detectors showed a lower dose response for R2 compared with R1 [111] and 
elsewhere a similar response but poor R2 precision [14]. More recently, Marrale et al 
showed negligible R2 response but a good R1 response, albeit for neutron irradiation 
[126]. In contrast, others have used T2 quantification successfully [19, 88]. In the next 
experiment, T1 and T2 methods were directly compared in terms of their inter-sample 
variation and dose response to clarify this issue.  
The final set of experiments investigated the effect of radiation dose rate and energy on 
the detector response. Ideally detectors would be independent of dose rate and energy as 
both dose rate and energy spectrum may vary during a clinical delivery. Previous 
literature reviewed in chapter 2 demonstrated that the Fricke gel response was 
independent of dose rate [16, 90, 91, 93, 104] although there was little evidence for the 
effect of energy for MV photon beams [104]. None of these previous experiments have 
been carried out following a baseline inter sample variation experiment to allow results 
to be analysed in the context of the basis precision. Dose rate and energy dependence 
were investigated for this Fricke gel composition and extended to include experiments 
on dose integration by delivering radiation dose with several beams to mimic a clinical 
radiotherapy plan.  
4.1.2 Chapter overview 
Fricke gel detectors were manufactured according to the optimum composition 
established from the literature (section 3.2.2). Experiments were then carried out using 
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batches of Fricke gel detectors. The aim of this set of experiments was to perform the 
basic characterisation of the Fricke gel detector itself. For each experiment only the 
characteristic under investigation was altered with all other variables controlled. 
Detector samples originated from the same batch and were irradiated, analysed and 
stored together in the same ambient conditions. Analysis was carried out with the 
spectrometer to reduce any additional uncertainty in T1 and T2 quantification introduced 
using a whole-body scanner for example image uniformity and artefacts.   
Experiments were carried out in a logical order with the chemical stability investigated 
first in order to establish whether there were any limitations on when detectors should 
be analysed or on the ambient storage conditions. The inter sample variation was then 
evaluated to establish a baseline precision ahead of experiments to investigate dose rate 
and energy dependence. Statistical analysis was then used to assess energy and dose rate 
dependence. Results for all these experiments were assessed in the context of the overall 
target of 3% for the dosimetric uncertainty for this detector set out in chapter 2.  
An initial experiment investigating the effect on the dose response of adding xylenol 
orange to the composition was carried out (section 4.2.3). The chemical stability was 
investigated, both long term signal drift for light versus dark storage conditions and 
short term reaction completion, described in section 4.2.4. T1 versus T2 quantification 
methods were compared in terms of dose response and precision across a dose range of 
0 to 20Gy. This was carried out over several batches of Fricke gel so dose response 
could be compared as a check of manufacture processes (section 4.2.5). Dose response 
and precision experiments were repeated at different times between manufacture and 
irradiation, to characterise the shelf life of the detector (section 4.2.6). Finally, dose rate, 
integration and energy dependence were investigated (sections 4.2.7 and 4.2.8).  
4.2 Methods 
4.2.1 Gel manufacture 
The composition of the Fricke gel dosimeters used throughout this chapter was 0.5mM 
ferrous ammonium sulphate, 25mM sulphuric acid and 5% gelatine (bw). Batches of 
Fricke gels were manufactured, according to the process described in section 3.3 
producing 1.05l each session. The Fricke gel was poured into 6mm inner diameter MR 
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test tubes (borosilicate glass, Bruker UK Ltd). Unless otherwise stated, the samples 
were placed in a refrigerator at 4
o
C until 2 hours prior to analysis or irradiation.  
4.2.2 Irradiation 
All irradiations were carried out with a Varian Clinac iX linear accelerator (Varian 
Medical Systems, Palo Alto, CA) as described in section 1.1.3. This linac has 6 and 
15MV photon beams and is capable of delivering radiotherapy plans using both IMRT 
and VMAT (known as RapidArc by this manufacturer). The linear accelerator output 
(dose per monitor unit under reference conditions) was measured before gel 
experiments using a Farmer ionisation chamber with calibration traceable to the UK 
National Physical Laboratory [4]. The precision of the radiation dose delivery has been 
previously measured and is better than 0.1%.  
A Perspex block with inserts for four test tubes was manufactured to allow the 
simultaneous irradiation of multiple samples (Figure 4.1). The Fricke gel samples were 
irradiated with 6MV photons at 600 MU.min
-1
 in a 20×20cm
2
 field. By positioning the 
test tubes within the central 6cm of this field, the variation in dose across the samples 
was kept within ±0.25% of the set dose. The Perspex phantom was sandwiched between 
two 5cm thick blocks of WT1 water equivalent material (St. Bartholomew’s Hospital, 
London, UK) which provided full scatter equilibrium. The monitor units to deliver the 
required dose were calculated and corrected for linac output. The temperature during 
each irradiation session was monitored and was stable to within ± 0.2
o
C.  
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(a) 
 
(b) 
Figure 4.1: Phantom used for the irradiation of Fricke gel samples with (a) and 
without (b) build up material block. 
 
4.2.3 Investigation into the effect of xylenol orange on dose response 
The dose response of Fricke gel detectors with and without xylenol orange were 
compared. Two batches of Fricke gel were prepared during the same session at the 
NPL, one with 0.1mM xylenol orange added at the same time as the ferrous ammonium 
sulphate solution. A 100ml stock solution of 0.1mM xylenol orange was prepared by 
adding 0.76g of xylenol orange powder to 100ml of the 25mM sulphuric acid solution.  
Otherwise, manufacture was carried out as described in section 3.3. Samples from each 
batch were irradiated in pairs to doses of up to 15Gy and the T1 was measured. The 
irradiation and T1 measurements of all samples were carried out at the same time to 
ensure all detectors had the same thermal and light exposure history. R1 was plotted 
versus dose.  
4.2.4 Chemical stability 
Two experiments were carried out to investigate the chemical stability of this Fricke gel 
detector over time. The aim of the first was to quantify for our detector composition the 
slow increase in gel reading previously reported for other Fricke gel detectors and to 
investigate the effect of visible light. T1 and T2 measurements were repeated over a 
period of 3 hours for two unirradiated Fricke gel samples from the same batch. One of 
the samples was stored in normal room light conditions between measurements and the 
other in a light-tight container. The detectors were at a constant temperature of 23
o
C 
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throughout. R1 and R2 were plotted versus time for both samples and the rate of change 
in the relaxation rate was quantified.  
The second experiment was designed to investigate the variation in R2 following 
irradiation. Three Fricke gel samples were irradiated to doses of 2, 8 and 15Gy. T2 
measurements were commenced immediately after irradiation and repeated for 3 hours, 
initially at short intervals to investigate the reaction completion time. Samples were 
stored in the dark in between measurements for this experiment.  
4.2.5 Inter-sample variation and dose response: T1 vs. T2 quantification 
The R1 and R2 measurement precision were quantified for doses over the range 0 to 
20Gy and dose response curves were compared. Two batches of gels were 
manufactured on separate occasions. 32 test tube detector samples were prepared from 
each batch. Pre-irradiation T2 values were measured for all 32 samples and the baseline 
coefficient of variation was calculated. Samples were then irradiated in groups of 8 to 
known doses. For the first batch, gel samples were irradiated to doses of 0 to 3Gy in 
1Gy increments and for the second batch gel samples were irradiated to doses of 5 to 
20Gy in 5Gy increments. For both batches, additional pairs of samples were irradiated 
to enable the dose response curves to be compared. The gel samples were all stored 
together in the dark and irradiated during the same session. To reduce measurement 
uncertainties due to signal instability established in the previous experiment, all MR 
measurements were commenced at least 10 minutes after irradiation and were 
completed within 3 hours.  
4.2.6 Time post-manufacture (shelf life) 
The experiments into precision and dose response were repeated with different intervals 
between gel manufacture and irradiation. Two batches were manufactured on separate 
occasions. Samples from the first were irradiated and read out on days 1 and 7 post 
manufacture. Samples from the second batch were irradiated on days 2, 16 and 22 post-
manufacture. For each measurement session, T2 of all remaining unirradiated samples 
was quantified prior to irradiation. Two samples were irradiated to doses of 0, 10 and 
15Gy to plot the dose response curve and 8 samples were irradiated to doses of 3 and 
20Gy to evaluate the precision.  
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4.2.7 Variation in detector response with radiation dose rate and integration 
The dose rate and dose integration were investigated using samples from the same 
batch, irradiated and measured during the same session. For each set of parameters, four 
samples were irradiated simultaneously, the T2 quantified, converted to R2 and the mean 
R2 was calculated. In the first set a dose of approximately 5Gy was delivered to the 
Fricke samples. The dose rate was varied (100, 400 and 600 MUmin
-1
) with 500 MU 
delivered in one shot. To investigate how the detector integrates multiple beams and 
mimic a clinical delivery, a further set of samples were irradiated with 500MU split into 
5 × 100MU beams, delivered at 60 second intervals. To mimic the delivery of high 
doses with multiple fields, a further set of samples were irradiated to a dose of 
approximately 20Gy (2000MU); in a single shot, 5 × 400MU (60s intervals) and 10 × 
200MU (45s intervals). 
4.2.8 Variation in detector response with radiation energy 
The effect of radiation energy was also investigated using samples from the same batch, 
irradiated and measured during the same session. Again, four samples were irradiated 
simultaneously, the T2 quantified and the mean R2 was calculated. The irradiation 
conditions were the same as previously, however the energy was varied (6MV and 
15MV) and measurements were also made at larger depths for each energy to confirm 
no effect of low energy scattered radiation. The monitor units required to deliver a dose 
of 5Gy were calculated for each experiment, and corrected for linac output, to enable 
comparison between 6MV and 15MV beams.  
4.3 Results 
4.3.1 Investigation into the effect of xylenol orange on dose response 
R1 was plotted versus dose (Figure 4.2). Error bars were calculated (2 s.d.) however 
they are too small to visualise udner the data markers. This is demonstrated as an 
example in Figure 4.8 of section 4.3.3. The Fricke gel detectors without XO 
demonstrated a greater dose response than those with XO which agrees with results 
reported in the literature [27, 31]. The benefit of xylenol orange is the reported 
reduction in the ferric ion diffusion post irradiation. The ferric ion diffusion for this 
detector will be investigated at clinically relevant dose levels in chapter 5. As the dose 
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response has been shown to be markedly worse, and we are not using optical methods, 
xylenol orange was excluded for subsequent experiments subject to the results of an 
investigation into ferric ion diffusion experiment.  
 
 
Figure 4.2: R1 versus dose for Fricke gel samples with and without xylenol orange.  
 
4.3.2 Chemical stability 
The variation in R1 and R2 relaxation rate with time was compared for unirradiated 
Fricke gel samples stored in normal indoor light conditions and in the dark (Figure 4.3). 
Once again error bars were too small to visualise. The relaxation rate increased steadily 
for samples stored in normal ambient light conditions by 2% per hour. When stored in 
the dark, the rate of oxidation for unirradiated gels was reduced to 0.2% per hour which 
indicates that visible light induces an oxidation reaction. During all subsequent 
experiments, Fricke gel samples were stored in the dark and completed within 3 hours.  
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Figure 4.3: Variation in signal with time for unirradiated Fricke gel samples 
stored in different ambient light conditions.  
 
The stability of the R2 signal following irradiation for detector samples irradiated to 2, 8 
and 15Gy is plotted in Figure 4.4 and as the rate of change in R2 versus time in Figure 
4.5.  These detectors were stored in the dark between measurements. A steep increase in 
relaxation rate was seen immediately following irradiation. The reaction completion 
time was dependent on radiation dose, but was within 12 minutes for all doses 
investigated. Thereafter the R2 signal increased by less than 0.2% h
-1
.  
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Figure 4.4: R2 signal versus time post-irradiation. 
 
Figure 4.5: Rate of change of signal with time for unirradiated Fricke gel samples 
stored in different ambient light conditions.  
 
4.3.3 Inter-sample variation and dose response: T1 versus T2 quantification 
The CV in R2 of 32 Fricke gel samples prior to irradiation was less than 0.5% for both 
gel batches indicating an excellent consistency of the gel (mean R2 0.828, s.d. 0.003 for 
the first batch, mean R2 0.850, s.d. 0.004 for the second batch). For groups of samples 
irradiated to the same dose, the CV was also less than 0.5% for both R1 and R2 for all 
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dose levels investigated in the range of 1 to 20Gy. All individual R1 and R2 values were 
within 1% of the mean value for each dose level (Figure 4.6 and Figure 4.7). This sets 
the baseline precision for subsequent experiments on dose rate and energy dependence 
which will involve multiple samples irradiated under different conditions.  
 
Figure 4.6: Deviation from the mean R1 for each sample. 
 
 
Figure 4.7: Deviation from the mean R2 for each sample. 
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The dose response curves for both Fricke gel batches and for both R1 and R2 versus 
dose are shown in Figure 4.8. A linear relationship between dose and signal was 
demonstrated for both R1 and R2 (r
2
 > 0.999 in all cases). There was a very slight 
improvement in the R2 dose sensitivity compared with R1 with the slope for batch C for 
R1 = 0.0314 s
-1 
Gy
-1
 and R2 = 0.0403 s
-1 
Gy
-1
 as an example. The dose response for the 
two batches was  similar and this is investigated further in section 4.3.7.  
 
Figure 4.8: R1 and R2 versus dose for two Fricke gel batches. The insert shows a 
small section of the Batch B R2 results with 2 s.d. error bars displayed. These are 
too small to visualise when data markers are added. 
 
To estimate the impact of the results of R1 and R2 uncertainty on the uncertainty in the 
calculated dose, the linear regression equations were used to convert the measured R1 
and R2 values for each individual gel sample to dose. The CV of calculated dose was 
determined for each dose level as a percentage of the planned dose (Table 4.1). 
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Table 4.1: CV in measured dose for 8 samples irradiated to different dose levels 
 
Dose (Gy) 
CV dose (%)  
R1 analysis R2 analysis 
0 n/a n/a 
1 6.1 7.1 
2 4.4 3.6 
3 2.8 3.0 
5 2.7 2.5 
10 1.3 0.9 
15 0.5 0.8 
20 0.3 0.6 
 
There was negligible difference in the precision in measured dose for R1 and R2. The 
CV decreases with increasing dose and is within the set limit of 3% only over a dose 
range of 3 to 20Gy. Below 3Gy, the CV is greater than 3%. This is only one potential 
source of uncertainty, if subsequent experiments highlight any other significant 
contributions to measurement uncertainty, this dose range may need to be reconsidered.  
4.3.4 Time post-manufacture (shelf life) 
The dose response curves for gel samples from a single batch but irradiated at different 
times post manufacture are plotted in Figure 4.9. It can be seen that the R2 increases 
over time due to the long-term signal drift previously demonstrated, despite being 
refrigerated at 4
o
C and kept in the dark. However, the slope only decreased from 0.0369 
s
-1
Gy
-1
 (2 days) to 0.0357s
-1
G
-1
 (22 days).  
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Figure 4.9: R2 dose response at different times post-manufacture. 
 
In terms of the inter-sample variation versus time between manufacture and readout or 
irradiation, the CV in R2 of all unirradiated samples was within 1.0% for each 
measurement session and the CV for the 8 samples irradiated to 3Gy and 20Gy was 
within 0.5% for every measurement session. All individual R2 values were within 1% of 
the mean value for each dose level and every measurement session. This would indicate 
that Fricke gels could be used up to 3 weeks after manufacture. However, the T2 range 
decreases with time post manufacture (Figure 4.10) therefore variations in T2 that occur 
across an MRI scanner due to inhomogeneity and image artefacts may have more 
impact. 
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Figure 4.10: T2 dose response at different times post manufacture. 
 
4.3.5 Variation in detector response with radiation dose rate and integration  
The variation in R2 versus dose rate is presented in Table 4.2. The R2 values presented 
are the mean of four samples irradiated for each set of conditions along with 95% 
confidence intervals (CI) calculated using the t-distribution. Results were all within 
0.3% of the mean value,  there was no trend with dose rate and the 95% confidence 
intervals overlapped. Therefore there was no evidence of dose rate or dose integration 
on dose response.  
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Table 4.2: Variation in R2 with dose rate and dose integration 
Planned 
dose (Gy) 
Dose rate 
(MU/min) 
Integration R2 (s
-1
) [95% CI] 
Normalised 
to mean 
5 600 Single shot 1.021 [1.013-1.029]  0.998 
5 100 Single shot 1.024 [1.016-1.032] 1.000 
5 400 Single shot 1.023 [1.015-1.031] 1.000 
5 600 5100MU (60s) 1.026 [1.018-1.034] 1.002 
20 600 Single shot 1.557 [1.544-1.577] 0.997 
20 600 5400MU (60s) 1.564 [1.551-1.577] 1.002 
20 600 10200MU (45s) 1.563 [1.550-1.576] 1.001 
 
4.3.6 Variation in detector response with radiation energy  
Results of detector response versus energy are shown in Table 4.3 along with 95% 
confidence intervals.  Within each set energy, confidence intervals overlap and there is 
no trend with depth. Therefore there is no evidence of any effect of low energy scattered 
radiation which increases with depth for large field sizes. However, there is possibly a 
small effect seen between 6MV and 15MV beams as shown by the 95% confidence 
intervals for the mean of all measurements. However, in practice, experimental and 
calibration samples would all be irradiated using one set energy, usually 6MV for 
VMAT and stereotactic techniques. Therefore this is not of practical concern.  
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Table 4.3: Variation in R2 with energy and depth (5Gy planned dose) 
Energy (MV) Depth (cm) R2 (s
-1
) [95% CI] 
Normalised 
to mean R2 
6 1.5 1.243 [1.233-1.253] 0.995 
6 5.5 1.243 [1.233-1.253] 0.995 
6 10.5 1.243 [1.233-1.253] 0.996 
6 15.5 1.244 [1.234-1.254] 0.997 
6 20.5 1.250 [1.240-1.260]  1.001 
6MV Mean N/A 1.244 [1.240-1.248] N/A 
15 3.0 1.247 [1.237-1.257] 0.999 
15 5.5 1.251 [1.241-1.261] 1.002 
15 10.5 1.258 [1.248-1.268] 1.008 
15 15.5 1.253 [1.243-1.263] 1.004 
15 20.5 1.252 [1.242-1.262] 1.003 
15MV Mean  1.252 [1.248-1.256] N/A 
 
4.3.7 Consistency of gel manufacture 
Finally, the dose response was compared for 6 different Fricke gel batches 
manufactured at St. Bartholomew’s Hospital. It is emphasised that for chemical 
dosimetry it is standard practice to characterise the dose response for every batch of 
detectors and commonly for each measurement session, therefore differences between 
batches are expected and are accounted for in the calibration process. However this 
inter-batch comparison of dose response was carried out as a general check of the  
consistency of the manufacture process. All batches were irradiated within a few days 
of manufacture. A comparison between different batches is shown in Figure 4.11. The 
slope of the R2 versus dose relationship for all 6 batches was within the range 0.0335 to 
0.0380 s
-1 
Gy
-1
 (mean 0.0358s
-1
 Gy
-1
 ). The intercept was more variable, but as 
demonstrated in section 4.3.2 this is due to chemical reactions vs. time.  
 
 
 105 
 
Figure 4.11: Dose response relationship for different Fricke gel batches 
manufactured at St. Bartholomew’s Hospital. 
4.4 Discussion 
This chapter described systematic investigations into some of the basic properties of our 
Fricke–MR system using test tube samples analysed using an NMR spectrometer. 
Investigations into the chemical stability of this detector demonstrated a sharp increase 
in relaxation rate immediately following irradiation due to reaction completion, in 
agreement with previous reports [23, 28, 91, 92]. It is likely due to reactions taking 
place in the organic matrix as free radical production in the water is completed within a 
very short time of irradiation (<<1s). Reaction completion time was longer for larger 
radiation doses. Reaction completion times of between 10 minutes and 2 hours have 
been previously reported. Our results showed that waiting for at least 12 minutes after 
irradiation before commencing measurements ensures that the ferrous to ferric ion 
reaction has fully completed even for the highest dose investigated here (15Gy). There 
followed a slower increase in relaxation rate over time, which again agrees with 
previous reports [22, 25, 27, 92, 106]. By storing the detectors in the dark container, the 
increase in the relaxation rate over time for unirradiated samples was reduced from 2% 
to 0.2% per hour. This indicates that visible light induces a reaction, as might be 
expected. Other investigators have shown an effect of storage temperature [25, 92, 106] 
and suggested storing the gels at temperatures of 5 to 10
o
C. We have shown that simply 
controlling the ambient light conditions reduces this ongoing drift to an acceptable level 
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for the experiments in this project which were all completed within 2.5 hours of 
irradiation, introducing less than 0.5% difference in results. In practice for the 
measurement of clinical plans, all experimental and calibration samples will be scanned 
simultaneously therefore chemical instability does not contribute to measurement 
uncertainty.  
The precision in the measured R1 and R2 relaxation rates was less than 0.5% for 
unirradiated samples and for samples irradiated to known doses of 1 to 20Gy 
demonstrating chemical consistency throughout the batch. This provided a baseline for 
the subsequent experiments on shelf life, dose rate and energy dependence. In 
comparison, similar analysis for a polymer gel dosimeter reported a coefficient of 
variation of up to 5% in R2 over the same dose range [39]. One paper described the 
inter-sample variation for a Fricke gel detector analysed optically [103] and reported a 
CV of 3% in optical density for 10 detectors both unirradiated and irradiated to 10Gy. 
The results presented here demonstrated a much lower CV than this previous study.  
The dose response was characterised over the dose range 0 to 20Gy. The dose response 
was linear (R
2
>0.999), which is a benefit when compared with other types of chemical 
detector as it simplifies detector calibration. Only two dose levels are required to 
characterise the dose response relationship reducing number of samples and irradiations 
required, further streamlining the process. A comparison between the dose response 
relationships of different batches showed some variation in detector sensitivity between 
batches, emphasising the need to calibrate each batch with known doses.  
The dose response relationship was then used to convert relaxation rate to dose for 
every Fricke gel sample in order to estimate the uncertainty in the measured dose at 
each dose level. At doses used in conventional radiotherapy of 0 to 3Gy, the dose 
uncertainty was greater than 3%. Despite the measurement precision of only 0.5%, 
when converted to dose, this translated to dose uncertainties for radiation doses of less 
than 3Gy which exceeded the 3% set limit. However, this detector shows potential over 
the dose range of 3 to 20Gy where the uncertainty in the measured dose was within 3%. 
This suggests that this detector is particularly suitable for higher dose per fraction 
techniques such as stereotactic radiotherapy (SABR and SRS).  
It is a limitation that the detector cannot be applied to all VMAT techniques. Currently, 
standard of care for many treatment sites including breast, prostate, head and neck, 
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gastrointestinal tract and brain lesions involves conventional fractionation radiotherapy 
schedules (1.5 to 3Gy per fraction). However, there has been a shift towards higher dose 
per fraction techniques over recent years. Stereotactic radiotherapy programmes have 
been implemented across the UK to treat intracranial and body sites. In addition, recent 
trials have investigated hypofractionated treatment schedules for two of the most 
common malignancies; breast and prostate cancer. The results of the FAST trial for 
breast cancer were recently presented at the American Society for Radiation Oncology 
(ASTRO) annual meeting, demonstrating no significant increase in normal tissue 
toxicity for a treatment schedule of 5 (weekly) treatment fractions of 5.7 Gy compared 
with 25 fractions of 2Gy. The PACE trial for prostate cancer is still in progress with the 
experimental arm involving 5 fractions of 7.27 Gy. Stereotactic and high dose 
techniques involve steep dose gradients often abutting critical normal tissue for which 
verification of the accuracy of the full 3D dose distribution is a crucial step in the 
commissioning. In addition, it is these techniques in particular where technology and 
treatment techniques are still evolving, again requiring 3D dosimetry for their 
validation. Therefore Fricke gel dosimetry can still perform an important function 
within clinical radiotherapy dosimetry.  
The experiments into the precision and dose response were repeated using both T1 and 
T2 quantification to enable a comparison between the two methods. There was 
negligible difference in terms of dose response and measurement precision. Over the 
range of doses evaluated here, average dose uncertainty was identical (2.6%) for both 
quantification methods  . This is in contrast to some previous studies [14, 111, 126] 
which showed worse sensitivity or detector precision for T2 quantification. Instead, it 
was demonstrated here that either method may be used for the analysis of irradiated 
Fricke gel detectors. The choice between T1 and T2 quantification methods on an MRI 
scanner may therefore be based on practical factors such optimising the signal-to-noise 
ratio and reducing the scan time. T2 protocols are more widely available on clinical 
scanners and in chapter 3 it was demonstrated that on ours, T2 maps with superior SNR 
and image uniformity were more easily produced.  
Experiments into precision and dose response were repeated for samples from a single 
batch irradiated at various times following manufacture to investigate the shelf life of 
the detector. The R2 precision was still within 0.5% even at 3 weeks. However, the T2 
range decreases with time, which would increase the effect of T2 variations across a 
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clinical scanner with time. All subsequent experiments in the thesis were carried out 
within 2 days of manufacture, however there would be little effect on results if this is 
not practically achievable. 
Finally, there was negligible dependence of detector response on the radiation dose rate 
or energy, agreeing with previous studies [16, 90, 93, 104, 111]. Additional analysis of 
dose integration also showed no effect of delivering the same dose with multiple beams 
compared with a single shot. This is another benefit of the Fricke gelatine detector as no 
corrections are required for dose rate and energy.  
4.5 Conclusion 
This investigation demonstrated the potential of our Fricke gel detector for the 
measurement of radiation dose over the 3 to 20Gy range, whilst keeping the dose 
precision within 3%. A systematic investigation into basic characteristics for a Fricke 
gel detector demonstrated many benefits of this detector system. Batches of Fricke gel 
are simple and quick to manufacture, requiring only simple lab facilities and involve 
nontoxic chemicals. There was negligible difference seen in the dose response and 
precision of T1 and T2 quantification methods, therefore detector readout can be 
optimised based on practical factors such as measurement time and optimisation of 
SNR; T2 protocols may be used. An inter sample variation of less than 0.5% indicated 
chemical consistency throughout a gel batch. Dose response was linear which simplifies 
the calibration as only two dose levels are required to characterise the dose response for 
each batch. Although the dose response will be calibrated for each different batch of 
detectors, the dose response of 6 different batches was compared to demonstrate 
consistency in the manufacture process only. The Fricke gel detector was also shown to 
be independent of both dose rate and local variations in the energy spectrum.  
However, a relatively low dose response may limit this detector to high dose techniques 
such as SABR and this is where efforts will be concentrated for the remainder of the 
thesis. This detector shows sufficient promise to move onto investigations using large 
volume detector samples which will be described in chapter 5.  
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Chapter 5. Evaluation of the homogeneity and volume 
dependence of Fricke gel detector response 
5.1 Introduction 
5.1.1 Aim of this chapter 
Having established basic dosimetric properties for test tube detector samples, the aim of 
the next set of experiments was to investigate factors which might affect the uncertainty 
of measurement for larger volume detectors. Experiments were all carried out using 
large volume Fricke gel samples analysed with a whole-body MRI scanner. In the 
previous chapter, it was demonstrated that in terms of the inherent precision and dose 
response of Fricke gel detectors there is negligible difference between T1 and T2 
quantification methods. In chapter 3, it was demonstrated that the SNR for a T2 CPMG 
pulse sequence was far superior to that for a Look Locker sequence for T1 quantification 
with comparable scan time and pixel size. Therefore, T2 quantification was used here 
and in all subsequent experiments.  
An important requirement for accurate 3D dosimetry is a uniform dose response across 
the detector volume. During Fricke gel manufacture, the mixture is first heated to melt 
the gelatine or agarose, then allowed to cool and finally put in a refrigerator to set. It has 
been reported for agarose gels, that the gel sensitivity varies considerably across large 
volume detectors because of the difference in cooling rate between the centre and edge 
[89]. In general agarose detectors are heated to much higher temperatures than gelatine 
(for example 90
o
C versus 45
o
C) due their high melting point, therefore a lesser effect 
might be expected for the gelatine based detector used in this thesis. It was 
demonstrated that the variation in sensitivity could be reduced by selecting agarose 
types with a lower melting point and using a polysaccharide additive. However, this 
analysis was based on the dose response for small vials of detector material cooled in air 
and in the centre of a gel phantom, rather than investigating the uniformity of a large 
volume gel detector itself. A large volume unirradiated Fricke agarose detector has been 
previously shown to exhibit adequate uniformity [114] and in only one study was a gel 
detector irradiated with a uniform radiation field [92]. The aim of the first experiment in 
this chapter was to evaluate the uniformity of the Fricke gelatine detector both for 
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unirradiated detectors and samples irradiated with a homogeneous radiation dose. 
Different cooling methods were compared.  
Similarly, detectors of different volumes might respond differently to equal doses as 
smaller samples cool more rapidly than large ones. This has previously been 
demonstrated for a commercial polymer gel detector where there was up to 35% dose 
error in the dose measured between test tube samples and larger volumes [40], but not 
investigated for Fricke gels. This is important as it would be beneficial to plot the dose 
response curve using samples of a much smaller volume than the experimental sample. 
This is only possible if detector response does not vary with sample volume. The 
detector response versus detector volume was investigated.  
In the literature review of chapter 2, it was shown that many previous publications had 
explored the issue of post irradiation diffusion of ferric ions. The diffusion coefficient 
has been determined by several groups for both agarose and gelatine based Fricke 
detectors with reasonable agreement [29-32, 87, 90, 108, 109]. However, the impact of 
ferric ion diffusion on clinically relevant dose gradients has not been fully quantified in 
terms of the spatial uncertainty versus time. In this study, the blurring of a range of 
clinically relevant dose gradients was investigated over time in order to determine the 
time within which irradiated detectors should be scanned to maintain a defined and 
acceptable spatial accuracy.  
5.1.2 Chapter overview 
The aim of this set of experiments was to extend the detector characterisation to larger 
detector volumes. Therefore analysis was with the whole-body MRI scanner. The 
homogeneity of response of larger detectors was first investigated (section 5.2.1). It was 
intended to investigate the impact of detector cooling processes following manufacture 
on the homogeneity. Due to the focus for this detector on simplicity of manufacture and 
use, only two cooling regimes were investigated in the first instance; simply leaving the 
detector at room temperature versus placing it in a water bath. Should there be any 
evidence of inhomogeneous response in this experiments, other cooling regimes would 
then be investigated further. The homogeneity of T2 across two unirradiated detectors 
manufactured using the two different cooling methods was assessed and compared. A 
further sample manufactured using the optimised cooling method was then irradiated 
with a uniform dose distribution across the detector volume and the homogeneity of T2 
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response was assessed (section 5.2.2). For this experiment, a radiotherapy plan was 
designed in combination with a rectangular phantom in order to deliver as uniform a 
dose as possible to the detector. The homogeneity of dose delivery depends on the 
number, energy, direction and relative weighting of radiation beams along with the 
phantom cross section (i.e. depth of the detector in the phantom); these were adjusted to 
produce a plan which delivered a dose across the detector which was uniform to within 
± 0.5%, which is as uniform as practically achievable. A tolerance of 1% will be set for 
detector homogeneity in line with the homogeneity of other 2D detectors used in the 
department.   
This same radiotherapy plan was then delivered to five samples with a range of detector 
volumes (8ml to 500ml) and the response versus volume was established (section 
5.2.3). The aim of this experiment was to establish whether small volume samples could 
be used to calibrate large volume samples, therefore detector volumes were selected to 
represent potential calibration and experimental samples. The phantom was modified 
with inserts to accommodate the selected samples to enable the detectors to be irradiated 
under identical conditions. Results were assessed in the context of baseline precision 
established in chapter 4. Ideally there would be no volume dependence. The dose 
response of Fricke gels scanned with the 3T scanner was compared with the 
spectrometer response by irradiating gel samples to known doses, and was also 
compared for several different batches (section 5.2.4), once again purely as a check of 
the manufacture process.  
Finally, an investigation into the diffusion of ferric ions post-irradiation was carried out 
for a range of clinically relevant dose gradients. Analysis focussed on establishing the 
time within which an irradiated detector should be scanned to maintain spatial accuracy 
to within defined limits in terms of distance to agreement between measured and 
calculated dose profiles (section 5.2.5). Typical dose gradients likely in stereotactic 
radiotherapy were considered and this experiment was designed to irradiate a detector 
with dose gradients which at least as steep than those encountered in clinical practice. 
For this experiment, the MRI scan protocol was adjusted to increase the in-plane spatial 
resolution as the steep dose gradient was in this plane. This was at the expense of an 
increased slice thickness. Results were presented in terms of distance to agreement 
between measured and reference profile versus time for each dose gradient. The 
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imaging time to maintain DTA within 1mm and 2mm was quantified; a sub-mm 
discrepancy over a typical imaging session of 1 hour post irradiation would be ideal. 
5.2 Methods 
5.2.1 Homogeneity of unirradiated Fricke gel detectors versus cooling method 
To investigate the effect of cooling on detector uniformity, a 1050ml batch of Fricke gel 
detector was manufactured according to the optimised recipe and manufacture process 
described in chapter 3. Two 500ml volume cylindrical Nalgene bottles (7.3cm diameter) 
(Fisher Scientific, Loughborough, UK) were filled with the Fricke gel mixture. One 
bottle was left at room temperature for 3 hours following manufacture before being 
refrigerated at 4
o
C. The other sample was placed in a water bath, also for 3 hours prior 
to refrigeration. The initial temperature of the water bath was set to be 32
o
C, which is 
the final temperature of the gel during manufacture; the water was then allowed to cool 
naturally. The aim was to reduce the difference in cooling rate between the centre and 
outside of the sample by creating an even temperature across the bottle. Both bottles 
were removed from the refrigerator the night before being scanned at 3T using the 
optimised CPMG sequence described in chapter 3. T2 maps were created using the 
OsiriX plugin and the homogeneity of T2 was evaluated and compared using profiles 
and region of interest analysis.  
5.2.2 Homogeneity of response of a uniformly irradiated Fricke gel detector 
The comparison between cooling methods demonstrated no difference between the two 
cooling methods and adequate detector uniformity for unirradiated samples for both (see 
section 5.3.1). For ease, for all subsequent experiments Fricke gel samples were left at 
room temperature for 3 hours following manufacture before being placed in the fridge. 
The next step was to quantify the homogeneity of detector response to a uniform 
radiation dose distribution. A batch of Fricke gel was manufactured and used to fill one 
500ml bottle.  
The aim of this experiment was to deliver a uniform dose of 10Gy to the sample. In 
order to accomplish this, a water equivalent phantom and a 4 field radiotherapy 
treatment plan were designed to create as uniform a dose distribution across the sample 
as possible. A 10cm (W)  15cm (H)  18cm (L) rectangular phantom was 
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manufactured at the workshop at Barts from WT1 water equivalent material (St. 
Bartholomew’s Hospital, London, UK) and is shown in Figure 5.1.  
 
The design allowed the 500ml bottle to be positioned in the centre of the phantom, with 
additional inserts to accommodate smaller bottles for the subsequent experiment on 
detector volume. 2.5cm thick WT1 blocks were added on top and underneath the 
phantom to create a cube of cross sectional area 15cm  15cm. A four field radiotherapy 
plan was created. Four orthogonal 10x10cm 6MV beams were applied and the isocentre 
(intersection point) was positioned at the centre of the bottle. The plan was normalised 
to deliver 10Gy to the isocentre. The dose was calculated using Eclipse TPS and the 
isodose distribution for the central axial plane is shown in Figure 5.2. The resulting dose 
within the central 6cm length of the bottle was within ± 0.5% of 10Gy.  
 
Figure 5.1: Phantom used for homogeneity experiments. 2.5cm WEP blocks were 
added on top and beneath the phantom.  
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Figure 5.2: 4 field plan used for homogeneity and volume dependence experiments. 
The cyan isodose line is the 10Gy (100%) isodose and the yellow circle indicates the 
diameter of the 500ml bottle. 
 
The Fricke gel sample was removed from the refrigerator several hours prior to 
irradiation and allowed to acclimatise to room temperature (air conditioned, 22
o
C). The 
sample was irradiated with the plan using the Clinac 2100iX linear accelerator. The 
detector was scanned immediately with the optimised CPMG sequence; scanning was 
complete within 40 minutes of irradiation. A T2 map was created within OsiriX and 
analysis of detector uniformity was carried out via profiles and region of interest 
analysis. 
5.2.3 Investigation into the effect of detector volume  
The aim of this next experiment was to investigate the volume dependence of Fricke gel 
detector response in order to establish whether small volume samples may be used to 
calibrate large volume experimental samples. 5 bottles were investigated, the geometry 
and volume of which is summarised in Table 5.1. The 250 ml and 500ml bottles 
represented potential experimental sample geometries, and 8, 15 and 30ml samples were 
selected to assess suitability as calibration samples.  
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Table 5.1 Geometry of cylindrical bottles used for volume dependence experiment 
Volume Diameter (cm) Height (cm) 
500ml 7.3 17.0 
250ml 6.1 13.3 
30 3.4 6.1 
15 2.5 5.8 
8 2.5 4.5 
 
The same phantom and radiotherapy plan was used as for the homogeneity experiment, 
again aiming to deliver 10Gy to each sample. The phantom was modified with inserts to 
accommodate each sample (Figure 5.3).  
 
 
Figure 5.3: Phantom modified with inserts to accommodate other geometry bottles. 
 
One batch of Fricke gel was manufactured and used to fill each of the bottles. 2 
additional 15 ml bottles were filled and left unirradiated to allow the dose response to be 
assessed. All samples were removed from the refrigerator several hours before 
irradiation and were stored together in an air-conditioned room in the dark. All 5 
samples were irradiated during the same session. The 7 samples were then scanned 
simultaneously within 45 minutes of irradiation with the optimised CPMG sequence. T2 
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maps were created and the T2 within regions of interest positioned at the centre of each 
bottle was compared.   
5.2.4 Dose response analysis 
The dose response was plotted using the results of the volume experiment; the 
unirradiated Fricke gel samples and samples irradiated to 10Gy. Additional test tube 
samples were prepared from this same batch, and irradiated to known doses over the 
range 0 to 10Gy according to the method of section 4.2. The test tube samples were 
readout using the spectrometer. Dose response curves for the scanner and spectrometer 
were compared.  
5.2.5 Investigation into the effect of ferric ion diffusion 
The aim of this experiment was to investigate the post-irradiation blurring of the dose 
distribution for a series of steep but clinically relevant dose gradients. A batch of Fricke 
gel was manufactured and poured into 5 small (8  5  3cm) rectangular containers. A 
WT1 water equivalent block (St. Bartholomew’s Hospital, London, UK) was 
manufactured to accommodate these containers and enable them to be irradiated with a 
single radiation field (gantry 0
o
). Irradiation was carried out with a Varian Clinac iX 
linear accelerator (Varian Medical Systems, Palo Alto, CA, USA). Each sample was 
placed in turn in the WT1 water equivalent phantom with 1.5cm of build-up material 
added above and 5cm WT1 material beneath (Figure 5.4). 
A half beam block was created by setting one jaw to 0 cm in order to create the steepest 
possible dose gradients. The field junction was positioned at the centre of the sample. 
The other three jaws were set to 10cm. Three samples were irradiated with this half-
blocked field only, with the open portion receiving 20, 12.5 and 5 Gy (6MV). The 
remaining two samples were irradiated with this field followed a 20  20cm2 open field 
to create dose differences across the junction of 20 to 10Gy and 20 to 5Gy.  
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Figure 5.4: Irradiation set up for diffusion experiments. Gel container in centre of 
a water equivalent block, half irradiated by half beam block field.  
Due to the main scanner being unavailable for this experiment, the irradiated Fricke gel 
samples were scanned on a 1.5T MRI scanner (Philips Achieva) in conjunction with an 
8-channel receive head coil (both Philips Medical System, Best, the Netherlands). The 
imaging requirements for this experiment were different to all other experiments in that 
spatial information was needed across a steep gradient only; therefore scan uncertainty 
was less relevant. Therefore acquisition was designed with a  high resolution was 
desirable in the direction of the steep dose gradient and the scan time was limited to a 
few minutes to allow multiple repeated scans post irradiation. As it can be assumed that 
the diffusion in the perpendicular direction is identical throughout the irradiated 
thickness, the imaging slice thickness was increased to 20mm. The sequence details are 
given in Table 5.2.   
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Table 5.2 CPMG sequence parameters for the scanner 
Parameter Value 
Slice thickness (mm) 20 
Pixel size (mm) 
1.0  1.0 acquired,  0.6 
 0.6 reconstructed 
TR (ms) 1800 
TE (ms) 30 
Echo train length 32 
TE interval (ms) 30 
NSA 4 
Scan duration (min) 3  
 
All five samples were positioned together in the scanner. Scans were acquired over the 
course of 5 hours following irradiation at approximately 10 minute intervals. T2 maps 
were created and analysed within OsiriX as follows. For each scan analysed, a T2 
profile was plotted across the steep dose gradient and exported. The profile was 
imported into Excel and T2 values were converted into R2. A reference profile was also 
exported from Eclipse TPS, which had previously been verified by measurement with 
diodes and small volume ionisation chambers.  
Measured R2 was converted to dose. R2 values at ± 2cm from the beam central axis of 
the measured profile (under the open and shielded part of the field and away from the 
steep gradient) were noted. The expected dose at these points was determined from the 
reference TPS profile and used to characterise the dose-response relationship. This was 
then used to convert R2 values to dose for the entire measured profile.  
At each time point, the maximum distance to agreement between the measured and 
reference profiles was determined in the steep part of the profile i.e. the largest 
difference in distance between the two profiles.  
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5.3 Results 
5.3.1 Homogeneity of unirradiated Fricke gel detectors versus cooling method 
The T2 map for two unirradiated 500ml samples cooled at room temperature and in a 
water bath is shown in Figure 5.5. Alongside are two smaller samples (30ml bottles).  
 
Figure 5.5: T2 map for unirradiated Fricke gel samples (large samples). Left: 
cooled at room temperature, right: cooled in a water bath. 
 
A series of horizontal and vertical profiles were plotted across the axial image of each 
Fricke sample. The central horizontal profile is shown as an example in Figure 5.6. 
There was no noticeable dip in the profiles for either cooling method and the T2 values 
were all within ± 1% of the mean. The mean and standard deviation in T2 within a large 
circular region of interest (22cm
2
, 5cm diameter) centred on the bottle was also 
calculated and results are presented in Table 5.3. The CV of < 0.5% indicates low 
variation between pixels in the region. Finally, the mean and standard deviation of 8 
small (2cm
2
) regions of interest placed in different locations across each bottle was 
619.3 ± 0.9 ms (CV = 0.2%) and 619.4 ± 0.9 ms (CV = 0.2%). The detector 
homogeneity was within the set limit of 1% and therefore deemed acceptable. The 
homogeneity of response to a uniform dose was investigated for a sample cooled at 
room temperature in the next section.  
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(a) 
 
(b) 
Figure 5.6: T2 profiles across unirradiated samples which had been cooled at room 
temperature (a) and in a water bath (b). 
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Table 5.3 Mean and standard deviation in T2 for unirradiated samples within a 
22cm
3
 ROI. 
 
5.3.2 Homogeneity of response of a uniformly irradiated Fricke gel detector 
A representative horizontal T2 profile across a 500ml sample from a different batch 
cooled at room temperature and irradiated with 10Gy is shown in Figure 5.7. Again, 
there was no noticeable dip or inhomogeneity in the profile and T2 values were within 
1% of the mean. The mean and standard deviation within a 22cm
2
 region of interest was 
459.8 ± 1.7 ms (CV = 0.4%).  The mean and standard deviation in T2 of 8 small regions 
of interest (2cm
2
) positioned at various locations across the sample was 459.8 ±0.7 ms 
(CV = 0.1%). 
 
Figure 5.7: T2 profile across sample irradiated to 10Gy which had been cooled at 
room temperature.  
 
Again, the detector inhomogeneity was within the set limit of 1%. It was therefore 
decided to cool the gel for 3 hours at room temperature prior to refrigeration for all 
subsequent experiments.  
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Sample Mean T2 (ms) Sd (ms) CV (%) 
Room temp. 619 1.9 0.3 
Water bath 620 1.7 0.3 
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5.3.3 Investigation into the effect of detector volume 
A T2 map of Fricke gel samples of different volumes irradiated to 10Gy is shown in 
Figure 5.8. Shown also are an additional two 15ml gel samples which were unirradiated 
to enable the dose response to be plotted. The mean and standard deviation in T2 within 
a region of interest (1.8cm
2
)
 
centred on each bottle was calculated and compared (Table 
5.4).  
 
Figure 5.8: T2 map of different volume samples irradiated to 10Gy (two additional 
samples unirradiated).   
 
Table 5.4 Mean T2 within a region of interest centred on different volume samples 
Sample volume 
(ml) 
Dose (Gy) 
Mean T2 (± 2 s.d.) 
in ROI (ms)  
Deviation from 
mean of all bottles 
(%) 
8 10 461 (± 8) 0.7 
15 10 458 (± 6) -0.4 
30 10 453 (± 6) -1.0 
250 10 455 (± 4) 0.1 
500 10 460 (± 4) 0.7 
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The mean T2 was within 1% for the different volume samples and importantly there was 
no trend in T2 with volume. This indicates no evidence of volume dependence for the 
Fricke gel detector.  
5.3.4 Dose response analysis 
The dose response for one batch of Fricke gel samples was compared for test tube 
samples analysed in the spectrometer and larger volume samples readout with 3T 
scanner (Figure 5.9).  
 
Figure 5.9: R2 versus dose for samples analysed in the spectrometer versus the 
scanner. 
There was a difference in dose response for samples analysed in the scanner compared 
with the spectrometer. Some mechanisms of T2 relaxation, for example chemical 
exchange and molecular diffusion, are more efficient at higher fields, particularly due to 
proximity to iron, causing a reduction in the T2 (increase in R2). The dose response is 
greater with the 3T scanner, which is a benefit of this readout method.  
5.3.5 Investigation into the effect of ferric ion diffusion 
Figure 5.10 shows an example T2 map is shown for the five Fricke gel samples 
irradiated with different dose gradients and scanned at approximately 20 minutes post 
irradiation. 
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Figure 5.10: Example T2 map for the five samples irradiated with different dose 
gradients, scanned at 20 minutes post-irradiation. From the top: 10 to 20Gy, 5 to 
20Gy, 0 to 20Gy, 0 to 12.5Gy, 0 to 5Gy. 
 
Profiles across the radiation beam edge were plotted for scans acquired approximately 
every 30 minutes up to 5 hours 20 minutes post-irradiation (a subsection are shown in 
Figure 5.11). There is an apparent blurring of the measured dose over this time period. 
This was quantified as follows. The maximum distance between the reference and 
measured dose profiles was calculated for each scan time (within the steep dose gradient 
region). This was plotted vs. time for the five different dose gradients (Figure 5.12). As 
expected, the DTA increases over time, and more rapidly for the steepest dose gradient 
of 0 to 20Gy.  
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(a) 
 
(b) 
 
(c) 
 
(d) 
 
(e) 
Figure 5.11: Profiles at various times post irradiation for different dose gradients: 
0 to 20Gy (a), 0 to 12.5Gy (b), 0 to 5Gy (c), 10 to 20Gy (d) and 5 to 20Gy (e). TPS = 
treatment planning system reference profile 
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Figure 5.12: Maximum distance to agreement between measured profiles and 
Eclipse TPS profile versus time post irradiation. Plotted for the five different dose 
gradients.  
 
The time at which DTA exceeded 1mm and 2mm is shown in Table 5.5 for each of the 
dose gradients. The dose gradient was quantified in terms of Gy per mm  
Table 5.5 Time to exceed 1mm DTA and 2mm DTA for the various dose gradients 
Irradiation 
details 
Dose gradient within 
+/- 2mm of CAX 
(Gy mm
-1
) 
Time to exceed 
1mm DTA (min) 
Time to exceed 
2mm DTA (min) 
0 to 20Gy 3.2 70 200 
5 to 20Gy 2.4  80 220 
0 to 12.5Gy 2.0  90 235 
10 to 20Gy 1.6  90 250 
0 to 5Gy 0.8  95 245 
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5.4 Discussion 
The first experiments in this chapter focussed on the effect of gel cooling on the 
homogeneity of Fricke gel detectors. Other groups have shown some detector 
inhomogeneity for agarose based gels [89]. However, agarose must be heated to much 
higher temperatures than gelatine during manufacture due to a higher melting point. The 
same investigators evaluated other agarose types with lower melting point and a 
polysaccharide added, with a reduction in inhomogeneity. However, their analysis was 
based on the difference in dose sensitivity of small volume samples cooled rapidly in air 
versus slowly in the gel mixture. They did not investigate the homogeneity across large 
volume samples. Here, we have shown an acceptable homogeneity across unirradiated 
and uniformly irradiated gel detectors, requiring nothing other than some time to cool at 
room temperature prior to refrigeration. Once again, this is aligned with our aim to 
create a simple detector for use in clinical radiotherapy departments.  
The volume dependence of Fricke gel detectors has not been investigated in the 
literature. A volume dependence might exist as smaller samples cool faster than larger 
ones. However, there was no volume dependence for the Fricke gel detector 
investigated here; T2 values for different volume samples irradiated to the same dose 
agreed to within 1%. This is in contrast to a similar experiment carried out using a 
commercial polymer gel detector where large variation (up to 35%) in measured dose 
between test tube samples and larger volumes was demonstrated [40]. It has been 
demonstrated that it is appropriate to use small volume samples to calibrate larger 
volume experimental samples, which simplifies the calibration methodology.  
The diffusion coefficient for ferric ions has been investigated and reported by many 
groups [29, 31, 32, 90, 110]. However, different conclusions have been drawn from 
these results. The diffusion of ferric ions has been reported to render Fricke gel 
dosimetry impractical due to the blurring of measured dose distribution over time 
following irradiation [110]. Balcom et al stated that 24 hours were required post 
irradiation for scanning therefore concluded that recovering the spatial information of 
the radiation dose is impractical [30]. Others concluded that gels should be scanned 
within an hour [22], 2 hours [29] or within 3 hours [87, 98]. Tseng et al concluded that 
for lower dose gradients < 2Gy mm
-1
 the gels could be scanned at least 2 hours post 
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irradiation but for higher gradients greater than 4Gy mm
-1
 spatial information is lost 
after only half an hour [33].  
It has been suggested that the impact of diffusion is dependent on the irradiated dose 
gradient [86]. One report in the literature attempted to quantify the blurring versus time 
by comparing measured with reference dose distribution via a gamma test [87]. This 
was carried out for various dose gradients up to 0 to 40Gy with gamma criteria of 3% 
dose difference and 2mm DTA. All analysis points passed these gamma criteria apart 
from the 0 to 40Gy gradient scanned at 3.25 hours post-irradiation, however the 
reference profile was measured with a large ion chamber which itself blurred out the 
steep gradient used for comparison. 
The aim of the diffusion experiment in this chapter was to systematically quantify the 
time within which gels should be scanned to maintain agreement between a measured 
distribution and reference distribution to within 1mm and 2mm for five steep dose 
gradients. These gradients were selected to be clinically relevant for high dose 
techniques e.g. stereotactic radiotherapy and are far greater than dose gradients achieved 
for conventional radiotherapy doses. These distance to agreement criteria were also 
selected to be clinically relevant. Our results indicate that, for the most relevant dose 
gradients (0 to 12.5 Gy and smaller), a 1mm DTA can be maintained if the irradiated 
Fricke gels are scanned within 1 hour 30 minutes. This is sufficient time to complete an 
MR scan of gel phantoms, however, immediate access to the MR scanner would be 
required. If a 2mm DTA is deemed acceptable, Fricke gels can be scanned up to 3 hours 
20 minutes for even the steepest dose gradients. For subsequent experiments in this 
dissertation, scanning was always completed within 45 minutes of irradiation, reducing 
this uncertainty due to diffusion to less than 1mm.  
These results were for a gelatine based Fricke gel. The composition can be modified to 
reduce the diffusion, for example adding a chelating agent such as xylenol orange [31]. 
However, this has the disadvantage of reducing the MR sensitivity as previously 
demonstrated.  
5.5 Conclusion 
Investigations into the basic properties of large volume Fricke gel detector samples 
were carried out. There was no evidence of any detector inhomogeneity for this detector 
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composition, as long as the detector samples were cooled at room temperature for a 
short time post manufacture. There was also no evidence of any volume dependence 
which means that small volume (e.g. 15ml) samples can be used to calibrate larger 
volume experimental samples, requiring less gel material to be manufactured. A 
blurring of steep dose gradients post-irradiation was seen, which agrees with previous 
literature. This was quantified in terms of the spatial disagreement versus time for 
different dose gradients.  
All the basic detector characterisation measurements have now been completed, 
according to the plan of section 2.5. If immediate access to an MR scanner can be 
arranged, the Fricke gel composition used in this work offers a simple option for 3D 
chemical dosimetry. For our purposes, it is possible to arrange scan time immediately 
following irradiation. The next chapter focuses on applying this optimised Fricke gel 
detector to increasingly complex treatment plans.  
 130 
Chapter 6. Clinical applications 
6.1 Introduction 
6.1.1 Aim of this chapter 
The experiments of chapters 4 and 5 systematically tested the basic properties of the 
Fricke gel detector in very simple radiation fields. The manufacture process has been 
optimised, including methods for cooling, producing gel samples of up to 500ml which 
uniformly respond to irradiation. There was no evidence of any clinically relevant 
dependence of detector signal on radiation dose rate, energy, fractionation or detector 
volume. The inter-sample variation was shown to be adequate over a dose range of 0 to 
20Gy although when converted to dose, percentage uncertainties became unacceptable 
for radiation doses of less than 3Gy due to a relatively low dose response. Chemical 
effects were evident whereby detector signal was shown to vary with time post-
irradiation, initially rapidly due to reaction completion then more slowly due to ambient 
conditions. It was also confirmed that the ferric ions diffuse throughout the gelatine 
matrix following irradiation leading to a blurring of the measured dose distribution. 
However, adequate and well quantified dose and spatial precision was achieved if the 
Fricke gels are scanned at least 12 minutes but within 90 minutes of irradiation and if 
they are stored in the dark.  
With basic characterisation measurements completed by irradiating samples with simple 
radiation fields and known radiation doses, the aim of the final experiments described in 
this chapter was to apply the  Fricke gel detector to a variety of complex radiotherapy 
plans. Firstly, a multiple field plan was created still with reasonably simple geometry. 
The plan was designed with an intentional modulation within the dose distribution to 
evaluate how well the detector can measure moderate variations in dose. The Fricke gel 
detector was then used to measure two high dose per fraction stereotactic VMAT plans.  
High dose radiotherapy plans were selected due to the larger dose uncertainties 
demonstrated in chapter 4 at doses of less than 3Gy. This ties in with an increased 
interest nationally in high dose stereotactic radiotherapy and locally with an aim to start 
delivering stereotactic treatments on Varian linacs. Therefore, the focus in this chapter 
was on investigating the ability of the Fricke gel-MR system to measure these 
treatments. This was accomplished by irradiating Fricke gel detectors with selected 
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treatment plans and comparing measured dose distributions in multiple planes with 
doses predicted by the treatment planning system.  
Dose distributions were compared quantitatively using the gamma evaluation method as 
described in section 1.2.7. In this project, gamma maps were calculated for each pair of 
measured and TPS calculated dose planes for relevant dose difference and distance to 
agreement tolerances. Tolerances were selected based on those currently used at St. 
Bartholomew’s Hospital for VMAT and stereotactic dosimetry as well as published 
recommendations.  
Gamma maps with tolerance values of 3%, 2mm and 5%, 1mm were calculated 
reflecting gamma tolerances currently set at St. Bartholomew’s Hospital for VMAT and 
stereotactic plans respectively. These are similar to those reported for IMRT, VMAT 
and stereotactic national dosimetry audits [74, 75, 128]. For example, a UK VMAT 
dose audit reported gamma pass rates for EBT3 GafChromic film comparison with TPS 
of 93% with a tolerance of 2%, 2mm. A similar UK IMRT dosimetry audit reported 
95% gamma pass rate for simple IMRT plans calculated with dose difference and DTA 
tolerances of 3%, 3mm. These also reflect uncertainties estimated by the IAEA as being 
achievable in their report on uncertainty in radiotherapy [70]. In terms of the accuracy 
of the TPS, within a single distribution, different limits are set: 3% in high dose, low 
gradient regions, 10% or 2mm in high dose, high gradient regions and 4% in low dose, 
low gradient regions. For end-to-end testing in a geometric phantom, this report 
recommends limits on the deviation between calculation and measurement of 3 to 10% 
and spatial uncertainty of 2mm. For stereotactic treatments with very steep dose 
gradients, it is common to have tighter distance but larger dosimetric criteria [73].  
6.1.2 Chapter overview 
Firstly, the procedure for the manufacture, irradiation, calibration and scanning of 
Fricke gels optimised throughout the previous chapters of this thesis and used for these 
final experiments is summarised in section 6.2.1. A commercial software program was 
used for the comparison of measured and calculated dose planes in this chapter, in 
particular the creation of gamma maps; this is described in section 6.2.2.  
Three different radiotherapy plans were evaluated and are described in section 6.2.3 to 
6.2.5. The plans were selected to gradually increase complexity of delivery. The first 
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was a simple conformal plan designed specifically to introduce some additional 
complexity compared with the characterisation measurements, before moving onto 
complex VMAT plans. Two VMAT plans were then selected in order to introduce 
different clinical challenges. The first was a single brain metastasis with no directly 
abutting organs at risk, therefore a more straightforward clinical scenario. The final plan 
evaluated was a much more complicated situation involving a spine lesion, directly 
abutting the spinal cord with conflicting dose constraints between treating the PTV 
versus sparing the cord. A steep dose fall off was required to achieve these constraints, 
and therefore this plan represents one of the most challenging clinical situations. 
For all three plans, delivered and calculated doses were compared with the gamma 
tolerances of 5%, 1mm and 3%, 2mm as outlined in the previous section with an aim of 
achieving a 95% pass rate according to common radiotherapy practice. In addition, 
measurements were made with other radiation detectors for comparison; using the  
PinPoint ionisation chamber, radiochromic film and ArcCheck diode array.  Results and 
analysis are presented in section 6.3. A summary of the dose response of several Fricke 
gel batches was included in section 6.3.1. A summary of the results and analysis for the 
three radiotherapy plans, including gamma analysis is presented in sections 6.3.2 to 
6.3.4. 
6.2 Methods 
6.2.1 Manufacture, irradiation and scanning 
For each experiment, one batch of Fricke gels was manufactured using the optimised 
procedure previously described in section 3.3. One 500ml experimental sample and two 
250ml calibration samples were produced. Whilst it was previously shown that smaller 
samples could be used for calibration, 250ml were selected for this experiment to 
improve the shimming for the MR scans. Shimming a larger region results in a more 
homogeneous magnetic field across the field of view. The Fricke gel samples were 
cooled at room temperature for 3 hours before being placed in the refrigerator. 
Irradiation was always carried out within 3 days of gel manufacture. In each case, the 
gel samples were removed from the refrigerator the night before irradiation and stored 
in an air conditioned, dark room in order to acclimatise to room temperature (22±2°C). 
Gels were then irradiated first thing in the morning, during a single irradiation session. 
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The Fricke gels were irradiated using either a Clinac 2100iX or a Varian Truebeam 
linac. Gel samples were positioned in the water equivalent phantom described in chapter 
5 with the set up shown in Figure 6.1. Marks were carefully drawn on the bottle to 
indicate the top (gantry 0
o
) and sides (gantry 90
o
 and 270
o
) in order to align the 
experimental sample within the phantom using the room lasers. The phantom was 
positioned so that the centre of the bottle was at the linac isocentre. Further details of 
the radiotherapy plans are given below, in sections 6.2.3 – 6.2.5. One calibration sample 
was irradiated with the uniform radiotherapy plan described in section 5.2.2 (either 10 
or 15Gy depending on the maximum planned dose) and the other was left unirradiated.  
Scanning was carried out on the MR scanner at least 15 minutes post-irradiation and for 
all experiments scans were completed within 45 minutes. For each experiment, the three 
Fricke gel samples (experimental plus two calibration samples) were positioned in the 
head coil and scanned simultaneously. The MR lasers were used to align the 
experimental phantom within the scanner. A selection of transverse, coronal and sagittal 
planes were acquired using the optimised CPMG sequence described in section 3.6.6.   
 
Figure 6.1: Irradiation set up for plan measurements. Dome only used for the 
VMAT plans, not the simple multiple field plan.  
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6.2.2 Analysis of dose maps 
T2 maps were first created in OsiriX using the T2 plugin described in section 3.6. A 
region of interest was positioned at the centre of each of the calibration samples and the 
mean T2 was noted. The dose response was plotted and the linear regression equation 
was used to convert the T2 maps to dose maps. The dose maps were then exported in 
DICOM format.  
To create the calculated dose planes for comparison, the radiotherapy plan for each 
experiment was applied to CT scans of the Fricke gel phantom in Eclipse treatment 
planning system (v11 for the simple plan, v13 for the VMAT plans). The 3D dose 
distribution on this phantom was calculated using the AAA photon dose algorithm. 2D 
dose planes corresponding to the scan planes of the irradiated Fricke gel phantom were 
exported as DICOM files.  
Comparison between measured and TPS calculated dose planes was carried out with 
OmniPro I’mRT (IBA Dosimetry, Bartlett, TN, USA). This is a commercial software 
package already in use within the radiotherapy department for the comparison of 2D 
dose planes measured with the MatriXX ion chamber array and the TPS. Within 
OmniPro I’mRT, measured and calculated dose planes were compared using profiles 
and gamma evaluation as described in section 1.2.7. An example gamma map is shown 
in Figure 6.2.  
In OmniPro I’mRT, the gamma map is plotted with a scale (also shown in Figure 6.2) 
such that pixels with a gamma of greater than 1 and therefore failing the gamma test are 
displayed in red. Pixels with a gamma of less than 1 and therefore passing are displayed 
in sliding scale from white to blue. The software also allows the pass rate to be 
calculated within a defined region of interest i.e. the percentage of measurement points 
within the ROI which have a gamma index of <1.  
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6.2.3 Simple multiple field radiotherapy plan 
A simple radiotherapy plan was designed. Three open rectangular 6MV beams (i.e. no 
MLC shielding) were applied from anterior and lateral opposed directions. The 
isocentre was positioned at the centre of the phantom. Relative beam weightings and 
wedges were adjusted to optimise the dose distribution in terms of homogeneity. The 
prescription dose was set to 7Gy (100% isodose).  An additional low weighted anterior 
field was added and MLC was introduced as in Figure 6.3. This produced an intentional 
dip in the horizontal dose profile through the isocentre to approximately 6Gy. The aim 
was to evaluate how well the Fricke gel models a moderate variation in the dose 
distribution. The dose distribution calculated by the treatment planning system is also 
shown in Figure 6.3 for the central transverse plane along with the horizontal dose 
profile across the centre of the Fricke sample.  
 
  
Figure 6.2: Example gamma map. 
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Figure 6.3: Dose distribution and field arrangement on phantom (a), MLC shape 
for low weighted anterior field (b) and horizontal dose profile across centre of 
the Fricke gel sample (c). 
6.2.4 VMAT plan for a brain metastasis 
A previously treated high dose VMAT plan was selected. The patient was prescribed 
radiotherapy for a solitary brain metastasis. The prescription dose was 30Gy in 5 
fractions to the 100% isodose. Two full 360
o
 6MV arcs were applied, the set dose rate 
was 600MU min
-1
 and the collimator angles were set to 30
o
 and 330
o
 for the clockwise 
and anticlockwise arcs. Within the inverse planning module, dose constraints and 
relative weightings were set to fulfil planning aims; in this case only for the PTV as any 
relevant organs at risk were sufficiently far away. Instead dummy planning structures in 
the form of shells around the PTV were used to create a steep dose fall off outside the 
PTV.  Constraints were added aiming to deliver a dose to the PTV within 95% and 
107% of the prescription dose. Once optimised, the dose distribution was calculated and 
the plan was evaluated. This was repeated until all dosimetric requirements had been 
achieved. The dose distributions across central transverse and coronal planes are shown 
in Figure 6.4 along with a horizontal dose profile through the centre of the PTV which 
illustrates the steep dose gradient.  
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The accuracy of delivery of this plan had previously been verified using the ArcCheck 
diode array as described in section 1.2.6 which is an array of 1386 diode detectors 
arranged in a cylindrical phantom used for the VMAT patient specific QC at St. 
Bartholomew’s Hospital. Measured ArcCheck dose distributions are compared with the 
TPS using dedicated software based on the gamma test method. For this plan, 94% of 
measured detector points passed a gamma test with tolerances of 5% and 2mm and this 
was deemed acceptable. 
 
Figure 6.4: Transverse (a) and coronal (b) planes through the PTV showing the 
dose distribution. The horizontal dose profile across the PTV is displayed for the 
transverse plane (a).  
 
The predicted dose distribution was then calculated on CT images of the Fricke gel 
phantom and is shown in Figure 6.5. Dose planes were exported in DICOM format for 
comparison with measurements. The steepest dose gradient in this plan was 1Gy mm
-1
 
which means at least 1.5 hours are available to scan the detector after irradiation to 
maintain a spatial uncertainty to within 1mm according to the previous experiment on 
ferric ion diffusion.  
(a)	 (b)	
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Figure 6.5: Dose distribution for the RapidArc plan re-calculated on a CT scan of 
the Fricke gel phantom.  
 
6.2.5 Stereotactic VMAT SABR spine audit plan 
Finally, a spinal plan used for a dosimetric audit by the national Radiotherapy Trials QA 
team (RTTQA) was used in the third clinical experiment. This had two benefits; firstly, 
the PTV is wrapped around the spinal cord therefore the additional challenge of a 
concave dose distribution was introduced. Secondly, this delivery was comprehensively 
measured by other dosimetric devices ahead of the dose audit.  
The prescription dose was 27Gy/3# to the 100% isodose. Three full 360
o
 arcs were 
applied (one clockwise and two counter clockwise) with collimator angles of 30
o
, 330
o
 
and 10
o
. Planning aims were set according to normal departmental protocols and SABR 
consortium guidelines [129], as follows. 95% of the PTV should receive at least the 
prescription dose and the maximum PTV dose (0.1cc) should be no more than 140% of 
the prescription dose (=37.8Gy). Dose limits for the spinal cord PRV (cord+2mm) were: 
maximum dose <22 Gy, 18Gy <0.35cc and 12Gy<1.2cc. Dose constraints and relative 
weightings were set in the optimiser aiming to fulfil these planning targets. Once again, 
the optimiser was run, followed by a full dose calculation and plan evaluation, repeating 
optimisation until final dose distribution met the plan aims.  Figure 6.6 shows the plan 
and dose distribution calculated on the RTTQA audit phantom.  
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Figure 6.6: Transverse (a) and coronal (c) planes through the PTV showing the 
dose distribution. The dose profile through the centre of the transverse plane is 
shown in (b). 
 
Prior to the RTTQA audit, measurements were carried out by radiotherapy physicists to 
verify the accuracy of dose distribution using existing dosimetry techniques.  The dose 
was recalculated on a water equivalent phantom which can accommodate a 0.015cm
3
 
PinPoint ionisation chamber (PTW, Freiberg, Germany) and piece of EBT3 
GafChromic film (Ashland, Bridgewater, NJ, USA). A dose measurement with the 
PinPoint ionisation chamber was carried out at a point in the centre of the PTV. A 
single sagittal dose plane was measured using the radiochromic film and compared to 
the corresponding plane exported from the TPS using gamma analysis within SNC 
patient software (Sun Nuclear Corporation, Melbourne, FL). These methods are used 
routinely at St. Bartholomew’s Hospital for the verification of the accuracy of 
stereotactic treatments delivered with the Cyberknife treatment machine. The PinPoint 
chamber measurement gave a measured dose of +3.2% when compared with the 
treatment planning system, which was deemed acceptable. The comparison between 
film distribution and TPS yielded excellent results as shown in Figure 6.7. A gamma 
test was carried out in relative dose mode with tolerances of 5% and 1mm and >97% of 
pixels passed.  
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Figure 6.7: Comparison between radiochromic film plane (top left) and TPS (top 
right) showing excellent agreement between measurement and TPS. Gamma test 
results (bottom left) were carried out for 5% 1mm, relative dose mode, both 
normalised to point of dose maximum on film.   
 
The dose distribution was recalculated on the CT scan of the Fricke gel phantom 
(Figure 6.8). This was then exported to enable comparison with the measured dose 
distribution. The calibration sample was irradiated to 15Gy in this instance as the 
maximum planned dose was 12Gy. The steepest dose gradient in this plan was again 
1Gy mm
-1
 which again allows at least 1.5 hours post irradiation to scan the phantom.  
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Figure 6.8: Dose distribution for the SABR spine plan calculated on a CT scan of 
the Fricke gel phantom.  
6.3 Results 
6.3.1 Calibration.  
A summary of the dose response curves for five Fricke gel batches used in the 
homogeneity experiments described in chapter 5 and clinical plan experiments in this 
chapter is shown in Figure 6.9. Again, this was carried out as a check of the consistency 
of the detector manufacture process as dose response will be characterised for each 
batch and measurement session. The slope for all 5 batches was within the range 
0.0631- 0.0697 s
-1
 Gy
-1
 (mean 0.0660 s
-1
 Gy
-1
, CV 4%) and the intercepts were all 
within the range 1.241-1.449 s
-1
 (mean 1.342 s
-1
, CV 7.5%). These results indicate 
consistency of manufacture process but again, it also  highlights the need to quantify the 
dose response for each gel batch.  
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Figure 6.9: Comparison between dose response curves for different Fricke gel 
batches.  
 
6.3.2 Simple multiple field radiotherapy plan 
The T2 map for the central transverse plane of the simple radiotherapy plan is shown in 
Figure 6.10a. The T2 within a region of interest positioned on each of the calibration 
bottles was noted and used to calculate the linear regression equation which 
characterises the dose response. This was then applied to the T2 map to create a dose 
map.  
Visual inspection of the measured and calculated dose profiles indicated good 
agreement in the shape albeit with a small systematic dose offset of 4%. The measured 
dose distribution was higher than the calculated. This agrees with the PinPoint chamber 
dose, which was 2% high compared with TPS dose, to within measurement uncertainty. 
OmniPro I’mRT analysis for this plan is shown in Figure 6.10b-d with this offset 
applied. The measured dose distribution is shown along with the distribution calculated 
by the treatment planning system.   
0.0
0.5
1.0
1.5
2.0
2.5
0 2 4 6 8 10
R
2
 (
s-
1
) 
Dose (Gy) 
P
S
T
W
X
 143 
 
Figure 6.10: T2 map of the transverse plane through the centre of the simple 
radiotherapy plan (a) and corresponding I’mRT software analysis; (b) measured 
dose plane, (c) TPS calculated dose plane and (d) example profile through 
measured and calculated dose plane.  
 
Gamma maps were calculated for  the selected dose difference and distance to 
agreement tolerances again with this offset applied. These are shown in Figure 6.11. 
Visually, only small regions of red on the gamma maps are seen, indicating good 
agreement between measured and TPS dose distributions. To quantify this in terms of 
percentage pass rates, a region of interest was positioned entirely within the bottle (to 
exclude high gamma values outside of the bottle) and the percentage of pixels passing 
the gamma test criteria were calculated (Table 6.1). The pass rate was greater than the 
set target of 95% for gamma tolerances of 3%, 2mm, and for 5%, 1mm.   
(a) (b)	 (c)	
(d)
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Figure 6.11: Gamma maps for different dose difference and DTA tolerances: (a) 
3% 2mm and (b) 5% 1mm. 
 
Table 6.1: Gamma test results for the multiple field plan 
Gamma 
settings 
Transverse 
pass rate (%) 
3% 2mm 98.5 
5% 1mm 96.2 
 
6.3.3 VMAT plan for a brain metastasis 
Transverse and coronal T2 maps through the centre of the first high dose RapidArc plan 
are shown in Figure 6.12a. Measured and calculated dose maps for the central 
transverse and coronal planes are shown along with a horizontal profile plotted through 
the centre of each plane in Figure 6.12b-d. In this case, visual inspection between 
measured and calculated dose profiles indicated no systematic dose offset and therefore 
no re-scaling necessary. Gamma maps for  the selected dose difference and DTA 
tolerances are shown for the central transverse plane and coronal plane in Figure 6.13. 
Gamma pass rates are shown in Table 6.2. More than 95% of pixels passed for both sets 
of tolerances for the transverse plane and the coronal plane. A region of gamma failures 
are seen on the coronal plane towards the edge of the Fricke gel sample, however this is 
away from the high dose, steep gradient region and gamma pass rates met the 95% set 
tolerance.  
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Table 6.2: Gamma test results for the stereotactic brain plan 
Gamma 
settings 
Transverse 
pass rate (%) 
Coronal pass 
rate (%) 
3% 2mm 99.8 96.6 
5% 1mm 99.8 99.1 
 
6.3.4 Stereotactic VMAT SABR spine audit plan 
Transverse and coronal T2 maps through the centre of the high dose SABR spine 
VMAT plan are shown in Figure 6.14a. The was again a small offset of 4% between 
measured and calculated doses, with measured dose greater than the TPS. This agreed 
with the PinPoint ionisation chamber dose measurement, which was +3% compared 
with the TPS. I’mRT software analysis is shown for the central transverse, coronal and 
sagittal planes (Figure 6.14b-d) with this re-normalisation applied. Visual inspection 
indicates good agreement between the measured and calculated dose profiles in terms of 
the shape especially in the steep fall of region. To quantify this, gamma maps for the 
selected dose difference and DTA tolerances were calculated, shown for the central 
transverse, coronal and sagittal planes in Figure 6.15.  
The percentage of pixels passing the gamma test tolerances within a region of interest is 
shown in Table 6.3. Larger regions of failure are seen for this plan, although these are 
away from the central high dose, high gradient region. Pass percentages were still 
greater than 95% for the transverse plane. For the coronal and sagittal planes, pass rates 
were below 95%. For the 5%, 1mm tolerance typically used for stereotactic dosimetry, 
the pass rate in the sagittal plane was 93% but for the coronal plane was only 84%. This 
can be seen in the gamma maps, where large regions of gamma failures are seen 
laterally towards the edge of the bottle.  
Table 6.3: Gamma test results for the SABR spine plan 
Gamma 
settings 
Transverse 
pass rate (%) 
Coronal pass 
rate (%) 
Sagittal pass 
rate (%) 
3% 2mm 98.7 85.5 92.1 
5% 1mm 98.4 84 92.9 
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Figure 6.12: T2 maps (a) and I’mRT software analysis of the brain VMAT plan for the central transverse and coronal planes. (b) measured 
dose map (c) TPS calculated dose map and (d) example measured (red) and calculated (green) dose profiles.  
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Figure 6.13: I’mRT software analysis for the central transverse and central coronal 
planes of the brain VMAT plan: (a) 3% 2mm and (b) 5% 1mm. 
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Figure 6.14: T2 maps (a) and I’mRT software analysis of the SABR spine radiotherapy plan for the central transverse, coronal and sagittal 
planes (b) measured dose map (c) TPS calculated dose map and (d) example measured (red) and calculated (green) dose profile. 
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Figure 6.15: I’mRT software analysis for the SABR spine plan showing gamma test 
results for tolerances of (a) 3%2mm and (b) 5% 1mm.  
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6.4 Discussion 
The focus of the final experiments described in this chapter was the irradiation of Fricke 
gel detectors with more complex radiotherapy plans in order to develop and assess the 
process by which they perform the function of a 3D commissioning measurement of 
VMAT dose calculation and delivery. The dosimetric characterisation of these detectors 
had been carried out in previous chapters in line with methods used to characterise other 
radiation dosimeters in the literature. The aim for a dosimetric uncertainty of less than 
3% was achieved, and is similar to other 2D detectors used for VMAT dosimetry 
summarised in table 2.1  
Fricke gel detectors were irradiated with a series of treatment plans and 2D dose maps 
in coronal, transverse and sagittal planes were created. These dose maps were compared 
against corresponding calculated dose distributions exported from the treatment 
planning system. In order to quantitatively compare distributions, gamma evaluation 
was carried out using a commercial software package, OmniPro I’mRT.  
Gamma evaluation is widely used in radiotherapy for the comparison of measured and 
calculated IMRT and VMAT dose distributions. Tolerances are set for acceptable 
values of dose difference and distance to agreement. To put the results obtained in this 
project into context, publications describing national dosimetry audits i.e. 
inter-comparison between different radiotherapy centres were reviewed. In the UK, 
national IMRT, VMAT and SABR (Lung) dose audits have been carried out [74, 75, 84, 
128].  
Budgell et al published details of a UK wide IMRT dose audit [128]. Less complex 
(non head and neck) IMRT plans were reported to all achieve greater than 95% pass 
rates for gamma tolerances of 3%, 3mm with evaluation within the 20% isodose. More 
complex head and neck plans were reported to achieve greater than 95% pass rates only 
for tolerances of 4%, 4mm. For VMAT, another UK dose audit was carried out using a 
2D PTW array and EBT3 radiochromic film. Here, the mean pass rate for H&N plans 
with tolerances of 2%, 2mm was 93.4% [75]. Seravalli et al reported on a Dutch dose 
audit including stereotactic treatments for which 5%, 1mm gamma tolerances were set 
and achieved greater than 98% pass rate, carried out using a EBT3 film and an 2D array 
[73].  
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In this investigation, gamma maps were calculated for selected gamma tolerances. 3%, 
2mm was selected to represent tolerances commonly used in radiotherapy for the 
verification of conventional dose VMAT plans and 5%, 1mm appropriate for 
stereotactic radiotherapy. A typical aim adopted in the radiotherapy literature is for 95% 
of measured points to pass a gamma test. 
For the first experiment in this chapter, a multiple field plan was created. The aim was 
to increase the complexity of radiation distribution beyond the previous characterisation 
experiments but still deliver the plan with conventional, non-modulated fields. An MLC 
field was added with central shielding to create an intentional dip in the dose 
distribution in order to investigate how well the Fricke gel measured this. The measured 
dose distribution for the central transverse plane was compared with the distribution 
predicted by the treatment planning system. Visual inspection indicated good agreement 
in the shape of the radiation distribution for this plan but a systematic offset in the dose 
of 4%. This dose agreed with the PinPoint ion chamber dose to within measurement 
uncertainty. If the measured dose distribution was re-normalised by 4%, then gamma 
test results achieved the set 95% pass rate.  
The second plan evaluated was a previously treated clinical VMAT plan for a brain 
metastasis. This was a reasonably straightforward clinical plan with no directly abutting 
critical structures. The dosimetric accuracy had been verified previously with the 
ArcCheck diode array.  Visual inspection of the dose distributions in terms of dose 
profiles indicated that no re-scaling was necessary for this plan. Again, the pass rate was 
greater than 95% for both sets of gamma tolerances and both image planes analysed. 
Visual inspection of the gamma maps and profiles showed a region of disagreement 
laterally in a reasonably low dose region (<40% of maximum dose) however this was 
away from the very steep dose gradient.  
The third experiment used a stereotactic spine test plan that was being used for a joint 
SABR consortium/ RTTQA UK dose audit. This was evaluated as part of the 
commissioning process for a Truebeam machine not clinical yet for stereotactic 
radiotherapy and represented a more complex clinical scenario. The PTV directly 
abutted the spinal cord, therefore introducing conflicting dose constraints into the 
planning process. The dosimetric accuracy of this plan was evaluated using the standard 
departmental procedure with a PinPoint ionisation chamber and a radiochromic film for 
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a single sagittal plane. The PinPoint chamber measured dose was 3% greater than that 
predicted by the TPS and film results showed acceptable agreement in the shape of the 
distribution in the sagittal plane. In terms of the Fricke gel results, visual inspection of 
the dose distributions and dose profiles indicated good agreement in the shape of the 
distribution in the three measured planes. However once again a dose offset was 
required; the Fricke gel measured dose was higher than that predicted by the TPS by 
approximately 4%. This agreed with the PinPoint measured dose to within 1%.  
For the transverse plane, gamma test results once again, achieved a pass rate of more 
than 95% for both sets of gamma tolerances.   For the 5%, 1mm tolerance commonly 
used in stereotactic radiotherapy dosimetry, the pass rate was 93% for the sagittal plane 
but only 84% for the coronal plane with areas of disagreement seen laterally on the 
gamma map. The cause of this disagreement is unclear. It is not seen in the transverse 
plane which also measures the dose laterally; gamma results for this dose map were 
within acceptable limits. Also, it seems unlikely to be due incorrect dose calibration. A 
steeper dose gradient and wider dose range is present in the anterior-posterior direction 
but in this direction measured and calculated doses agree very well as shown by profiles 
for the sagittal plane in Figure 6.14.  
This should be further investigated. The beam model within the treatment planning 
system may possibly need to be further optimised very slightly for stereotactic 
radiotherapy with this treatment machine, although even with these discrepancies, this 
dose disagreement is only seen in a low dose region, away from any steep dose 
gradients. In this plan, the critical structure is the spinal cord, therefore the verification 
of the fall-off in the dose in the anterior-posterior direction is of particular interest. The 
measured and delivered dose profiles showed excellent agreement in this direction, 
confirming the dose accuracy to the cord. According to our clinical practice, this plan 
would be accepted for treatment. 
6.5 Conclusion 
In this final set of experiments, a comparison was carried out between dose distributions 
measured with the optimised Fricke gel-MR system and those predicted by the 
treatment planning system for three radiotherapy plans. For two of the plans evaluated, 
a small re-normalisation was required to the measured dose distribution (4%). This dose 
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deviation did agree with the dose measured by the PinPoint ionisation chamber to 
within measurement uncertainties and is likely to be a combination of detector 
uncertainty and a small actual deviation in dose calculation and delivered dose. PinPoint 
dose measurements were within local clinically acceptable tolerances. Combining 
chemical dosimetry with a more precise ionisation chamber dose measurement is a 
common approach [7, 74].  
Measured and calculated distributions were then compared quantitatively using the 
gamma evaluation method for a range of dose difference and DTA tolerances. Standard 
departmental tolerances of 3%, 2mm for VMAT and 5%, 1mm for the stereotactic plans 
were used. For a simple multiple field plan and a high dose VMAT plan for a brain 
metastasis a 95% pass rate was achieved for the standard departmental tolerances. For 
the spine stereotactic VMAT plan, these criteria were also achieved for the transverse 
plane. Gamma pass rates were less than 95% for the central sagittal and coronal planes 
of this plan. However, the gamma maps indicated that disagreement was mostly in 
regions away from the high dose region and in practice this plan would be accepted for 
treatment. Measured and calculated doses agreed well in steep dose gradients, critically 
across the junction between the PTV and the spine.  
These experiments described in this chapter demonstrated the ability of the Fricke gel 
detector to measure complex VMAT, stereotactic dose distributions. In this study, 
multiple 2D planes were analysed so full 3D dosimetry has not yet been demonstrated.  
However, the ability to acquire multiple 2D dose maps for one detector irradiation is 
already an advantage over existing 2D measurement devices such as radiochromic film. 
For 2D films one irradiation is required per measured dose plane. The extension to 3D 
will be the subject of future work. For now, this device has been demonstrated to be a 
useful tool for future work to commission and test the accuracy of new high dose 
radiotherapy treatment techniques, equipment and software.  
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Chapter 7. Discussion 
7.1 Review of project background 
This project was prompted by the difficulties encountered by physicists within a clinical 
radiotherapy department when trying to commission and verify the accuracy of modern 
radiotherapy techniques. Over recent years, radiotherapy technology has evolved and 
now offers the ability to focus dose distributions precisely to the tumour volume in 3D. 
This is accomplished in various ways; with IMRT by moving MLC leaves across the 
beam during treatment and with VMAT by rotating the linac gantry around the patient 
and simultaneously varying the dose rate, gantry speed and MLC shape. These advances 
in technology allow radiation doses to tumour volumes to be boosted and doses to 
neighbouring organs at risk to be spared, however alongside this is an increased risk of 
errors in dose calculation and delivery. MLC shapes and leaf motions are complex and 
it has been shown that sub-mm errors in MLC position can cause dose errors of several 
percent. Since the start of this project, there has also been an increased interest in 
stereotactic radiotherapy whereby large (ablative) radiation doses are delivered with 
precise spatial accuracy to tumours over only a few treatment fractions. Typical doses in 
conventional radiotherapy are in the region of 2-3Gy per fraction whereas stereotactic 
doses may be up to 20Gy in a single fraction. Stereotactic radiosurgery describes the 
treatment of intracranial tumours whereas stereotactic ablative body radiotherapy 
describes the delivery of high dose treatments to other body sites. At St. Bartholomew’s 
Hospital, stereotactic radiotherapy is currently delivered using a Cyberknife unit which 
is a linear accelerator mounted on a robotic arm. The treatment is delivered with many 
tens of small radiation beams directed from a wide range of non-coplanar beam angles 
which sum together to create the 3D dose distribution. It is proposed to start delivering 
stereotactic treatments using Varian Truebeam linacs which offer benefits for certain 
tumour sites in terms of a faster treatment delivery and pre-treatment soft tissue imaging 
via on board cone beam CT (CBCT). Stereotactic treatments involve very high dose 
gradients and therefore there are stringent requirements on spatial accuracy in 
particular.  
It is no longer appropriate to check the accuracy of the treatment planning system for 
specific patient plans by hand calculation only as the dose to one point is not reflective 
of the whole 3D distribution. The steep dose gradients introduce additional dosimetric 
 155 
challenges. It was proposed that with the introduction of IMRT and VMAT, another 
type of verification was required. Rather than checking each individual step in the 
radiotherapy process, it was proposed that the overall accuracy of calculation and 
delivery would be verified and this would be carried out by a measurement of delivered 
dose in a phantom. This measurement is compared with the dose predicted by the 
treatment planning system. For the commissioning of new radiotherapy technology, 
software and techniques, a high resolution dose measurement is recommended.  
Dose measurements in radiotherapy are currently carried out using a variety of point, 
2D and pseudo-3D detector arrays which offer benefits for particular applications but 
none of which allow a high resolution measurement of the entire 3D dose volume. The 
most commonly used systems are radiochromic film, the EPID and pseudo-3D arrays 
such as the ArcCheck and Delta 4. Radiochromic film offers a high resolution 
measurement but only for a single selected 2D plane. The EPID is emerging as a useful 
tool in terms of transit dosimetry whereby the exit dose transmitted through the patient 
is measured and reconstructed to predict the dose actually delivered to the patient. The 
EPID may also be used for pre-treatment QC of patient plans, however, this method 
does not provide a direct measurement of the delivered dose within the patient (or a 
phantom) and software tools are required to predict the dose distribution within the 
patient which must itself be rigorously checked. In addition, the EPID, rotates with the 
linac gantry and therefore will not pick up errors in gantry speed or motion. 3D detector 
arrays are commonly used for patient specific QC and are useful for this task as they 
give an immediate, fast measurement of dose. However, the devices available such as 
the ArcCheck and Delta4 involve large detector spacing (>0.5cm) and the detectors are 
not positioned throughout the entire 3D volume. None of the detectors currently 
available offer a high resolution measurement required for the commissioning stage of 
new techniques and technology.  
3D chemical dosimetry was proposed as a solution to this dosimetric challenge. 
Chemical detectors undergo a measurable change when irradiated for example a colour 
change or a rise in temperature. When mixed into a solid matrix, such as gelatine or 
agarose, the chemicals are fixed and the 3D delivered dose distribution may be mapped. 
Fricke gel dosimetry was proposed in the early 1980’s, based on the radiation induced 
oxidation of ferrous to ferric ions. This causes a change in the optical density which 
may be quantified using optical-CT scanners, but also a change in the R1 and R2 
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relaxation rates enabling 3D dose mapping using MRI scanners. Benefits of Fricke gel 
detectors include a simple chemistry, low toxicity chemicals, linear dose response and 
no dose rate or energy dependence. However, concerns about the post irradiation 
diffusion of ferric ions causing a blurring of the measured dose distribution turned the 
focus towards polymer gel dosimetry. Polymer gel detectors involve a monomer such as 
acrylamide which polymerises on irradiation forming long polymer chains. Again, this 
affects the optical density and R2 relaxation rate therefore readout may be with optical 
CT or MRI. Polymer gel detectors involve more toxic chemicals, and require oxygen to 
be removed from the mixture. This was either achieved by bubbling nitrogen through 
the mixture (requiring a fume hood) or adding oxygen scavengers. Either way, the 
manufacture of these detectors is less straightforward than Fricke gel dosimetry. 
Alternate radiochromic detectors were proposed, such as Presage, also involved more 
complicated manufacture procedures and at the inception of this project were not 
commercially available. 
Despite the potential benefits of 3D chemical dosimetry and many years of research, 
focussing on detector composition, manufacture methods and readout methodology, 3D 
chemical dosimetry is still not implemented widely in clinical radiotherapy. This was 
true at the start of this project and is still the case now. A recently published text book 
on 3D dosimetry for modern radiotherapy highlighted again the need for a 3D detector 
and the potential for 3D chemical dosimetry to fulfil this function but acknowledged 
that chemical detectors still hadn’t been widely adopted beyond research groups. This 
has been attributed to complicated manufacture procedure in polymer gel detectors and 
Presage, difficult access to scanners but importantly a lack of confidence in their 
dosimetric performance. It is crucial to establish the dosimetric performance for any 
radiation detector prior to applying to them to complex dose distributions. For any 
detector, a systematic characterisation of detector properties such as dose rate, energy 
dependence, and homogeneity is required. 
The aim of this project was to evaluate a 3D chemical detector for use within a clinical 
radiotherapy department. In the absence of commercial options, it was decided to 
manufacture this detector in-house, therefore Fricke gel dosimetry was selected as it is 
based on non-toxic chemicals and may be manufactured in a simple laboratory with 
basic equipment. Optical-CT and MRI have been used for the readout of Fricke gel 
detectors. MRI was selected for this study, again due to the availability of a clinical 
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MRI scanner within the hospital. It has been suggested that optical-CT could be more 
suitable as accessing an MRI scanner can be difficult due to clinical workload, however, 
access was possible within the department at St. Bartholomew’s Hospital. In contrast, 
an optical-CT scanner would have to be purchased, or built, and commissioned 
specifically for chemical dosimetry. There are still only limited commercial options, the 
most common being a Vista cone-beam CT scanner which has reported issues with stray 
light. Manufacturing an optical-CT scanner within the department at St. Bartholomew’s 
Hospital was considered beyond limits of available time and expertise. 
With the detector-imaging system selected, the focus of the project was then on the 
systematic evaluation of detector performance before application to complex 
radiotherapy scenarios, which is summarised in the following sections.   
7.2 Project overview 
7.2.1 Chapter 2: Literature review 
The first step in this project was to outline and quantify at the outset the requirements of 
a detector for the 3D measurement of VMAT radiotherapy techniques. This was 
accomplished with reference to international guidance documents [9, 10, 70]. Basic 
requirements were that this detector should offer a 3D measurement, and that this 
measurement should be a direct dose measurement in a phantom throughout the high 
dose region. Ideally, it would be possible to position a detector in a variety of geometric 
and anthropomorphic phantoms. Limits for dosimetric and spatial uncertainty of 3% and 
1mm were set based on analysis of reference reports on the accuracy practically 
achievable in radiotherapy and the measurement uncertainty achieved in non 3D 
detectors. It is also acknowledged in radiotherapy that there are inherent compromises 
with radiation dosimetry, i.e. increasing detector resolution is done at the expense of 
dosimetric uncertainty [76]. The detectors currently in use in clinical radiotherapy do 
not meet these requirements as none offer a true 3D measurement.  
A literature review was then carried out to search for existing evidence on detector 
performance for Fricke gel dosimetry. The entire manufacture, irradiation and readout 
process was analysed to identify all possible sources of measurement uncertainty. These 
included inter-sample variation, chemical and spatial instability, dose rate, energy and 
volume dependence and inhomogeneity of detector response. The literature was then 
 158 
reviewed to identify papers which described any of these factors for Fricke gel 
detectors.  
Whilst many papers investigated specific properties for particular compositions, there 
was a lack of systematic approach to their commissioning. There was no or very little 
evidence for some factors including inter-sample variation, volume dependence and 
detector homogeneity. Other factors were shown to depend on the detector composition 
and constituent chemicals, such as dose response, homogeneity, chemical and spatial 
stability which highlighted the importance of performing this systematic 
characterisation for each specific detector composition.  
Chemical stability had been studied previously by several groups, albeit for optical-CT 
analysis, demonstrating a steep initial increase in signal due to reaction completion 
followed by a more gradual change due to chemical reactions caused by other effects. 
However, the effect of ambient light, often a cause of signal drift for chemical detectors, 
had not been investigated despite being a common cause of signal instability for 
chemical detectors. Dose response had been widely studied and shown to be dependent 
on chemical composition, time between manufacture, irradiation and scanning and was 
shown to vary for different batches of the same detector. Most authors had 
demonstrated a linear relationship between detector signal (optical density of relaxation 
rate) and dose for doses of at least 20Gy, although some had shown a deviation from 
linearity. Linearity is desirable as it makes calibration and the characterisation of the 
dose response relationship simpler. 
Inhomogeneity of detector response across large volume agarose based detectors had 
been previously demonstrated, due to the different cooling rate following manufacture 
between the centre and edge of the detector. This had not been fully investigated for 
gelatine based detectors which are heated to lower temperatures during manufacture and 
therefore might be less of an issue. Finally, many groups had highlighted a post-
irradiation diffusion of ferric ions causing a blurring of the measured dose distribution 
over time. The focus in previous work had been on quantifying the diffusion coefficient 
and the effect of this diffusion on measured dose distributions had not been fully 
quantified. Only one paper was found which had attempted to quantify diffusion for a 
range of dose gradients in a systematic way. Therefore, the time within which detectors 
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should be scanned following irradiation had been reported as between 0.5 to 3 hours or 
that the ferric ion diffusion rendered Fricke gel dosimetry impractical altogether.  
This review was used to develop an experimental plan for this project; a systematic 
method of commissioning a 3D chemical detector. It was recommended that basic 
dosimetric characteristics including chemical stability, dose response and inter-sample 
variation will be evaluated first using test tube samples of Fricke gel irradiated with 
simple radiation fields and analysed with an NMR spectrometer. Larger volume 
samples analysed with an MRI scanner could then be used to explore detector 
homogeneity, the impact of ferric ion diffusion on clinically relevant dose gradients and 
volume dependence. Finally, only if results show adequate detector performance, would 
the detector be applied to increasingly complex radiotherapy plans.  
7.2.2 Chapter 3: Gel Manufacture and MR analysis methods 
The first aim of chapter 3 was to develop methods for the manufacture of Fricke gel 
detectors. The chemical composition was decided by reviewing the literature for 
existing evidence on the effect of different chemical constituents on parameters such as 
detector sensitivity. The focus was on simplicity, aiming to incorporate as few 
chemicals as possible with a low toxicity. This was accomplished and the final 
composition was 0.5mM ferrous ammonium sulphate, 25mM sulphuric acid, 5% 
gelatine and distilled water. The manufacture of approximately 1l batches of Fricke gel 
detectors within a simple laboratory was streamlined. The final optimised process took 
2 hours plus cooling time.  
Once the manufacture process had been developed, attention turned towards the readout 
of detectors. A bench-top NMR spectrometer was commissioned for the analysis of test 
tube Fricke gel samples, and a whole-body MRI scanner for the quantification of larger 
volume samples. It was unclear from the literature review whether T1 or T2 
quantification was more appropriate for Fricke gel dosimetry, therefore this was to be 
the subject of future investigation.  
For the NMR spectrometer, an inversion recovery sequence was used for T1 
quantification, and a CPMG sequence for T2 quantification. Copper sulphate QC 
samples were used to evaluate and compare different pulse sequence parameters in 
terms of repeatability and linearity of R1 and R2 versus copper sulphate concentration. 
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Repeatability was within 0.2% for both sequences and the relationship between 
relaxation rates and copper sulphate concentration was linear for both sequences as 
expected. The measurement time for the typical relaxation times expected for Fricke gel 
samples was 5 minutes for T1 compared with 1 minute for the optimised T2 sequence.      
Pulse sequences were then customised for a Philips Achieva 3T MRI scanner. Analysis 
software was written within OsiriX open source image analysis platform for the creation 
of T1 and T2 maps and dose maps. A Look Locker sequence was used for T1 
quantification and CPMG sequence used for T2 quantification. Pulse sequence 
parameters were set to optimise the sequence in terms of maximizing SNR. Larger 
volume copper sulphate samples were prepared for the evaluation of sequences in terms 
of SNR, noise, homogeneity and repeatability. SNR was higher and image uniformity 
was improved for the optimised protocol for T2 quantification when compared with the 
Look Locker protocol for scan times of similar duration.  
7.2.3 Chapter 4: Establishing basic detector properties 
The next chapter described systematic investigations into some of the basic properties 
of our Fricke–MR system using test tube samples analysed using an NMR spectrometer. 
Investigations into the chemical stability of this detector demonstrated an increase in 
relaxation rate immediately following irradiation due to reaction completion, in 
agreement with previous reports. The reaction time was shown to depend on radiation 
dose, but was a maximum of 12 minutes for the highest radiation dose. There followed a 
slower increase in relaxation rate over time, however this was reduced from 2% to 0.2% 
per hour by storing the detectors in the dark in between measurements.  
The precision in the measured R1 and R2 relaxation rates was less than 0.5% for 
unirradiated samples and for samples irradiated to known doses of 1 to 20Gy indicating 
an excellent chemical consistency throughout the batch. In comparison, similar analysis 
for a polymer gel dosimeter reported a coefficient of variation of up to 5% over the 
same dose range [39]. The dose response was characterised over the dose range 0 to 
20Gy. The dose response was linear, which simplifies detector calibration as only two 
dose levels are required to characterise the dose response relationship. A comparison 
between the dose response relationships of different batches showed good agreement. 
The dose response relationship was then used to convert relaxation rate to dose for 
every Fricke gel sample in order to estimate the uncertainty in the measured dose at 
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each dose level. At doses used in conventional radiotherapy of 0 to 3Gy, the dose 
uncertainty was greater than 3%. Despite the excellent measurement precision, the 
relatively low dose response causes dose uncertainties below 3Gy that are unacceptable 
in clinical radiotherapy. Uncertainties were less than 3% for doses of greater than 5Gy, 
suggesting that this detector is more suitable for high dose per fraction techniques.  
Results were equivalent in terms of dose response and measurement precision for T1 
and T2 quantification methods, in contrast to some previous studies indicating that 
either method may be used for the analysis of irradiated Fricke gel detectors. In this 
study T2 quantification was selected due to the much improved SNR and image 
uniformity for the CPMG sequence when compared with Look Locker sequence. 
Finally, there was no dependence of detector response on the radiation dose rate or 
energy, agreeing with previous studies.  
This chapter showed benefits of this Fricke gel detector of a linear dose response, no 
dose rate, or effect of fractionated dose delivery and negligible energy dependence. T2 
was demonstrated to be at least equivalent to T1 quantification in contrast to some other 
reports in the literature which is important as it is generally simpler to obtain high SNR 
and uniformity for clinical T2 sequences when compared with T1. There was some 
chemical instability but this is minimised by waiting at least 12 minutes before scanning 
the detectors, and storing them in the dark. However, results demonstrated dose 
precision within 3% only for doses of greater than 3Gy.  
7.2.4 Chapter 5: Larger volume suitability 
Attention then turned to larger volume detectors readout using the optimised CPMG 
sequence using the MRI scanner. The homogeneity of detector response, detector 
volume and the effect of ferric ion diffusion were investigated. Previous studies had 
shown an unacceptable detector inhomogeneity for agarose gels due to a different 
cooling rate in the centre of a detector compared with the edge during manufacture. This 
might be expected to be less of an effect for gelatine based detectors due to lower 
melting point. This was investigated for unirradiated detectors and for a detector 
irradiated with a homogeneous 10Gy dose. Fricke gel batches with different cooling 
methods were compared; in water bath and cooled at room temperature for 3 hours prior 
to being placed in a refrigerator at 4
o
C. The samples were then scanned with the CPMG 
sequence and a T2 map created. The homogeneity was better than 1%, deemed 
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acceptable in terms of visual inspection of profiles plotted across the T2 map, statistical 
variation in T2 within a large region of interest and small variation in T2 for small ROIs 
positioned in varying locations across the bottle.  
Similarly, a volume dependence might exist as smaller samples cool faster than larger 
ones. This was investigated by irradiating different volume samples with the same 
homogeneous dose distribution. There was no volume dependence for the Fricke gel 
detector investigated here. This in contrast to a similar experiment carried out using a 
commercial polymer gel detector where large variations with volume and shape of 
detector were seen. This indicates that small volume samples may be used to calibrate 
larger volume experimental samples.  
Ferric ion diffusion has been reported by many groups which causes a blurring of the 
measured dose distribution with time post-irradiation. The aim of the diffusion 
experiment in this chapter was to quantify the time within which gels should be scanned 
to maintain agreement between a measured distribution and reference distribution to 
within a specified spatial limit. This was carried out for 5 clinically relevant dose 
gradients of between 0.8Gy mm
-1
 to 3.2Gy mm
-1
 in their steepest section. Repeated 
scans were carried out for 5 hours following irradiation with a slightly modified 
sequence with a higher resolution in the direction of the dose gradient at the expense of 
the slice thickness. The maximum distance between the measured and reference TPS 
profile was noted at each time point. The time at which the maximum distance between 
measured and reference profile exceeded 1 and 2mm was quantified. These distance to 
agreement criteria were also selected to be relevant to spatial accuracy required for 
stereotactic techniques. 
For the most relevant dose gradients, a 1mm DTA can be maintained if the irradiated 
Fricke gels are scanned within 1 hour 30 minutes. This is sufficient time to complete an 
MR scan of gel phantoms, however, immediate access to the MR scanner would be 
required. If a 2mm DTA is deemed acceptable, This Fricke gel composition can be 
scanned up to 3 hours 20 minutes for even the steepest dose gradients.  
The composition can be modified to reduce the diffusion, for example adding xylenol 
orange. However, as this also reduces the dose response and immediate access to the 
MRI scanner can be arranged at St. Bartholomew’s Hospital, it was decided to continue 
with the existing chemical composition for the clinical studies.   
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7.2.5 Chapter 6: Application to clinical plans 
The focus of the final set of experiments was the irradiation of Fricke gel detectors with 
more complex radiotherapy plans. Fricke gel detectors were irradiated with a series of 
treatment plans, scanned with the optimised CPMG sequence in selected transverse, 
coronal and sagittal planes and 2D dose maps were created. These 2D dose maps were 
compared against corresponding calculated dose distributions exported from the 
treatment planning system. Plans had already been independently  measured by existing 
radiation detectors such as ion chambers, radiochromic film and an ArcCheck diode 
detector array.  
In order to quantitatively compare measured with calculated dose distributions, gamma 
evaluation was carried out using a commercial software package, OmniPro I’mRT. 
Gamma maps were calculated for two sets of gamma tolerances selected based on 
current VMAT and stereotactic practice at St. Bartholomew’s Hospital and published 
recommendations. The percentage of pixels within a region of interest with a gamma of 
< 1 and therefore passing the gamma test was presented. A typical aim is for 95% of 
measured points to pass a gamma test although in practice results are a guide and 
analysed in terms of where failures occur for example whether they are in a low or high 
dose region, or near a critical structure. 
Three radiotherapy plans were measured and analysed. They were selected with the aim 
to gradually increase plan complexity. The first was a simple, multiple field plan with 
some MLC shielding in one field to create a small dip in the dose distribution in order 
to investigate how well the Fricke gel measured this. The measured dose distribution for 
the central transverse plane was compared with the distribution predicted by the 
treatment planning system. If the measured dose distribution was re-normalised by 4%,  
the gamma pass rate was greater than 95% for both sets of gamma tolerances used.  
The second plan evaluated was a previously treated clinical VMAT plan for a brain 
metastasis. In this case, no re-normalisation was required. For the central transverse and 
coronal planes, the gamma test pass rate was greater than 95% both sets of dose 
difference and DTA tolerances. A small region of disagreement was seen laterally in a 
low dose region (<40% of maximum dose) away from the very steep dose gradient.  
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The third experiment used a stereotactic spine test plan as part of the commissioning 
process for stereotactic treatments on a Varian Truebeam linear accelerator. This was a 
more complex treatment situation. A Fricke gel was irradiated and dose maps were 
created for the central transverse, coronal and sagittal planes. Again a small re-
normalisation of 4% was required. When applied, the shape of the distribution agreed 
well in high dose and high dose gradient regions although again some disagreement was 
seen in the lateral direction in lower dose regions towards the edge of the bottle.  
Gamma test pass rates were greater than 95% for the transverse plane for both sets of 
gamma criteria. For the 5%, 1mm tolerance commonly used in stereotactic radiotherapy 
dosimetry, the pass rate was 93% for the sagittal plane but only 84% for the coronal 
plane with large areas of disagreement seen on the gamma map. This should be 
investigated further and perhaps indicates a slight further optimisation required in the 
TPS beam model for this machine and technique. However, the dose disagreement is 
only seen in a low dose region, away from steep dose gradients. In high dose, high 
gradient regions, the measured and calculated distributions agreed to within set 
tolerances and this plan would be accepted for treatment in clinical practice.  
In terms of the re-normalisation required for two of the three plans, this is a common 
approach for other chemical dosimetry techniques. It is common to combine a 
measurement which supplies 2D or 3D spatial dose information with a higher precision 
measurement at a single dose point for example an ionisation chamber. This would also 
be reasonable solution for 3D chemical dosimetry. In all three plans, the dose measured 
by the Fricke gel agreed with the PinPoint measured dose to within measurement 
uncertainty and the PinPoint dose was clinically acceptable according to local clinical 
tolerances.  
Gamma test results were similar to those presented in the literature for other 2D and 
pseudo-3D dosimetry techniques. The ability of this Fricke gel detector to carry out 3D 
dosimetry for complex dose distributions was demonstrated  
7.3 Overall conclusions 
Several reasons have been proposed for the lack of uptake of chemical dosimetry within 
clinical radiotherapy. Firstly, for some detectors such as polymer gel and Presage, the 
manufacture process requires laboratory facilities beyond those available to most 
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clinical radiotherapy physics departments. In terms of imaging, the recent focus has 
predominantly been on optical-CT scanners which would need to be purchased and 
commissioned specifically for gel dosimetry. Once again, it is beyond the expertise and 
time available for most clinical departments to develop their own scanners. Fricke gel 
detectors are simpler, but it was suggested that MR imaging was limited to T1 
quantification. As was shown in this project, T1 sequences typically available on clinical 
scanners such as the Look Locker sequence tend to be very fast sequences for cardiac 
imaging with inherently poor SNR. The issue of ferric ion diffusion has written off 
Fricke gel dosimetry for some. Finally, a lack of evidence for dosimetric performance 
for chemical detectors in general has led to uncertainty regarding the reliability of these 
techniques.  
These issues have been addressed in this project. A Fricke gel detector has been 
evaluated for use as a 3D dosimeter in a structured and logical way. The Fricke gel–MR 
system was optimised in terms of manufacture process and scan protocols. Focus was 
on simplicity and application within a clinical radiotherapy department. Detector 
manufacture was within a simple laboratory, involved non-toxic chemicals taking less 
than 2 hours and scanning was accomplished with clinically available MR pulse 
sequences. Consistency of dose response was demonstrated for different batches even 
with these basic facilities. T2 quantification was demonstrated to be at least equivalent 
to T1 quantification in terms of dose precision and response. A readily available clinical 
CPMG sequence was customised with little effort resulting in T2 and dose maps with 
high SNR and excellent uniformity. 
The optimised system was then subjected to commissioning measurements as if it were 
a commercial detector to quantify all factors which might affect its measurement 
accuracy. The dosimetric requirements were defined and quantified at the start. Detector 
characterisation was then accomplished in a systematic way, starting with basic 
characteristics evaluated using small volume test tube samples analysed with an NMR 
spectrometer before moving onto larger samples and dose mapping with a clinical MRI 
scanner.  
A tolerance of 3% was set at the outset for the overall dosimetry uncertainty based on 
available evidence in reference reports and dosimetric performance achieved by 2D 
detectors. The experimental dosimetric results demonstrated many benefits of this 
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detector. The T1 and T2 inter-sample variation was small (CV <0.5%) indicating a 
uniform chemical composition. The dose response was linear to doses of at least 
20Gy.There was no evidence of any dose rate, energy or volume dependence; results 
were all within measurement uncertainty. Detector inhomogeneity was demonstrated to 
be within acceptable limits (<1%)  for samples of up to 500ml. If detectors were 
scanned at least 15 minutes following irradiation and were stored in the dark, chemical 
instability was minimal, and in any case for all clinical irradiations in this project 
experimental and calibration samples were stored together and scanned simultaneously.  
The characterisation experiments highlighted two main contributions to measurement 
uncertainty. Firstly, despite very small variations between the T2 of different samples, 
the relatively low dose response meant that when converted to dose, dose uncertainties 
were greater than 3% over the 0 to 3Gy dose range 
For doses of greater than 3Gy, dose uncertainty was less than 3%. Therefore, for the 
remainder of this project, the focus was on higher dose techniques. This restriction is a 
limitation. However, there has been an increased interest in stereotactic radiotherapy 
over recent years. UK wide programmes are underway to evaluate the efficacy of 
stereotactic ablative body radiotherapy for a variety of treatment sites and there has 
been a rollout of stereotactic intracranial radiosurgery. In addition, stereotactic 
radiotherapy involves very steep dose gradients for which 3D dosimetry would be of 
particular benefit. Recent clinical trials have investigated hypofractionated radiotherapy 
for two of the most common cancers: breast and prostate cancer, with results recently 
reported for the FAST trial for breast cancer indicating that hypofractionated 
radiotherapy (>5Gy per fraction) should be adopted. The PACE trial is also 
investigating high dose per fraction (> 7Gy) treatments for prostate cancer.  
The second issue highlighted, as previously reported, was the blurring of the measured 
dose distribution with time post-irradiation due to ferric ion diffusion throughout the 
gelatine matrix. This is particularly important for the higher dose stereotactic treatments 
which involve steep dose gradients, often close to critical normal tissues. However, this 
was quantified and even for dose gradients higher than seen clinically, spatial accuracy 
is maintained to within 1mm as long as scanning is completed within 1.5 hours. This 
was easily achievable for the clinical studies where imaging was within an hour of 
irradiation, introducing only sub-mm errors.  
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Calibration has not been the focus of many publications for Fricke gel dosimetry. The 
T2 versus dose response must be characterised for each measurement session due to 
chemical instability and variation in dose response between different batches. This 
potentially can be cumbersome requiring multiple additional samples to be irradiated to 
known doses. In fact, several factors for this Fricke gel detector are beneficial in terms 
of simple detector calibration. A lack of volume dependence means that small samples 
may be used for calibration. Small inter-sample variation and a linear dose response 
meant that only two samples can be used to characterise the dose response.  
When applied to clinical radiotherapy plans, gamma test results were compared to those 
presented in the literature for other detector types. For a brain plan, gamma test results 
achieved the set 95% pass rate. The results for a spine plan demonstrated a 4% high 
measured dose compared with the TPS, in agreement with the ionisation chamber 
measurement. When re-normalised, gamma test results again achieved the set pass rate 
for high dose and high gradient regions. For both plans, recommended accuracy 
requirements for the high dose, high gradient regions of 2-3mm DTA and 3-5% dose 
difference were satisfied [127]. 
The Fricke gel system demonstrated similar dosimetric results to other detectors used 
for VMAT dosimetry with the added benefit of performing a 3D measurement. This 
technique could now be implemented for the commissioning of new techniques and 
technology in our department, with some work required to streamline the imaging and 
analysis process which will be outlined in the next section. To increase the confidence 
with the Fricke gel system still further, a range of clinical plans could be measured and 
evaluated. With another year, I would use the Fricke gel detectors for a range of clinical 
plans, covering different treatment sites and scenarios before moving onto plans with 
known errors introduced.  This would complete the structured validation of this 
detector.  
7.4 Future work 
The dosimetric performance of this Fricke gel detector has been demonstrated to be 
sufficient for the verification of the accuracy of complex radiotherapy plans. Further 
work is required however to finalise MR and analysis methods. So far, analysis has 
been via the creation of 2D dose planes with relatively large slice thickness in order to 
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improve the in-plane spatial resolution whilst maintaining SNR. These sequences were 
designed specifically for the characterisation experiments of this PhD where the dose 
did not vary greatly out of plane. However, for the measurement of clinical plans the 
MR methodology should be developed further in terms of 3D analysis. 3D MR 
sequences are available [130], and have been applied to Fricke gel dosimetry [99]. 
Alternatively a greater number of contiguous 2D planes could be acquired if required.  
To automate the analysis, work is also required to develop the software further. 
Currently T2 maps are created automatically within OsiriX, but the dose response has to 
be manually plotted and the code manually edited to create dose maps. The DICOM 
header then has to be manually edited to allow exported dose planes to be successfully 
imported into OmniPro I’mRT software. This could all be automated within the plugin. 
Optionally, the plugin could be developed to also calculate gamma maps.  
Localisation so far was accomplished by manually marking up the bottle and aligning 
with linac lasers and MR lasers. Small adjustments were required during the analysis to 
fine tune the location of the measured dose map versus calculated dose map i.e. the 
measured map was moved where an obvious systematic shift was seen. This was again 
reasonable for this investigation into the dosimetric capability of the Fricke gel detector, 
but in the verification of clinical plans a higher spatial accuracy is required. 
Incorporating fiducial markers which are visible on the T2 map would accomplish this 
and would further streamline the whole process.  
Alternatively, a phantom could be designed to hold the detector both during 
radiotherapy delivery and MRI scanning which would allow localisation by registering 
images. This could be more patient like and manufactured using a 3D printer. The end-
to-end testing of the entire radiotherapy process using anthropomorphic phantoms 
manufactured using 3D printers is the subject of current research [131-134]. The use of 
3D chemical dosimetry within 3D printed anthropomorphic phantoms, would be a 
powerful dosimetric tool for the end-to-end testing of complex radiotherapy techniques.  
The whole process should then be validated for a wider range of clinical plans covering 
a different prescription doses, treatment sites and techniques. It is possible, although not 
straightforward, to introduce intentional errors into VMAT plans. Proving the ability of 
the Fricke gel detector to correctly identify treatment errors in this way would be a 
worthwhile concluding investigation.  
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Appendix A. Code for T1 and T2 quantification 
To illustrate the work carried out to develop T1 and T2 quantification plugins, this 
appendix introduces selected excerpts from the code written. The plugins were written 
in objective-c for use within OsiriX as described in section 3.6.4 of the main report. 
The user interface for OsiriX is shown in Figure A.1. The top pane displays the list of 
image series acquired during a measurement session. Bottom left are all images from 
one image series, in this case the images at different TE for a T2 scan. Bottom right is a 
larger display of the selected image, in this case the first echo from this T2 scan. 
 
Figure A.1: screen shot of the main user interface for OsiriX. 
A.1 T1 quantification 
The following excerpt of code: 
(1) defines a function, f, which describes the recovery in longitudinal magnetisation for 
the Look Locker pulse sequence according to the equation of the form  
 y = A – B exp (-t / T1eff) 
as described in the main report, section 3.6.5 
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(2) defines starting points for the parameters A, B and T1eff of 3000, 6000 and 500 
respectively. 
(3) calls a routine lmcurve_fit. This runs the Levenberg-Marquardt optimisation to find 
optimum values of A, B and T1eff which best fit the actual recovery curve. 
(4) returns the value for T1eff.  
This is carried out for every pixel. The code then continues to display the T1eff  for each 
pixel: the T1 map.  
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@implementation ControllerT1Fit 
 
/*define the function equation A - B * exp [ -t/T1eff]*/ 
 
double f( double t, const double *p ) 
 
{ 
    return p[0] - p[1] * exp(-t/p[2]); 
} 
 
/*this defines the parameters required as inputs into the LM optimiser*/ 
/*these are n_par, par[], m_dat, t, y, f*/ 
/*the value for t1 is returned back to controller.m*/ 
 
double computeLevenbergMarquardt(int pixList, float ttemp[], float ytemp[], double *t1) 
 
{ 
    /* parameter vector */ 
  
    int n_par = 3; // number of parameters in model function f 
    double par[3] = { 3000, 6000, 500 }; // array containing starting values for A, B and T1eff 
  
 int m_dat = pixList; // number of data pairs 
  
 double t[100];   //array containing x-values (time) 
 double y[100];   //array containing y-values (signal) 
  
 /*convert time and signal array elements from floats to doubles*/ 
  
 int i; 
 for( i = 0; i < pixList; i++) 
 { 
  t[i] = (double) ttemp[i] * 1000; 
  y[i] = (double) ytemp[i]; 
 } 
  
    /* auxiliary parameters */ 
  
    lm_status_struct status; 
    lm_control_struct control = lm_control_double; 
    control.printflags = 3; // monitor status (+1) and parameters (+2) 
  
    /* perform the fit */ 
 
    lmcurve_fit( n_par, par, m_dat, t, y, f, &control, &status );  
    *t1 = par[2];  //T1 effective 
    return *t1; 
} 
 
1 
2 
3 
4 
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A.2 T2 quantification 
The T2 for each pixel in the image is calculated from the data of MXY versus echo time 
(t) according to the equation: 
 
MXY is the residual transverse magnetisation (signal) at echo time, t.  By plotting 
log(MXY) versus echo time, t, the T2 may be calculated according to     T2 = -1 / slope 
The following excerpt of code: 
(1) for each pixel, calculates log(MXY) for every T2 echo image.  
(2) sets the T2 of the background pixels (outside of the phantom) to zero 
(3) for each pixel, plots log(signal) versus echo time, performs a linear 
regression and returns the slope and the intercept.  
(4) calculates T2 =  - 1 / slope 
The code then goes on to display the T2 map and allow analysis of the data.  
  
  2t/T0XY eMtM

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for( x = 0; x < [firstPix pwidth]; x++) 
 { 
 for( y = 0; y < [firstPix pheight]; y++) 
  { 
  if( curROI == nil || [firstPix isInROI: curROI :NSMakePoint( x,  y)]) 
      
   { 
   float logvalues[ 1000]; 
   float values[ 1000]; 
   long pos = x + y*[firstPix pwidth]; 
        
   for( i = 0; i < [teSequence count]; i++) 
        
    { 
    logvalues[ i] = log( [[teSequence objectAtIndex: i] fImage] [ pos] - 
background); 
    values[i] = [[teSequence objectAtIndex:i] fImage] [pos]; 
    } 
        
    if(values[0] <100) 
       
     { 
     dstImage[x+y*[firstPix pwidth]] = 0; 
     } 
       
    else  
     { 
  [self computeLinearRegression: [teSequence count] :TEValues :logvalues :&intercept :&slope]; 
        
  dstImage[ x + y*[firstPix pwidth]] = 1 / -slope; 
   
 …. 
     } 
    } 
   }    
} 
2. 
3. 
4. 
1. 
